University of Mississippi

eGrove
Electronic Theses and Dissertations

Graduate School

2011

The Effects of Chronic Prophylactic Naproxen Sodium on Skeletal
Muscle Adaptation to Resistance Exercise in RecreationallyTrained College-Aged Males
Christi Brewer

Follow this and additional works at: https://egrove.olemiss.edu/etd
Part of the Physiology Commons

Recommended Citation
Brewer, Christi, "The Effects of Chronic Prophylactic Naproxen Sodium on Skeletal Muscle Adaptation to
Resistance Exercise in Recreationally-Trained College-Aged Males" (2011). Electronic Theses and
Dissertations. 63.
https://egrove.olemiss.edu/etd/63

This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more
information, please contact egrove@olemiss.edu.

THE EFFECTS OF CHRONIC PROPHYLACTIC NAPROXEN SODIUM ON
SKELETAL MUSCLE ADAPTATION TO RESISTANCE EXERCISE IN
RECREATIONALLY-TRAINED COLLEGE-AGED MALES

A Dissertation
presented in partial fulfillment of requirements
for the degree of Doctor of Philosophy
in the Department of Health, Exercise Science, and Recreation Management
The University of Mississippi

by
CHRISTI BREWER
December 2011

Copyright Christi Brewer 2011
ALL RIGHTS RESERVED

ABSTRACT
Resistance exercise causes exercise-induced muscle injury (EIMI), triggering an acute local
inflammatory response associated with delayed-onset muscle soreness (DOMS). DOMS is
characterized by a predictable discomfort and decreased level of muscle performance and is believed
to be the product of both mechanical and inflammatory processes. From the latter perspective,
non-steroidal anti-inflammatory drugs (NSAIDs) have been investigated for their potential to
alleviate DOMS-associated symptoms. Such analgesics exert their effects by blocking the formation
of prostaglandins; however, prostaglandins, specifically prostaglandin F2α, also play an important role
in skeletal muscle regeneration. While some have advocated the use of NSAIDs for the relief of
EAP, research demonstrating the necessity of inflammation for adaptation and regeneration suggests
their use may be counter-productive for those striving toward muscular fitness goals. In this
double-blind design, twenty-three recreationally-trained college-aged males were randomly assigned
to placebo or naproxen sodium treatment groups. Treatments were prophylactically administered
twice per week, in conjunction with a supervised periodized upper body resistance training program.
Main effects for time and exercise were seen for repeated acute systemic plasma PGF2α metabolite
concentrations, acute arm circumference response to exercise, strength, dominant arm lean and fat
tissue, and non-dominant arm bone mineral content. No significant treatment effects were detected
for any dependent variables, thus twice weekly naproxen sodium (440mg) does not appear to inhibit
skeletal muscle adaptation to resistance exercise in recreationally-trained college-aged males over a 6week time period.
ii

LIST OF ABBREVIATIONS AND SYMBOLS

AA

Arachidonic acid

COX

Cyclooxygenase enzyme

DOMS

Delayed-onset muscle soreness
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Exercise-induced muscle injury
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Exercise-associated pain
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Fractional synthesis rate

MVC

Maximal voluntary contraction

NSAIDs

Non-steroidal anti-inflammatory drugs

PG

Prostaglandin
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Prostaglandin F2α
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Repetition maximum
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Chapter I
Introduction

Novel or intense exercise, particularly resistance training, causes exercise-induced muscle
injury (EIMI). Such injury triggers an acute local inflammatory response and is associated with
delayed-onset muscle soreness (DOMS). DOMS is characterized by a predictable discomfort and
decreased level of muscle performance that peaks 24 hours and persists 48-72 hours post-exercise
(Jones, Newham and Torgan, 1989; Donnelly, Maughan and Whiting, 1990; MacIntyre, Reid, Lyster,
Szasz and McKenzie, 1996; Lecomte, Lacroix and Montgomery, 1998; Almekinders, 1999; Semark,
Noakes, St Clair Gibson and Lambert, 1999; MacIntyre, Reid, Lyster and McKenzie, 2000; Baldwin,
Stevenson and Dudley, 2001; Trappe, White, Lambert, Cesar, Hellerstein and Evans, 2002). DOMS
is also characterized by diffuse muscle pain, swelling, and stiffness; and while several therapeutic
options are available to ameliorate the discomfort associated with exercise-induced muscle injury,
non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most popular. NSAIDs belong to a
family of drugs that have achieved widespread use in sports medicine in both prescription and nonprescription forms (Hertel, 1997). Their use as a therapeutic treatment for EIMI has increased
dramatically over the last 20 years (Lanier, 2003), and 40% of non-prescription analgesic users cite
exercise-associated pain as their primary impetus to take NSAIDs (Wilcox, Cryer, and
Triadafilopoulos, 2005).
Skeletal muscle adaptation to resistance exercise involves changes in nervous,
musculoskeletal and endocrine systems, including enhanced motor unit recruitment, strengthened
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muscle and connective tissue, and hormonal adaptations. The cumulative effects of these changes
result in protection from damage incurred during subsequent bouts of similar exercise, a
phenomenon referred to as the repeated bout effect (Ebbeling and Clarkson, 1989; McHugh,
Connolly, Eston and Gleim, 1999). Specific patterns of nervous system stimulation during
resistance training result in the simultaneous activation of hormonal changes related to recovery and
adaptation of skeletal muscle tissue (Kraemer, Vingren and Spiering, 2008). The type of resistance
training program performed dictates hormonal responses, which are intimately involved in protein
synthesis and degradation, as well as the shifts between the two during remodeling (Kraemer,
Vingren, Spiering, 2008). This is particularly true of prostaglandins (PG), hormones synthesized
from skeletal muscle constituents upon membrane disruption and whose response has been shown
to be affected by stimulus intensity (Boushel, Langberg, Gemmer, Olesen, Crameri, Scheede, Sander
and Kjaer, 2002).
Animal research employing electrical stimulation and passive movement has demonstrated
adaptation to muscular contraction relies on inflammation (Lapointe, Fremont and Cote, 2002;
Pizza, Koh, McGregor and Brooks, 2002), making suppression of the acute inflammatory response
controversial. While some have advocated the use of NSAIDs for the relief of exercise-associated
pain (Donnelly et al., 1990; Gulick, 1996; Pizza, Cavender, Stockard, Baylies and Beighle, 1999;
Baldwin et al., 2001; Lanier, 2003), aforementioned research demonstrating the necessity of
inflammation for adaptation and regeneration suggests their use may be counter-productive for
those striving toward muscular fitness goals (Lapointe et al., 2002; Pizza et al., 2002). Additional
animal research has also demonstrated that suppression of the acute inflammatory response may
provide immediate benefit, but this was followed by a decrement in muscle function at both early (37 days) and delayed (1 month) time points post-passive movement and laceration injury models,
respectively (Mishra, Friden, Schmitz and Lieber, 1995; Shen, Li, Tang, Cummins and Huard, 2005).
2

It is important to acknowledge inherent pathophysiological differences between certain
inflammatory responses and the necessity of NSAIDs in the associated injury models. In the clinical
field, NSAIDs are prescribed to reduce inflammation resulting from muscle strains, contusions, or
surgical lacerations. The substantial inflammation resulting from such types of injuries impedes
rehabilitation and delays the return to activity, and NSAIDs are considered a requisite component of
treatment. The inflammatory response associated with EIMI is less than that seen in the
aforementioned injury models (Almekinders, 1999), and the use of NSAIDs is often optional. Due
to these differences, the effects of NSAIDs on the inflammatory response associated with one type
of injury cannot be assumed for other types of injuries. As an example, Almekinders, Banes, and
Ballenger have cited a lack of fibroblast activation in exercise-induced injury models (1993). The
current investigation will thus focus on the use of non-steroidal anti-inflammatory drugs in exerciseinduced muscle injury, incorporating human and animal experimental research that investigated
inflammation using muscular contraction models of injury.
Much of the existing literature concerning the role of NSAIDs in exercise-induced muscle
injury has been investigated from the standpoint of DOMS treatment or prevention. While the
majority has found no therapeutic benefit of NSAIDs on these symptoms (Donnelly et al., 1990;
Gulick, 1996; Howell, Conatser, Chleboun, Karapondo and Chila, 1998; Pizza et al., 1999; Trappe et
al., 2002; Peterson, Trappe, Mylona, White, Lambert, Evans and Pizza, 2003; Krentz, Quest,
Farthing, Quest and Chilibeck, 2008; Mikkelsen, Langberg, Helmark, Skovgaard, Andersen, Kjaer
and Mackey, 2009), some research has reported a positive effect of NSAIDs on exercise-induced
muscle injury (Hasson, Daniels, Divine, Niebuhr, Richmond, Stein and Williams, 1993; Dudley,
Czerkawski, Meinrod, Gillis, Baldwin and Scarpone, 1997; Baldwin et al., 2001). A less thoroughly
investigated aspect of the role of NSAIDs in EIMI is the potential to unintentionally suppress
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skeletal muscle regeneration or adaptation to resistance exercise in an attempt to alleviate symptoms
associated with the acute inflammatory response.
Baldwin, Stevenson, and Dudley (2001) demonstrated an immediate preservation and
maintenance of concentric and isometric strength in older males and females (n=15) who consumed
naproxen sodium for 10 days (220 mg three times per day) after an acute bout of eccentric knee
extensions. Dudley, Czerkawski, Gillis, Baldwin, and Scarpone (1997) reported reduced thigh
soreness and improved recovery of concentric one-repetition maximum (1RM) in young males
(n=8) who consumed naproxen sodium for 10 days after acute eccentric knee extensions. Using
therapeutic administration of naproxen (500 mg twice per day for 6 days) after two 8-day bouts of
eccentric single leg exercise separated by seven days for washout of the repeated bout effect,
Lecomte, Lacroix, and Montgomery (1998) also reported decreased soreness and preserved peak
quadriceps torque in naproxen-treated male participants (n=10) versus placebo-treated males
(n=10). Hasson et al. (1993) also reported ibuprofen-treated participants perceived 40-50% less
soreness and experienced significantly less decline in torque and EMG magnitude after acute
exercise compared to placebo and control groups (N=20); however, animal research demonstrating
long-term decrements accompanying initial short-term benefits should not be forgotten (Mishra et
al., 1995; Shen et al., 2005). It is interesting to note that three of the four papers to report any
beneficial effect of NSAIDs on DOMS employed naproxen sodium.
Mechanisms postulated to explain the phenomenon of DOMS are controversial. Some have
argued DOMS is independent of inflammation (Almekinders, 1999; Semark et al., 1999), thus
treatment with NSAIDs would be unlikely to yield dramatic results; however, the analgesic effect of
these drugs confounds the assessment of muscle performance. Tidball, Berchenko, and Frenette
(1999) pointed out there is little experimental evidence to demonstrate muscle injury and
inflammation associated with muscle loading is exclusively attributable to mechanical factors.
4

Research that has reported a bimodal response in strength recovery after resistance exercise has
postulated the initial decrease is attributable to mechanical events (Gulick, 1996), while the second
decrease is due to phagocytic activity at the initial site of damage (MacIntyre et al., 1996; MacIntyre
et al., 2000).
The inflammatory response is considered to begin with the influx of calcium into the cell
through the abundant stretch-activated calcium channels located on the cell membrane. Neutrophils
are the first of many inflammatory mediators to arrive at the site of an injury. Approximately 50%
of neutrophils released from bone marrow are sequestered along blood vessel walls. Neutrophil
infiltration is stimulated by chemotaxic factors, including prostaglandins, tumor necrosis factor-α,
interleukin (IL)-1β, and IL-6 (Stupka, 2000). Neutrophils are activated as they circulate through a
blood vessel in an injured area. One consequence of this activation is a “respiratory burst,” during
which neutrophils generate high concentrations of reactive oxygen species (ROS), or free radicals
such as nitric oxide and hydrogen peroxide, which destroy engulfed pathogens (Martini, 2004;
Butterfield, 2006). In addition to free radicals, neutrophils also release proteolytic enzymes such as
elastase and lysozyme from their granules (Cannon, Orencole, Fielding, Meydani, Meydani,
Fiatarone, Blumberg and Evans, 1990; Stupka, 2000). These molecules are chemically unstable
compounds that attack and degrade cell membranes. This degradation is somewhat non-specific
and may damage neighboring cells (Stupka, 2000). Very well-designed animal studies have clearly
demonstrated secondary damage occurring as a result of these superoxide-dependent mechanisms
(Tidball, Berchenko and Frenette, 1999; Toumi, F'guyer and Best, 2006).
Human research has also demonstrated a bimodal pattern of maximal voluntary contraction
(MVC) recovery after isometric and concentric muscle action (Jones et al., 1989; Gulick, 1996) and
eccentric torque after eccentric muscle action (MacIntyre et al., 1996; MacIntyre et al., 2000). While
mechanical factors explain the initial and immediate decrease in muscle contractile ability, the second
5

decrease in muscle contractile ability is believed to be explained by the concomitant increase in white
blood cells and associated free radicals in the hours after exercise (Cannon et al., 1990; Fielding,
Manfredi, Ding, Fiatarone, Evans and Cannon, 1993; MacIntyre et al., 1996; Malm, 1999; MacIntyre
et al., 2000; Malm, 2000). A positive correlation (rho=0.66, p<0.001) between neutrophil infiltration
and intracellular z-band damage has been reported post-downhill running in males (n=9) (Fielding et
al., 1993).
Further evidence for non-mechanical factors in exercise-induced muscle injury has been
provided by research demonstrating neutrophil activation in ischemic and inactivity injury models.
Using Western blot analysis and electron microscopy of myotubes co-cultured with neutrophils
and/or macrophages muscle, non-exercise models of injury in animals have shown secondary
damage resulting from neutrophils and macrophages (Nguyen and Tidball, 2003). Their action in
non-contractile injury models strongly suggests the primary mechanism of tissue destruction is their
release of cytotoxic agents (Butterfield, Best et al. 2006). Further evidence for this cytotoxic
damage has been provided by Brickson et al. (2003) and Nguyen and Tidball (2003), who
demonstrated significantly less myofibril damage in animals treated with a specific antibody to block
neutrophil oxidation post-electrical stimulation and in myotubes cultured with specific free radical
blockers, respectively. Human research has suggested eccentric exercise causes an up-regulation in
the functional capacity of neutrophils to produce reactive oxygen species (Pizza et al., 1999).
Regardless of the exact mechanism of injury, inflammation is always followed by an attempt
at regeneration (Martini, 2004; MacIntosh, 2006). The two processes are mechanistically linked, and
suppression of initial inflammatory response could theoretically blunt the subsequent regenerative
response. For instance, while macrophages, like neutrophils, have also been shown to elicit damage
through free radical–mediated mechanisms, they also stimulate repair and release cell growth
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regulatory cytokines such as fibroblast growth factor (FGF), insulin-like growth factor (IGF-1), and
transforming growth factor-β1 (TGF- β1) (Butterfield, Best et al. 2006).
Prostaglandins (PGs) are a particularly interesting molecule in the inflammatory response.
While it has been suggested virtually all mammalian cells may produce and respond to
prostaglandins, they are not considered to exist pre-formed in any cellular reservoir (Pettipher,
1998). Rather, the precursor C20 unsaturated fatty acid is present in tissues and is hydrolyzed by
phospholipase A2 (Rifai, Bachorick and Albers, 1999). Prostaglandins’ role in inflammation is vital,
as they contribute to increased blood flow, vascular permeability, and pain sensation resulting from
injury. It is for these reasons that prostaglandins are the primary target of non-steroidal antiinflammatory drugs.
Prostaglandins, however, also stimulate satellite cell proliferation (PGF2α), differentiation and
fusion (PGE2), as well as the incorporation of new proteins into existing muscle (Zalin, 1987;
Phillips, Tipton, Aarsland, Wolf and Wolfe, 1997; Trappe, Fluckey, White, Lambert and Evans,
2001; Trappe et al., 2002). Prostaglandin F2α (PGF2α) specifically, has been described as an
endogenously-produced growth factor requisite for muscle growth (Zalin, 1987; Horsley and
Pavlath, 2003).
Human research has demonstrated local increases in PGF2α concentrations (Trappe et al.,
2001; Trappe et al., 2002), with concomitant increases in skeletal muscle fractional synthesis rate
(FSR) after resistance exercise (Phillips et al., 1997; Phillips, Tipton, Ferrando and Wolfe, 1999).
Research by Phillips et al. (1999) demonstrated effects of training status on fractional synthesis rate,
with trained participants exhibiting less protein synthesis post-resistance exercise compared to
sedentary subjects after an acute bout of resistance exercise. These findings hold implications for
interpretation of research by Trappe et al. (2001, 2002), who reported a significant increase in FSR
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post-acute resistance exercise in a mixed participant pool of both sedentary and recreationallytrained males (n=24).
NSAIDs similar to ibuprofen have been shown to blunt protein metabolism in human and
animal skeletal muscle via mechanisms which inhibit prostaglandin production (Rodemann and
Goldberg, 1982; Palmer, 1990; Trappe et al., 2001; Trappe et al., 2002). Trappe et al. (2001, 2002)
reported significant acute inhibitory effects of analgesics on fractional synthesis rate after one bout
of resistance exercise, but the effects of continued consumption of NSAIDs in conjunction with
resistance exercise are not known.
Like ibuprofen, naproxen sodium is a proprionic acid. While most human research
examining post-exercise effects of anti-inflammatory drugs has employed ibuprofen (Donnelly et al.,
1990; Hasson et al., 1993; Howell et al., 1998; Trappe et al., 2001; Trappe et al., 2002), less human
research has been conducted using naproxen sodium (Dudley et al., 1997; Lecomte et al., 1998;
Bourgeois, MacDougall, MacDonald and Tarnopolsky, 1999; Baldwin et al., 2001). Limited
investigations of the effects of naproxen sodium on various indices of muscle damage, performance,
and recovery have been conducted in animals, with Thorsson, Rantanen, Hurme, Kalimo (1998)
employing naproxen in a study of the inflammatory response resulting from imposed contusion
injury in rats. A considerable amount of research has also been conducted using formulations not
commonly available in non-prescription form (ie, flurbiprofen, meclofename, ketoprofen).
Those human studies employing naproxen sodium have examined the efficacy of such drugs
on exercise-associated pain. Of those to utilize naproxen, all looked at functional measures of
muscle recovery, such as soreness, strength, torque, and/or EMG magnitude. Only one examined
the response of an inflammatory molecule (creatine kinase) in response to exercise and naproxen
sodium (Bourgeois et al., 1999). In light of the paucity of research examining the influence of
naproxen sodium on inflammatory mediators, as well as previous research to demonstrate its
8

efficacy in DOMS (Dudley et al., 1997; Lecomte et al., 1998; Baldwin et al., 2001), research
examining the influence of naproxen sodium on inflammatory molecules related to protein synthesis
and satellite cell activity seemed warranted.
The hypertrophic process involves an increase in the net accretion of the contractile proteins
actin and myosin within the myofibril, as new myofilaments are added to the periphery of the
myofibril, resulting in an increase in its diameter (Kraemer et al., 2008). Muscular hypertrophy can
be accomplished by more than one mechanism, including either an increase in protein synthesis or a
decrease in protein degradation. However, hypertrophy is usually achieved by an increase in protein
synthesis, often with a proportionately smaller increase in degradation (Palmer, 1990). Likewise,
while atrophy is usually characterized by a decrease in protein synthesis or an increase in protein
degradation, rates of protein synthesis may still be elevated during atrophy, as demonstrated by
Goldspink (1977) in an immobilization model of injury in rats. It is the overall net balance between
synthesis and degradation that determines the ultimate outcome, and muscle growth can only occur
if there is net anabolism within the muscle (Phillips et al., 1997). The magnitude of protein synthesis
is influenced by a host of variables including amount and timing of macronutrient intake, amino acid
availability, intensity of the imposed mechanical stress, muscle cell hydration levels, and the anabolic
hormonal response (Kraemer et al., 2008).
In terms of impacts on muscle function and inflammatory cells, it has been suggested a
therapeutic dose of an NSAID is not as effective as a prophylactic dose, due to its administration
after the injurious event (Hasson et al., 1993; Gulick, 1996; Pizza et al., 1999; Willoughby, 2000;
Lanier, 2003; Lapointe, Fremont and Cote, 2003). Theoretically, prophylactic treatment should
reduce the immediate inflammatory response. A prophylactic approach to NSAID administration
has been shown to attenuate muscle soreness and dysfunction in humans (Hasson et al., 1993) and
inflammatory cells in rats after induced pleurisy (Gilroy, Colville-Nash, Chivers, Paul-Clark and
9

Willoughby, 1999). Prophylactic indomethacin (non-selective acetic acid) given to rats prior to
endotoxin injection inhibited the onset of fever, the increase in PGE2, and the resulting increase in
protein degradation (Goldberg, 1988). In contrast, when indomethacin was administered
therapeutically two hours after endotoxin injection, PGE2 production was inhibited, but the elevated
rate of protein breakdown was unaffected (Goldberg, 1988).
Hasson et al. (1993) reported subjects treated prophylactically with ibuprofen perceived 4050% less soreness and experienced significantly less decline in isometric, concentric, and eccentric
torque 24 hours post-eccentric exercise compared to those treated therapeutically or with placebo.
These results indicate therapeutic use of NSAIDs may be ineffective in inhibiting protein
degradation and soreness if the contributing factors are elevated before drug administration, creating
an argument for a prophylactic approach. At 48 hours, both drug groups (prophylactic and
therapeutic) reported significantly less soreness and torque decline than placebo and control groups.
Since the inflammatory and regenerative phases are coupled, it is logical to suppose druginduced inhibition of the initial phase could negatively affect the subsequent phase. This
mechanistic link, along with research highlighting the necessity of inflammation for muscular
adaptation (Lapointe et al., 2002; Pizza et al., 2002), seem to indicate inhibition of inflammation may
be undesirable for those pursuing muscular fitness goals. The purpose of this study was to
investigate the effects of a six-week period of resistance training coupled with prophylactic naproxen
sodium (Aleve®) consumption on skeletal muscle response to exercise in recreationally-trained
college-aged males. Like ibuprofen, naproxen sodium is a proprionic acid; however, unlike
ibuprofen, naproxen sodium has a long half-life of 12-15 hours post-oral administration. In fact,
naproxen sodium is the only non-prescription NSAID with a long half-life. While these
pharmacokinetics are slower in comparison to ibuprofen, research has shown patients tend to be
more compliant in taking medication when prescribed drugs with longer half-lives (Leadbetter,
10

1995). Indeed, recent marketing campaigns by Procter and Gamble-owned Bayer Healthcare, the
company responsible for the manufacture and distribution of Aleve®, highlight this unique feature of
naproxen sodium.
Skeletal muscle adaptation was examined through both hormonal, performance, and
anthropometric changes in response to exercise over time. Hormonal adaptations were studied
through examination of repeated systemic plasma prostaglandin F2α metabolite concentrations
(pg/ml) pre- and post-exercise at three times points over 6 weeks. Strength was studied by
examining changes in one and ten repetition maximum (1- and 10-RM) testing at three time points
over 6 weeks. Acute changes in dominant upper arm circumference in response to exercise were
taken as an indirect marker of exercise-induced hyperemia. Basic anthropometrics were studied
through comparison of pre- and post-study DXA measurements. The main outcome variables
included the acute PGF2α response to exercise, acute arm circumference response to exercise,
strength development, and arm tissue composition.

11

Chapter II
Literature Review

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Aspirin (acetylsalicylic acid) was the first non-steroidal anti-inflammatory drug (NSAID).
Although it was developed in the 1800s, its use dates back thousands of years, when patients were
advised to chew on salicin-containing white willow bark to reduce fever and inflammation.
Although aspirin was used for centuries, its mechanism of action was not discovered until 1971,
when Vane determined it inhibited production of all prostaglandins (Vane, 1971; Vane and Botting,
1987), work which coincidentally garnered him and his colleagues the Nobel Prize for Medicine in
1982. Vane (1971) also determined a linear relationship between percent inhibition of prostaglandin
F2α activity and the log concentration of indomethacin, aspirin, and sodium salicylate.
Although heralded as a wonder drug and used to treat a variety of ailments, aspirin is also
associated with adverse side effects, particularly the risk of stomach bleeding. These side effects
inspired the search for chemically similar drugs with similar analgesic and anti-inflammatory
properties but without associated side effects. While aspirin is technically an NSAID, it is not
included in the generic term generally reserved for the newer agents, as its effects on the
cyclooxygenase (COX) enzyme differ from those of the newer generation NSAIDs. In contrast to
newer generation NSAIDs whose COX inhibition is reversible, aspirin-induced COX inhibition is
irreversible due to the fact platelets have no DNA and are thus unable to synthesize new COX
enzymes.
12

Most NSAIDs inhibit COX by transacetylation of the active center of the enzyme,
competing with the cell membrane substrate arachidonic acid for the enzyme’s active site.
Specifically, drugs such as aspirin and indomethacin, acetylate prostaglandin endoperoxide
synthetase (PGG and PGH), resulting in loss of COX activity, which subsequently inhibits
prostaglandin production.
COX exists in two distinct isoforms- COX-1 and COX-2. COX-3 is a third isoform
recently identified as a variant of the COX-1 gene, and it appears to regulate fever within the central
nervous system (Vane and Botting, 1987; Vane and Botting, 1996; Chandrasekharan, 2002). Despite
a high sequence of homology between the two isoforms, differences in the active sites of the
enzymes have been pharmaceutically exploited to develop inhibitors selective for COX-2
(Willoughby, 2000). As shown in Tables 1 and 2, NSAIDs may be classified according to their COX
selectivity or chemical structure. COX-2-selective indicates selective and sole inhibition of COX-2,
while non-selective indicates inhibition of both isoforms. NSAIDs are most commonly
administered in oral form; however, transdermal patches have recently been developed and
represent a novel mode of administration.
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Table 1
Non-Steroidal Anti-Inflammatory Drug COX Classification System
Non-Selectivea

COX-2 Selectivea

COX-1 Selectiveb

Chemical Name (Brand®)

Chemical Name (Brand®)

Chemical Name (Brand®)

Diclofenac (Voltaren)

Celecoxib (Celebrex)

Aspirin

Diflunisal (Dolobid)

Valdecoxib (Bextra)

SC-560

Etodolac (Lodine)

Rofecoxib (Vioxx)

FR122047

Fenoprofen (Nalfon)

NS-398

Mofezolac

Flurbiprofen (Ansaid)

P6

Ibuprofen (Motrin, Advil)

TFAP

Indomethacin (Indocin)
Ketoprofen (Orudis)
Ketorolac (Toradol)
Naproxen (Aleve, Naprosyn,
Anaprox, Naprelan)
Oxaprozin (Daypro)
Piroxicam (Feldene)
a
b

Information from Food & Drug Administration
Perrone, Scilimati, Simone, & Vitale (2010)
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Table 2
Brief Non-Steroidal Anti-Inflammatory Drug Chemical Classification System
Acetic Acid

Proprionic Acid

Chemical Name (Brand®)

Chemical Name (Brand®)

Diclofenac sodium (Voltaren)

Fenoprofen calcium (Nalfon)

Etodolac (Lodine)

Flurbiprofen (Ansaid)

Indomethacin (Indocin)

Ibuprofen (Motrin)

Ketorolac (Toradol)

Ketoprofen (Orudis)

Sulindac (Clinoril)

Naproxen (Naprosyn, Anaprox)

Tolmetin sodium (Tolectin)

Oxaprozin (Daypro)

COX-1 is a constituent enzyme found in most tissues and is responsible for the regulation of
normal cell activities in the gastrointestinal (GI) tract, kidneys, liver, and other organs (Vane and
Botting, 1996). The concentration of COX-1 remains largely stable within the body. In the GI
tract, prostaglandins decrease secretion of gastric acid while increasing secretion of bicarbonate and
cytoprotective mucus (Miller, 1983; Vane and Botting, 1987). GI tract issues represent the most
common side effects associated with NSAID use and stem from COX-1 inhibition and the resulting
inhibition of protective prostaglandin activities.
COX-2 is found in the kidneys and central nervous system. Novak et al. (2009) also revealed
its expression in the skeletal muscle fiber periphery, as well as in and near nuclei of myogenic
precursor cells (satellite cells). This discovery was important in clarifying the isoform present in
skeletal muscle, as questions concerning the specific isoform(s) present in skeletal muscle had been
raised by Trappe et al. (2002). Unlike COX-1, whose concentration remains largely stable (Vane and
Botting, 1996), COX-2 is not normally present in resting cells. Its expression can increase
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dramatically after exposure of fibroblasts, vascular smooth muscle, or endothelial cells to growth
factors, cytokines, and highly immunogenic lipopolysaccharides in monocytes/macrophages (Vane
and Botting, 1996). COX-2 expression is tightly regulated and induced by inflammatory mediators
such as growth factors, cytokines, and endotoxins. This specificity to the inflammatory process led
to considerable interest in COX-2 inhibition and the subsequent introduction of Celecoxib
(Celebrex®), Valdecoxib (Bextra®), and Rofecoxib (Vioxx®).
Generally, selective COX-2 inhibitors reduce pain and inflammation without the
gastrointestinal side effects associated with non-specific NSAIDs. However, animal research has
demonstrated the necessity of COX-2 activity for skeletal muscle successful regeneration in
cryogenic, laceration, and synergist ablation models of injury, respectively (Bondesen, Mills, Kegley
and Pavlath, 2004; Shen et al., 2005; Novak, Billich, Smith, Sukhija, McLoughlin, Hornberger and
Koh, 2009). Research has demonstrated COX-2 inhibition after mouse laceration injury results in
increased fibrosis, transforming growth factor-β1, and myostatin, a negative regulator of skeletal
muscle growth (Shen et al., 2005). These findings suggest negative implications for COX-2
inhibition in terms of impacts on muscle growth, corroborating research demonstrating the necessity
of COX-2 activity in regeneration and hypertrophy (Bondesen et al., 2004; Novak et al., 2009). In
addition to selective pharmacological inhibitors, COX-2 is also regulated by mechanical
deformation. While cyclical stretch of cultured myoblasts has been shown to have no effect on
COX-1 mRNA, it was shown to significantly increase COX-2 mRNA expression 3.5 fold (Otis,
Burkholder and Pavlath, 2005).
NSAIDs differ in their anti-inflammatory effectiveness as well as their ability to inhibit
COX-1 and COX-2. Several commonly known NSAIDs such as piroxicam, indomethacin, and
aspirin preferentially inhibit COX-1 and are associated with a greater risk of gastrointestinal and
renal complication. Non-selective NSAIDs (Table 1) inhibit both COX isoforms, but it is their
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preferential inhibition of COX-2 that is their primary analgesic mechanism. This selective COX-2
inhibition also tends to result in fewer GI complications (Vane and Botting, 1996).
Activity ratios represent inhibition of COX-1 versus COX-2. Compounds with lower
activity ratios are more potent inhibitors of COX-2 and have fewer GI and renal side effects (Vane
and Botting, 1996). Naproxen has the lowest activity ratio of 0.6 versus piroxicam, which has an
activity ratio of 250. This value indicates the drug is 250 times more active on COX-1 than COX-2.
Epidemiological data indicate that among non-selective NSAIDs, ibuprofen has one of the most
favorable GI safety profiles, with an activity ratio of 15. Comparison of activity ratios for naproxen
and ibuprofen suggest naproxen should result in fewer gastrointestinal complications and support its
use in the current investigation.
The effects of COX–inhibiting drugs are tissue-specific. Ibuprofen, for instance, has a
major effect on COX in the peripheral tissues, while acetaminophen performs its COX–inhibition in
the central nervous system. The effects of COX-inhibiting drugs are also dose-dependent, and
analgesic doses tend to be 50-75% of anti-inflammatory doses, both in terms of dosage and duration
of treatment (Vane and Botting, 1987; Amadio, 1993; Koester, 1993). Over-the-counter, or nonprescription NSAIDs are available in doses that primarily yield analgesic and antipyretic, but not
anti-inflammatory, effects.

Applications of Use and Pharmacokinetics of Naproxen Sodium
According to MICROMEDEX DRUGDEX® database, naproxen sodium is a member of
the following dug classes: analgesic, antimigraine, antirheumatic, central nervous system agent,
musculoskeletal agent, NSAID, and a proprionic acid (Table 2). Naproxen sodium provides its
initial analgesic response in ~30 minutes, reaches peak blood concentrations ~1-2 hours, and
endures ~12-15 hours after oral administration. Naproxen ranked twelfth on a list of the top forty
17

most commonly used prescription and non-prescription drugs (Kaufman, 2002). Between 2008 and
2009, use of ibuprofen increased 6.9%, while use of naproxen increased 0.4% (SDI/Verispan, 2009).
Naproxen sodium is the only non-prescription NSAID with a long half-life, a characteristic which
seems to improve compliance (Koester, 1993; Leadbetter, 1995). Its bioavailability is complete, and
effects of food on its absorption are clinically insignificant. After absorption, 99% is protein-bound;
however, some distributes to synovial fluid. Naproxen sodium undergoes extensive metabolism in
the liver, where it is broken down into two inactive metabolites: 6-desmethyl-naproxen and
glucuronide conjugate. After undergoing metabolism in the liver, nearly all (95%) of naproxen is
excreted in the kidneys, with 28% of that being demethylated naproxen and the remainder being
glucuronidated naproxen (MICROMEDEX, 2011)

Incidence of Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Non-steroidal anti-inflammatory drugs are used for their analgesic, antipyretic, antiinflammatory, and anticoagulant effects (Hertel, 1997). The use of NSAIDs as a therapeutic
modality for EIMI has increased dramatically over the last 20 years, in conjunction with the growing
popularity of exercise and sport (Lanier, 2003). NHANES data revealed the number of Americans
using NSAIDs on a frequent monthly basis doubled between 1994 and 2000 (Paulose-Ram, Hirsch,
Dillon and Gu, 2005).
Exercise-associated pain has been described as a “lurking threat” to movement fluidity and
maximum performance (Reider, 2009). While various treatment modalities exist for the relief of
exercise-associated pain, NSAIDs remain the most popular choice. Numerous studies have revealed
a pervasive use in a range of populations, much of this without regard for label directions and the
potential for adverse reactions (Chambers, Reid, McGrath and Finley, 1997; Tricker, 2000;
Kaufman, 2002; Warner, 2002; Corrigan and Kazlauskas, 2003; Paulose-Ram et al., 2005; Wilcox,
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Cryer and Triadafilopoulos, 2005; Gorski, Cadore, Pinto, da Silva, Correa, Beltrami and Kruel, 2009;
Tscholl, Feddermann, Junge and Dvorak, 2009; Wolf, 2011) (Table 3).

Table 3
Prevalence of NSAID Use in Various Populations
Study

Population (sample size)

Prevalence (%)

Corrigan & Kaslauskas (2000)

Olympic athletes (n=2,758)

25.6

Chambers et al. (1997)

Junior high students (n=651)

58.7-95.9

Gorski et al. (2009)

Ironman athletes (n=327)

59.9

Kauffman et al. (2002)

US adults (>18 yrs.) (n=2590)

17-23

Paulose-Ram et al. (2005)

US adults (>20 yrs.) (n=4,880)

20-34

Tricker (2000)

Collegiate athletes (n=563)

55-62

Tscholl et al. (2009)

Elite soccer players (n=2,488)

17.3-30.7

Warner et al. (2002)

High school football players (n=651) 75

Wilcox et al. (2005)

US adults (>18 yrs.) (n=9,062)

17-83

Wolf et al. (2010)

Collegiate football players (n=144)

73

Furthermore, much literature has revealed the majority of users independently decide to
medicate. Aside from analgesia, a desire to accelerate healing, to permit an earlier return to
competition, to mask injury with prophylactic use, and to improve performance are oft-cited reasons
for using analgesics (Tricker, 2000; Reider, 2009). While NSAIDs are useful for treating pain and
inflammation, the ease with which these drugs can be procured, along with a lack of knowledge
concerning potential adverse effects, create a potential for misuse and abuse. The next few sections
will describe use in a range of populations.
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NSAID Use - U.S. Adult Population
Several important surveys examining the frequency of use of NSAIDs have been conducted
over the past several years. Wilcox, Cryer, and Triadafilopoulos (2005) examined patterns of use and
public perceptions of non-prescription NSAIDs using combined data from the 1997 Roper survey
(n=4,799) and the 2002 National Consumers League (NCL) survey (n=4,263). The Roper survey
was commissioned by the American Gastroenterological Association and conducted by Roper
Starch Worldwide Proprietary Telephone Research Center in September and October 1997. The
NCL survey was conducted December 16-29, 2002 by Harris Interactive, one of the largest market
research and consulting firms in the world. The Roper survey included both prescription and nonprescription analgesics, while the NCL survey examined only non-prescription analgesics. Although
not an NSAID, acetaminophen was included in both surveys; however, those who used
acetaminophen exclusively were excluded from the Roper results.
With use defined as having used prescription or non-prescription pain relievers for any type
of pain on at least 2 occasions in the past 12 months for at least 5 consecutive days at a time, the
Roper survey reported non-prescription analgesic use in 17% of respondents. Of these, 30% used
prescription only, 32% used non-prescription only, and 38% used a combination. Of those who
used non-prescription NSAIDs exclusively, the median duration of use was 5 years. Seven percent
reported use for <2 years, while 16% reported use for >15 years. Twenty-seven percent used nonprescription NSAIDs on a daily basis, while 73% used on an as-needed basis. Twenty-six percent
consumed more than the recommended amount, while 57% used the exact dosage. Compared to
the values presented for exclusive non-prescription users, prescription users’ mean duration of use
was 6.6 years, with 44% reporting daily use, and 8% reporting a tendency to consume a dose larger
than the one prescribed.
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The NCL survey found 83% of respondents reported use of a non-prescription analgesic in
the past year. Fifteen percent reported daily use, 29% reported frequent weekly use, and 27% report
frequent monthly use. Of daily users, the frequency of daily use ranged from once (44%) to five or
more (5%) times per day, with a median of two. Alarmingly, it was daily users who were less likely
to be concerned about potential side effects from non-prescription medications compared to those
taking non-prescription medications on a frequent monthly basis. Of the 27% of respondents who
reported frequent monthly usage, the median uses per month were two, with 24% using nonprescription NSAIDs five or more times per month. Forty-four percent consumed more than the
recommended dosage, which could be achieved by taking the next dose sooner, taking more pills at
a single time, or taking more doses per day than directed by the label. The most often reported
reasons for non-prescription NSAID use included arthritis or joint pain (42%), back pain (41%), and
muscular ache (40%).
The NCL survey reported 63% of non-prescription analgesic users selected NSAIDs (versus
acetaminophen) when taking non-prescription analgesics, with ibuprofen-based medicines chosen by
38% of non-prescription users. The popularity of ibuprofen-based drugs was also seen in the Roper
survey, with 57% of respondents selecting ibuprofen-based drugs most often. The NCL survey also
highlighted gender differences in reasons for non-prescription NSAID use, with women being more
likely to consume NSAIDs for headaches, migraines, and arthritis, and men being more likely to use
them for sport or exercise-related pains. Opposite findings have been reported in athletic female
populations, however, with female soccer players reporting greater NSAID use than their male
counterparts (Tscholl et al., 2009). By demographically weighting results according to U.S. Census
Bureau figures, Wilcox et al.’s (2005) extrapolation of their finding to the general population
suggested 36 million Americans use non-prescription pain relievers daily, with approximately 23
million using NSAIDs. Twenty-five percent of these users exceed the recommended dosage.
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Kauffman, Kelly, Rosenberg, Anderson, and Mitchell (2002) conducted the Slone Survey
(n=2,590) between February 1998 and December 1999. With a sample reflecting the general
population according to U.S. Census Bureau data comparison, participants were asked about use of
prescription and/or non-prescription drugs, vitamin/mineral supplements, and any herbal
supplement taken seven days preceding telephone contact. Eighty-one percent (81%) of participants
had taken at least one medication during the preceding week, and 25% took at least 5 medications.
According to the authors, these percentages reflect use in 169 million and 52 million individuals,
respectively. Rates of use of these medications increased with age and were greater in women than
in men in every age group. The finding of increased rates of use with age has been confirmed in
other studies of differing populations (Chambers et al., 1997; Tscholl et al., 2009; Wolf, 2011).
Among FDA-regulated drugs, non-prescription analgesics were the most frequently used
individual products, taken by 17-23% of the population. Of the three categories of medication
inquired, acetaminophen, ibuprofen, and aspirin were the top three drugs used. Other research
demonstrated these drugs are also the analgesics most commonly used on a frequent monthly basis,
in addition to being the three products most commonly obtained without a prescription (PauloseRam et al., 2005). The Slone Survey revealed ibuprofen was more frequently used by younger (18-44
years) subjects. Estimates provided by the Slone Survey were only for aspirin, acetaminophen, and
non-aspirin NSAIDs (ibuprofen, piroxicam, diclofenac, sulindac, indomethacin, naproxen, and
tolmetin). Of the non-aspirin NSAIDs, ibuprofen was chosen by 80% of lifetime frequent monthly
users, confirming findings by others (Kaufman, 2002; Wilcox et al., 2005). The data also revealed
males had a greater tendency to use aspirin on a frequent monthly basis, while females had a greater
tendency to use acetaminophen and non-aspirin NSAIDs on a frequent monthly basis.
In a report generated from 1999-2000 National Health and Nutritional Examination Survey
(NHANES), Paulose-Ram, Hirsch, Dillon, and Gu (2005) presented data concerning frequent
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monthly use of non-prescription and prescription non-narcotic analgesics among U.S. adults. The
cross-sectional survey (n=4,863) was characterized by detailed in-person home interviews and a
standardized health examination. ‘Lifetime’ frequent monthly users were defined as individuals who
ever used a pain reliever nearly every day for as long as a month. ‘Current’ frequent monthly users
were defined as lifetime frequent monthly analgesic users who were currently using a pain reliever daily
or nearly every day (Paulose-Ram et al., p. 258).
According to 1999-2000 NHANES data, approximately 20% of U.S. adults met the criteria
for lifetime frequent monthly use, doubling NHANES III (1988-1994) data, in which only 10% of
U.S. adults met the criteria for frequent monthly use. Seventy-two percent of these lifetime frequent
monthly analgesic users reported currently using an analgesic nearly every day for as long as a
month. Additional comparisons to NHANES III data also revealed an increase in current frequent
monthly use in 20-39 and 40-59 year old age groups. In addition to the 20% meeting criteria for
lifetime frequent monthly use, another 14% (27 million) were current frequent monthly users. Seven
percent (2 million) of these current frequent monthly analgesic users reported using two or more
analgesics nearly every day during the month. Thirty-six to forty percent of all lifetime frequent
monthly users reported a duration of use ranging 1-4 years.

NSAID Use - Pre-Adolescent and Adolescent Populations
To examine non-prescription medication use and self-administration among adolescents,
Chambers, Reid, McGrath, and Finley administered a survey to seventh, eighth, and ninth graders
(n=651). Their purpose was to determine the prevalence of non-prescription medication use for
different types of pain, source of medications, the level of responsibility adolescents assume for selfadministering analgesics, as well as potential relationships between both personal and pain
characteristics and self-administration.
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Fifty-eight to seventy-five percent of junior high students reported having taken a nonprescription medication for pain without first checking with an adult within the past three months.
It was suggested this large percentage evolved both from the observation of adults using nonprescription medications as well as direct instruction. Surprisingly, the mean age at which children
begin self-administering medication for muscle, joint, and back pain was reported to be 11.5 + 2
years of age. The study also revealed the tendency for self-administration increased with grade.
Ninety-seven percent (97.8%) of students surveyed reported experiencing muscle pain across a range
of frequencies over the previous three months. Of these, 83.8% chose to self-medicate, with
acetaminophen and ibuprofen being chosen by 85.3% and 26.7%, respectively. Of the different
types of pain assessed, muscle, joint, and back pain were second only to menstrual pain in terms of
highest pain intensity. While the muscle pain received the second highest average pain intensity
score, this type of pain was experienced by the largest number of participants (97.8%). Interestingly,
higher levels and frequencies of pain were related to higher scores for self-administration in all cases
except muscle, joint, and back pain. The authors suggested this may be due to the fact alternative
treatment strategies exist for such pain. Such information is meaningful given the potential for
adverse complications associated with long-term use of such drugs.

NSAID Use - U.S. Adolescent Athletic Population
Additional data highlighting the early self-administration of analgesics during adolescence
was provided by Warner, Schnepf, Barrett, Dian, and Swigonski (2002), who analyzed selfadministered questionnaires given to high-school football players (n=681). Attitude was assessed
through questions concerning potential beliefs that NSAIDs benefited performance by decreasing
pain, lessening fatigue, and/or reducing cramping. Behavior was assessed through questions
concerning independent or guided/directed use, prophylactic versus therapeutic use, and use before
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versus after practice or games. Of those surveyed, 90% were white males (mean age 15.8 years).
Seventy-five percent reported using an NSAID over the past 3 months, and 15% reported daily use.
Daily use was greater in those with the attitude NSAIDs aided performance, those who decided
independently, and those who used NSAIDs to block pain. The survey was distributed by the
coach, which the authors cited as a limitation of the study, as the possibility for dissuasion by the
coach could result in underreporting.
Similar rates of use were revealed by Wolf, Miller, Pescatello, and Barnes (2011), who
examined use of non-prescription analgesics by NCAA Division I-A football players (N=144). The
Over the Counter Drug Screen for Athletes, a 23-item survey, was utilized to assess use, dose, and
consecutive days of use. Seventy-three percent of participants reported using non-prescription
analgesics for football-related pain, with offensive players (85%) reporting greater use than both
special teams’ players (75%) and defensive players (59%). Those with more years of football
experience were also more likely to use non-prescription analgesics than those with less experience,
corroborating research showing use increasing with age (Chambers et al., 1997; Kaufman, 2002).
Ibuprofen was the most commonly chosen analgesic, selected by 80% of football players,
confirming the analgesic’s popularity as reported in other surveys of the general adult population
(Kaufman, 2002; Paulose-Ram et al., 2005; Wilcox et al., 2005). Ibuprofen was followed by aspirin
(71%), acetaminophen (29%), naproxen sodium (20%), and ketoprofen (3%). Six percent of those
using non-prescription analgesics reported use for more than 10 consecutive days or daily. Of these,
78% believed they could take non-prescription analgesics as long as they wanted. Sixty-five percent
used the recommended dose or less, while 35% used more. Twenty-five percent indicated they read
labels every time they used non-prescription analgesics, while 22% read them only prior to the first
use, and 15% never read label directions. Not surprisingly, those who did not read label directions
were more likely to take a dose larger than that recommended.
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Sixty-four percent self-decided to use non-prescription analgesics, with the remainder using
such medicines at the recommendation of individuals ranging from the team physician to a
teammate. Nearly half (47%) self-purchased these medication versus reception from an athletic
trainer or physician. Those who self-purchased were also more likely to use more than the
recommended dose (51%). Forty-one percent reported using non-prescription analgesics in
anticipation of pain, and 31% used them to avoid missing a practice or game.
Tricker (2000) examined the frequency of use, as well as knowledge and attitudes concerning
use of prescription and non-prescription analgesics in student athletes (N=563) from two NCAA
Division I universities. The sample was comprised of males and females representing all sports in
which the universities participated. Fifty-five percent reported use of painkilling drugs to alleviate
soreness after workouts or competition. Fifty-eight percent regularly used painkillers throughout the
duration of the season, and 62% used them after tough workouts. Fifty-eight to sixty percent
obtained these medications from teammates or friends, while only 14% obtained from a physician.
Based upon responses to a set of attitude questions, nearly one-third (29%) of the total
sample was defined as high risk for painkiller abuse (n=165). These student athletes perceived
nothing wrong with the use of painkilling medications on the day of competition to prevent
competing in pain, and this perception was significantly higher in males than females. Twenty-one
percent reported they would take painkillers when injured to facilitate participation, while 32% were
undecided on this matter. Thirty-three percent of this subset reported they felt painkilling drugs
were necessary to facilitate recovery from participation in sporting events, while 33% were
undecided. Analysis revealed many athletes felt that not only are painkilling drugs necessary to
overcome soreness but also are necessary to achieve success in sport.
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NSAID Use - International Athletic Population
To describe the use of analgesics in female and adolescent male soccer players, Tscholl,
Feddermann, Junge, Dvorak (2009) performed a descriptive epidemiological study, gathering data
obtained from team physicians at six FIFA (Federation Internationale de Football Association)
World Cup tournaments. Information was collected in connection with doping controls carried out
during the FIFA Women’s World Cup 2003 and 2007, and the FIFA U-17 and U-20 World Cup
2005 and 2007. All team physicians were asked to give a certification of medication that s/he
prescribed to all qualified players in the 72-hours preceding match play. Substances were classified
as painkilling and NSAIDs, other analgesics, injected corticosteroids and local anesthetics, muscle
relaxants, respiratory agents, intestinal medication, antimicrobial medication, contraceptive
medication, and other medication, including psychotropics and topical corticosteroids.
NSAIDs were the most frequently prescribed type of medication in all tournaments.
Compared to adolescent males, a larger percentage of females used NSAIDs per match, with 30.7%
of females reporting use versus 17.3% of U-17 males and 21.4% U-20 males. Females in this study
were found to take NSAIDs at a rate comparable to professional male soccer players, which had
previously been reported at 30.8% before tournament play (Tscholl, Junge and Dvorak, 2008).
Rates of use over the entire tournament duration (~1 month) were expectedly higher, with 41.9% of
U-17 males, 45% of U-20 males, 51.1% of professional females, and 54.5% of professional males
using NSAIDs. Of all players taking NSAIDs, 8.9% were using at least two preparations. The
liberal use of NSAIDs highlighted by Tscholl et al. (2009) led to speculation whether these
medications were being prescribed solely for therapeutic purposes. Indeed a discrepancy between
the frequency of drug use and the rate of acute injuries, as reported by team physicians’ medical
diagnoses, was noted to exist. These discrepancies were believed to suggest a prophylactic approach
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to analgesic prescriptions (Reider, 2009). Corrigan and Kazlauskas (2003) also reported an abusive
and dangerous use of NSAIDs in Olympic athletes during the 2000 Sydney Olympics.
In summary, research has shown use of NSAIDs begins at an early age and continues
throughout the lifespan. Unfortunately, many consumers do not adhere to dosing guidelines and
many are unaware of the consequences of long duration and/or larger-than-recommended dosages.
The next sections will describe the structure of skeletal muscle, with subsequent description of the
effects of NSAIDs on various indices of muscle physiology and performance.

Skeletal Muscle Anatomy & Physiology
Individual skeletal muscle cells (muscle fibers) develop as a result of the fusion of embryonic
stem cells called myoblasts, whose growth into large multi-nucleated cells requires multiple steps.
Each nucleus reflects the contribution of a single myoblast. The multi-nucleated characteristic of
muscle cells allows protein metabolism within a given fiber to be differentially regulated along its
length by the respective nuclei in a given nuclear domain (Kraemer, Vingren and Spiering, 2008).
Upon receipt of the appropriate stimulus, new proteins are incorporated as either non-contractile
structural elements or as contractile proteins actin and myosin into existing or new sarcomeres
(Kraemer et al., 2008).
Nucleic genes direct the production of enzymes and structural proteins required for normal
muscle contraction. The presence of multiple copies of these genes accelerates this process and is
an important feature due to rapid metabolic turnover in skeletal muscle fibers. Metabolic turnover is
the continual removal and replacement of temporary organic molecules and reflects cellular
adaptation to environmental stimuli. The average recycling time for muscle cell total protein is 30
days (Martini, 2004).
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Mature skeletal muscle fibers are incapable of dividing, so new muscle fibers are produced
through divisions of adult myoblasts or satellite cells. Satellite cells have aptly been described as a
population of muscle-derived stem cells whose activity provides the potential for skeletal muscle to
repair after injury (Crameri et al. 2004; Mendias et al. 2004). Satellite cells provide new myonuclei
during hypertrophy and assist in repair of damaged muscle fiber segments (Mendias, Tatsumi and
Allen, 2004; Mikkelsen et al., 2009). Satellite cells are generally located under the basal lamina but
can also found outside the fiber within the endomysium (Mackey, Kjaer, Dandanell, Mikkelsen,
Holm, Dossing, Kadi, Koskinen, Jensen, Schroder and Langberg, 2007; Novak et al., 2009).
Once activated, satellite cells give rise to myoblasts. While satellite cell activation is
necessary for skeletal muscle development, it represents only the first stage of the cell cycle, which
sequentially includes proliferation, differentiation, alignment, and fusion. Fusion allows increased
protein synthesis and increases in cell size (Horsley and Pavlath, 2003). After satellite cell fusion
with the existing myofiber, muscle cell size continues to increase through enhanced protein
synthesis, which is regulated by specific prostaglandins and their effects on protein degradation and
synthesis (Smith, Palmer and Reeds, 1983; Palmer, 1990; Trappe et al., 2002).
Each phase of the cell cycle is necessary for the incorporation of new proteins into a muscle
in order to maintain a constant nuclear domain ratio (Crameri et al. 2004), and each phase of the cell
cycle is dependent upon myogenic regulatory factors (MRFs), including myo-D, myf-5, pax-7,
myogenin, and mRF-4 (myf 6). Myoblast proliferation is governed by a multitude of signaling
cascades initiated by various cytokines and autocrine/paracrine growth factors, including
prostaglandins (Otis et al., 2005). During the repair process, satellite cells proliferate and migrate
into the necrotic area, where they differentiate into myoblasts. If the endomysium is still intact,
satellite cells will fuse to damage fibers; however, if the endomysium is ruptured, satellite cells will
escape into interstitial fluid where they will align and fuse to produce a new fiber (MacIntosh, 2006).
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It is probable that the interaction of myogenic genes (genes that code for myogenic regulatory
factors) and growth factors during regeneration is similar to that occurring during embryological
muscle development (MacIntosh, 2006), although the role for PGF2α has been shown to be
dependent on the developmental stage of the myotube (Horsley and Pavlath, 2003).
It has been suggested primary activation of satellite cells most likely occurs roughly one week
after resistance and aerobic exercise (Crameri, Langberg, Magnusson, Jensen, Schroder, Olesen,
Suetta, Teisner and Kjaer, 2004; Mackey et al., 2007; Mikkelsen et al., 2009). It appears the extent of
satellite cell proliferation is influenced by both the prior training status of the individual as well as
the type of exercise, with a single bout of maximal eccentric muscle actions on an isokinetic
dynamometer inducing a much stronger satellite cell response than a bout of regular resistance
training (Crameri et al., 2004; Mackey et al., 2007; Mikkelsen et al., 2009). Aerobic exercise also
stimulates satellite cell activation, as demonstrated by Mackey et al. (2007), who reported a
significant increase in satellite cells in male endurance athletes (n=14) eight days post-36 km run.
Satellite cells are not only needed for the regeneration of damaged muscles fibers but also for
the general adaptation to muscle loading (Mikkelsen et al., 2009). Force itself may directly activate
satellite cells by force transduction via integrins (plasma membrane proteins that anchor actin and
myosin myofilaments) on the satellite cell surface (MacIntosh, 2006; Mikkelsen et al., 2009).
Crameri et al. (2004) reported a single bout of eccentric exercise performed by sedentary males
(n=8) is sufficient for satellite cell activation, but terminal differentiation of these cells is dependent
upon additional bouts of exercise. Taken together, the results of Crameri et al. (2004), Mackey et al.
(2007), and Mikkelsen et al. (2009) indicate satellite cell activity is influenced by both the intensity
and frequency of exercise.
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Pathophysiology of Muscle Injuries – Inflammation & Regeneration
Skeletal muscle inflammation can result from a variety of stimuli, including biological
(venoms, streptococcus), thermal, chemical (pathogens), and mechanical sources. Examples of the
latter include strains, contusions, lacerations, and exercise-induced muscle injury (EIMI). The
pathophysiology of mechanical modes of injury varies somewhat between strain, contusion, and
laceration models and that produced by exercise, with the former injury models being characterized
by an inflammatory response of a larger magnitude. Although muscle fiber damage occurs with
aerobic forms of exercise such as downhill running (Donnelly et al., 1990), the eccentric phase of
resistance training is particularly associated with the occurrence of exercise-induced muscle injury.
The initial inflammatory response is directed at the tissue level and is characterized by the
cardinal signs of inflammation - swelling, redness, warmth, and pain (Martini, 2004). With EIMI
specifically, diffuse muscle pain, swelling, and stiffness characterize the acute inflammatory response.
Regardless of the exact mechanism of injury, each results in the unregulated influx of calcium into
the muscle through abundant stretch-activated calcium channels located on the fiber membrane.
Once inside the muscle cell, calcium ions activate a calcium-activated protease known as calpain and
phospholipase A2, which digest structural proteins and lipid membranes, respectively (MacIntosh,
2006). Along with calcium, the increased blood flow occurring during exercise also activates
membrane-bound G-protein coupled receptors associated with various prostaglandins, further
contributing to the activation of phospholipase A2, which frees arachidonic acid from the
phospholipid bilayer with subsequent metabolism within the COX pathway to produce
prostaglandins (Boushel et al., 2002).
Damaged cells release prostaglandins, proteins, and postassium ions (Martini, 2004). These
changing chemical conditions alter the composition of the interstitial fluid and potentiate the
inflammatory response through the activation of mast cells, small mobile connective tissue cells
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found near blood vessels. Like COX-2, mast cells play a pivotal role in the inflammatory response,
being stimulated by mechanical stress or chemical changes in the local environment. Mast cells
contain histamine, heparin, and prostaglandins, all of which further potentiate the local
inflammatory response (Martini, 2004). PGE2 and PGI2 trigger vasodilation (Boushel, Langberg,
Risum and Kjaer, 2004), while histamine and bradykinin increase capillary permeability and
accelerate the flow of blood into the injured area (Martini, 2004). This increased blood flow elevates
local temperature, increasing the rate of enzymatic reactions and accelerating phagocytic activity
(Martini, 2004).
Strains and contusions are characterized by a disruption of fiber architecture, including both
ruptured muscle fibers and connective tissue. Hematoma, an abnormal localized collection of
clotted or partially clotted blood, and necrotic tissue are generally obvious at the site of injury. The
initial acute inflammatory response is followed by a more intense inflammatory response within 2-3
days. Myoblasts provide evidence of regeneration within the first week, and fibroblasts mount a scar
response (Almekinders, 1999). The combined regenerative and scar responses result in a healed
muscle that has fewer and smaller muscle fibers in the injured area as well as an increased amount of
collagenous tissue between the fibers (Almekinders, 1999).
Dynamic resistance training is characterized by repeated concentric and eccentric muscle
actions. Although the metabolic demands of eccentric activity are less than that for concentric and
isometric activity, eccentric activity causes the greatest change in muscle function (Jones et al., 1989).
Although the number of strongly attached cross bridges during eccentric activity is only 10% greater
than that during isometric activity, the force developed during eccentric activity is approximately
twice that developed during isometric activity (MacIntyre et al., 1996). Furthermore, although EMG
activity is significantly greater (~40%) during concentric action, as demonstrated by Gibala,
MacDougall, Tarnopolsky, Stauber, and Elorriaga (1995), approximately 40% of skeletal muscle
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damage occurs during the eccentric phase, as demonstrated by magnetic resonance imaging (Baldwin
et al., 2001) and electron microscopy (Gibala et al., 1995). However, the rates fractional synthesis,
fractional breakdown, or the net balance between the two, has not been found to be significantly
different between concentric versus eccentric activity (Phillips et al., 1997).
In a comparison of the effects of concentric versus eccentric muscle actions in untrained
men, Gibala et al. (1995) reported eccentric exercise resulted in significantly more myofiber
disruption, as well as a persistent depression of voluntary and evoked strength measures compared
to concentric activity. Jones, Newham, Torgan (1989) also reported eccentric activity caused greater
fatigue and DOMS than either isometric or concentric activity. Contraction type is an important
study characteristic to note, as static muscle activity has not been shown to increase protein
synthesis as seen in dynamic muscle action (Smith et al., 1983).
In comparison to the pathophysiology of strains and contusions, DOMS is characterized by
a limited inflammatory response (Almekinders, 1999). Morphological changes are barely evident
within the first 24-hours and are then restricted to Z-disk streaming (MacIntosh, 2006); however,
Mishra et al. (1995) reported myofibrillar damage in the A-band of the sarcomere as well. According
to MacIntosh (2006), 10-15 days post-exercise-induced injury, a significant proportion of skeletal
muscle fibers have undergone necrosis; however, Crameri et al. (2004) reported necrosis in only one
of eight sedentary male subjects after one session of intense isokinetic eccentric exercise,
demonstrating that necrosis is not necessary for satellite cell activation. Fibroblast activation does
not seem to occur in DOMS as seen in strain and contusion injury models (Almekinders, 1999).
Furthermore, the regenerative response associated with EIMI appears fully capable of restoring the
muscle’s architecture in contrast to strain and contusion models (MacIntosh, 2006).
Symptoms of EIMI are resolved at different rates. Acute soreness subsides before muscle
function recovers. Human research (n=3, males) has reported recovery of maximal voluntary
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contraction (MVC) strength in response to elbow flexion required 24-48 hours, while long-lasting
fatigue required 3-4 days to fully dissipate (Jones et al., 1989). Donnelly, Maughan, and Whiting
(1990) found isometric MVC required 72 hours to recover in untrained males (n=40; 18-30 years)
post-downhill running. Other human research has demonstrated significant decreases in isometric
MVC persisting 10 days post-resistance exercise (Pizza et al., 1999), while others have reported
recovery of isometric MVC 8 days post-acute resistance training (Mikkelsen et al., 2009). Lanier et
al. (2003) reported strength reductions of 30-60% 24-48 hours post-exercise followed by a continued
depression for two weeks. Crameri et al. (2004) found necrosis resulting from a single bout of high
intensity eccentric work in sedentary males required 8 days for full recovery. Howell, Conatser,
Chleboun, Karapondo, and Chila (1998) found isometric strength had recovered only 50% 14 days
post-acute elbow flexion exercise (70-90% maximum voluntary isometric force performed for an
average of 18.6 repetitions) in a young untrained co-ed population (n=24). Animal studies
employing in situ eccentric activity injury models have demonstrated resolution of exercise-induced
inflammation by two weeks and complete regeneration by 3 weeks (Mishra et al., 1995; Pizza et al.,
2002). It appears the length of the recovery phase is dependent not only on the parameter of muscle
recovery examined but also on the model of injury.
In defense of a prophylactic approach to NSAID use for exercise-associated pain, some have
cited an increased risk for injury if activities are undertaken while symptoms of DOMS are evident,
while others have cited the potential for exercise-associated pain to discourage future participation in
exercise (Donnelly et al., 1990; Baldwin et al., 2001). Furthermore, a prophylactic approach has been
demonstrated to be more effective for exercise-associated pain relief in humans (Hasson et al., 1993)
and fever resulting from endotoxin injection in rats (Goldberg, 1988).
While certain characteristics of the inflammatory response are dependent upon stimulus
characteristics, the inflammatory response is also influenced by individual factors such as sex and
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training status. One study found significantly higher radionuclide-labeled neutrophils in females
(n=10) versus males (n=12), as well as a biphasic pattern of eccentric torque recovery in females that
was not exhibited in males (MacIntyre et al., 2000). Neutrophils were significantly higher in females
2 hours post-eccentric exercise, but sex difference were no longer evident at 4 hours (MacIntyre et
al., 2000). In this study, recreationally-trained was defined as less than but not greater than or equal
to 6 hours of recreational exercise, not including jogging or weight training, and damage was
produced by the performance of 300 fatiguing eccentric contractions on an isokinetic dynamometer.
Conversely, using a muscle biopsy technique, another study of males (n=8) and females
(n=8) reported plasma granulocyte (neutrophils, basophils, eosinophils) counts decreased in females
but increased in males 48 hours after eccentric exercise (Stupka et al., 2000). In this study, all
participants were engaged in some form of moderate cardiovascular training but no resistance
training. Damage was produced by performance of 12 sets of 12 eccentric muscle actions of lower
body musculature at 120% concentric one repetition maximum. Stupka et al. (2000) concluded
muscle damage resulting from eccentric exercise is similar between the sexes, but the inflammatory
response is attenuated in women versus men. These findings are important to bear in mind when
considering research involving exercise-induced inflammation, NSAIDs, and co-ed subjects.

Necessity of Inflammation
To test the hypothesis that suppression of the inflammatory reaction after an initial bout of
eccentric muscle actions attenuates adaptation, Lapointe, Fremont, and Cote (2002, 2003)
investigated the effects of twice–daily diclofenac (non-selective acetic acid NSAID) given
therapeutically for either two or seven days beginning six hours after an initial bout electrical
stimulation of rat skeletal muscle. Diclofenac almost completely abolished the increase in serum
PGE2 levels normally accompanying electrical stimulation and voluntary contraction.
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After the initial bout of stimulation, the placebo group suffered a significant decrease in
absolute and specific tension compared to its pre-bout value. The 2–day diclofenac group also
suffered a significant decrease in tension compared to its pre-bout value; however, its deficit was
significantly less than that experienced by the placebo group, seemingly demonstrating a short-term
protective effect of diclofenac treatment.
A second bout of electrical stimulation was performed fourteen days later, at which time all
groups had returned to baseline. Two days after this second bout, only the 7–day diclofenac group
showed significant deficits in absolute tetanic tension compared to its corresponding pre-bout value.
Both treatment durations resulted in significant decreases in specific tension compared to
corresponding pre-bout values; however, the 7-day diclofenac group showed significantly less
specific tension versus the 2-day treatment group.
Inflammatory molecules, including ED1+ and ED2+ macrophages, were measured to
examine the acute inflammatory response. ED1+ macrophages circulate as monocytes until
undergoing activation and appear 3-24 hours post injury, while ED2+ macrophages are the primary
resident macrophage population in skeletal muscle and appear to be elevated 24-48 hours postlaceration injury (McLennan, 1996). Over the fourteen days between bouts, ED1+ macrophages
remained significantly elevated in both NSAID-treated groups compared to placebo. These elevated
macrophage concentrations were taken to indicate a persistent inflammatory response. This
significant difference in macrophage concentration persisted even after the second bout. After the
second bout, ED2+ macrophages significantly increased only in drug groups. Both 2- and 7-day
drug groups exhibited significant increases in ED2+ concentrations compared not only to their
corresponding pre-bout value but also compared to placebo at that time point. The authors
suggested the lack of significant increase in the concentration of either subpopulation of
macrophages in the placebo group after the second bout could indicate a lack of muscle damage,
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indicating stimulus adaptation had occurred. Conversely, adaptation in the treated groups seemed to
have been impeded by diclofenac. According to the authors, the repeated bout effect was most
prominent in terms of force production in the control rats which experienced a “non–existent”
inflammatory response to the second bout. The authors concluded by stating inflammation should
be viewed as an integral component of skeletal muscle repair and adaptation.
Animal research has reported a more complete functional recovery three and seven days
post-electrical activation in rabbits (Mishra et al., 1995), attenuated force decrements in rats two days
post-electrical stimulation (Lapointe et al., 2002; Lapointe et al., 2003) and controlled muscle strain
injury in NSAID-treated animals (Obremsky, Seaber, Ribbeck and Garrett, 1994). Although these
acute results appear beneficial, measurements performed at later time points showed disparities
between drug and control groups. Mishra et al. (1995) reported force and torque deficits in NSAIDtreated animals versus controls twenty-eight days post-electrical stimulation. These results were
corroborated by Lapointe, Fremonte, and Cote (2002, 2003) who reported NSAID-treated rats
continued to exhibit significant force decrements after subsequent bouts of stimulation compared to
controls. Shen, Li, Tang, Cummins, Huard (2005) also reported disadvantages to NSAID ingestion,
manifested in delayed and blunted muscle regeneration and increased fibrosis seven and fourteen
days post-laceration.
Similar to animal research, human research has also reported initial short–term advantages of
NSAID ingestion after contraction-induced injury (Hasson et al., 1993; Dudley et al., 1997;
Bourgeois et al., 1999; Baldwin et al., 2001). Concentric and isometric strength was reported to be
preserved three days post-acute exercise accompanied by consumption of naproxen sodium in older
males and females (Baldwin et al., 2001). What remains to be known is if these short term
improvements are followed by performance decrements at later time points, as demonstrated in
animal literature.
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Prostaglandins
Hormones can be divided into four groups: peptide and protein hormones, steroid
hormones, monoamines, and lipid-based hormones. Prostaglandins (PGs) are a type of eicosanoid,
or lipid-based hormone, derived from the unsaturated fatty acid arachidonic acid, Figure 1.

Figure 1

Chemical Structure of Arachidonic Acid and Prostaglandin

In contrast to traditional hormones, prostaglandins are not secreted from a specific gland.
Prostaglandins may be produced by all cells except erythrocytes (Ciccone, 1990; Koester, 1993;
Pettipher, 1998; Rifai et al., 1999), but the majority are produced from the 20-carbon (C20) fatty acid
known as arachidonic acid (C20:4) located within the phospholipid bilayer by the COX enzyme (Rifai
et al., 1999; Boushel et al., 2004). Within the circulation, the vascular endothelium is the most
prominent source of prostaglandin formation (Boushel et al., 2004), with PGI2 being the major
COX product in endothelial cells (Pettipher, 1998).
The majority of prostaglandins operate in autocrine or paracrine fashion, indicating local
production and exertion of local effects. According to Mikkelsen, Helmark, Kjaer, and Langberg
(2008), concentration of prostaglandins increases locally in response to exercise. Almekinders,
Banes, and Ballanger (1993) found PGE increased 1.3 – 1.8 fold as a result of cyclic deformation of
cultured human tendon fibroblasts. Likewise, Otis, Burkholder, and Pavlath (2005) found levels of
PGE2 and PGF2α significantly increased in stretched culture media 6 hours after cessation of stretch.
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PGE2 itself is considered a pro-inflammatory molecule. It is produced and released by
ED1+ macrophages (Scott, Khan, Roberts, Cook and Duronio, 2004) and in response to in vitro
cyclic deformation (Almekinders, Banes and Ballenger, 1993). It is the predominant eicosanoid
detected in humans in inflammatory conditions ranging from acute edema to chronic arthritis (Vane
and Botting, 1996). Prostaglandins are extremely potent and are capable of producing physiological
actions at concentrations as low as 1µg/L (Rifai et al., 1999).
Skeletal muscle membrane disruption leads to an increase in intracellular calcium. This
calcium then activates phospholipase A2, which cleaves arachidonic acid (AA) from the membrane
phospholipid bilayer. Once arachidonic acid is free, it can proceed either of two ways: it may be
converted into leukotrienes through the lipoxygenase pathway or into prostaglandins or
thromboxanes through the cyclooxygenase pathway. Exactly what controls entry into a specific
pathway remains speculative (Rifai et al., 1999); however, it has been shown that production of
leukotriene B4 (LTB4) is increased when prostaglandin production is inhibited (Almekinders et al.,
1993). Free arachidonic acid is then acted upon by the PG synthetase complex, an enzyme complex
that includes COX. COX is required to produce the key cyclic endoperoxides intermediates - PGG2
and PGH2. PGH2 is then acted on by various isomerases to produce the various PG subclasses.
Exactly which prostaglandin is produced depends on enzymes present in the biosynthetic pathways
(Norman, 1997). Substitutions on the five-membered ring structure (Figure 1) determine the specific
subclass and activity. Sixteen naturally-occurring prostaglandins have been described. While seven
are commonly found throughout the body (Rifai et al., 1999), only three - PGF, PGE, and PGA occur in abundance (Norman, 1997).
In denotation of prostaglandins, “F” stands for phosphate buffer-soluble structures, which
are the most hydrophilic or polar of the PGs. The E (ether soluble) series is intermediate in
solubility. Numerals and Greek symbols are two subscripts that may be used when designating PGs.
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The number denotes the number of double bonds in the structure. For instance, PGF2α has two
double bonds. The Greek letter following the number refers to the steric position of the C-9
substituent, with α specifically indicating extension behind the plane of the ring (Figure 1) (Norman,
1997).
PGF2α is one of five primary prostaglandins enzymatically derived from the cyclic
endoperoxide PGH2. PGF2α is rapidly metabolized to 13, 14-dihydro-15-keto PGF2 in vivo by the
enzymes 15-hydroxy PG dehydrogenase and ∆13-reductase (Trang, Granstrom and Lovgren, 1977).
Due to this rapid metabolism, estimated primary prostaglandins, including PGF2α, in the peripheral
circulation do not reflect the true endogenous levels of these compounds. However, the main
metabolites in plasma (13,14-dihydro-15-keto PGF2α) and urine (5α,7α-dihydroxy-11ketotetranorprosta-1,16-dioic acid) are much more stable, are not formed during sample collection,
and are the recommended target of measurement for PGF2α (Trang et al., 1977).
Prostaglandin synthesis can be regulated by controlling the activity of phospholipase A2 or
the COX enzyme. These two different mechanisms of control account for the differing actions of
steroids versus non-steroidal anti-inflammatory drugs. Steroids act early to inhibit phospholipase A2
through production of lipocortin (Norman, 1997), while NSAIDs act at a later stage to inhibit the
COX enzyme, through which arachidonic acid is converted into prostaglandins. Steroids inhibit the
formation of all prostaglandins, thromboxanes, and leukotrienes (Vane and Botting, 1996), while
NSAIDs do not affect leukotrienes or lipoxins (Norman, 1997). The COX enzyme is regulated by
analgesic drugs, as well as mechanical stimulation (Mendias et al., 2004; Otis et al., 2005).
After synthesis, prostaglandins are released into the cellular cytoplasm or cell exterior. In
either case, PGs mediate signaling through G protein-coupled receptors that are distinct for each
prostaglandin (Horsley and Pavlath, 2003). There are specific receptors for PGD2, PGE2, PGF2α,
and PGI2. These receptors can raise or lower cellular levels of cyclic AMP or stimulate
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phosphatidylinositol (IP3) metabolic pathway, both of which are major secondary signal transduction
pathways for G-protein coupled receptors (Norman, 1997). PGF2α facilitates increases in
intracellular calcium by binding to its receptor, FP (Breyer, Bagdassarian, Myers and Breyer, 2001;
Horsley and Pavlath, 2003). Horsely and Pavlath (2003) reported skeletal muscle cell growth is
mediated through the PGF2α receptor, which activates stretch activated calcium channels on the
skeletal muscle membrane.
Prostaglandins have pleiotropic effects in a range of cell and tissue types (Horsley and
Pavlath, 2003). Complicating the situation is the fact that a single prostaglandin may have opposing
effects at different times in the inflammatory response (Willoughby, 2000). PGs play an integral
role in the inflammatory response, sensitize nociceptors in a pain response, stimulate parturition,
contribute to the control of blood pressure (Norman, 1997), contribute to vasodilation and the local
control of blood flow during exercise (Wilson and Kapoor, 1993; Boushel et al., 2002; Mikkelsen,
Helmark, Kjaer and Langberg, 2008) stimulate in vitro proliferation and differentiation of human
and animal myoblasts (Zalin, 1987; Otis et al., 2005), stimulate in vivo human satellite cell
proliferation after exercise (Mackey et al., 2007; Mikkelsen et al., 2009), stimulate nuclei accretion to
existing myotubes (Horsley and Pavlath, 2003), and stimulate skeletal muscle protein metabolism
(Trappe et al., 2001; Trappe et al., 2002). Along with bradykinine, histamine, and nitrous oxide,
PGE2 and PGI2 are the two vasodilatory prostaglandins that facilitate shifts in fluid volume from the
blood to the intracellular compartment and cells as a result of exercise (Koester, 1993; Boushel et al.,
2002).

Prostaglandins and Pain
Prostaglandins, especially PGE2, play a crucial role in inflammatory reactions, signaling a
cascade of pro-inflammatory events including induction of vasodilation, increased vascular
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permeability, increased local blood flow, and increased body temperature via action on the
hypothalamus (Hertel, 1997). PGEs are released upon stimulation of sympathetic nerves and inhibit
adrenergic transmission by depressing responses to norepinephrine at a post-junctional synapse and
may also inhibit transmitter release from nerve terminals (Norman, 1997). Opposite effects are seen
with PGFs, which often heighten the responses of effectors to norepinephrine. PGF2α can facilitate
the release of epinephrine from the adrenal medulla (Norman, 1997).
PGE2 sensitizes type IV (C) nociceptors which transmit dull, aching pain to higher centers.
Along with Aδ fibers, C fibers represent the two classes of nociceptive afferents. Aδ fibers are
associated with sharp, focused pain, while C fibers are associated with dull, burning, diffuse pain, as
exemplified in DOMS (Norman, 1997). Endogenous chemicals such as PGE and bradykinin
facilitate spatial and temporal summation of nociceptor impulses, causing them to discharge at
stimulation levels below that eliciting a “frank sensation of pain” (Norman, 1997). These proinflammatory and algesic characteristics of prostaglandins are the fundamental reasons they are the
targets of non-steroidal anti-inflammatory drugs.

Prostaglandins and Skeletal Muscle Protein Metabolism
In addition to their roles in inflammation, prostaglandins (PGs) have been shown to
modulate skeletal muscle protein metabolism (Rodemann and Goldberg, 1982; Smith et al., 1983;
Trappe et al., 2001; Trappe et al., 2002). The following section will discuss human and animal
research demonstrating prostaglandins’ role in this activity vital to skeletal muscle adaptation to
resistance exercise.
Smith, Palmer, and Reeds (1983) proposed the primary effect of mechanical activity on
protein synthesis is the release of arachidonic acid from membrane-bound phospholipids. Human
and animal research has demonstrated arachidonic acid metabolites PGE2 and PGF2α increase locally
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as a result of resistance exercise (Smith et al., 1983; Langberg, Skovgaard, Karamouzis, Bulow and
Kjaer, 1999; Trappe et al., 2001; Boushel et al., 2002; Trappe et al., 2002; Mikkelsen et al., 2008), and
protein synthesis and degradation are then modulated through metabolites of this fatty acid
(Rodemann and Goldberg, 1982). Langberg et al. (1999) reported a 100% increase in the interstitial
concentration (ng/ml) of PGE2 in response to intermittent static plantar flexion. Trappe et al.
(2001) reported 70-80% and 60% increases (pg per mg wet weight) in PGF2α and PGE2 respectively
in response to acute intense eccentric knee exercise. Boushel, Langberg, Gemmer, Olesen, Crameri,
Scheede, Sander, and Kjaer (2002) reported an intensity-dependent release of PGs, with heavier
loads of dynamic knee extension (15W versus 45 W) eliciting a two-fold increase in interstitial PGE2
content (ng/ml). Using multiple microdialysis catheters inserted directly into exercising
musculature, Mikkelsen et al. (2008) reported PGE2 concentrations during exercise of 1,722 + 259 in
a control leg versus 879 + 183 and 400 pg/ml in a leg subjected to two local prostaglandin blocks
(indomethacin) via catheters at 4 and 1 cm sites. After exercise, PGE2 concentrations in a control
leg were 1,201 + 204 versus 876 + 168 and 318 pg/ml at 4 and 1 cm locations, respectively, in an
NSAID-blocked leg.

Prostaglandins and Skeletal Muscle Protein Metabolism – Animal Research
Some of the initial research illuminating prostaglandins’ role in protein turnover was
performed by Rodemann and Golderg (1982), who provided evidence for a role of PGE2 and PGF2α
in the acceleration of muscle protein metabolism in isolated rat skeletal (soleus and extensor
digitorum longus), atrial, and diaphragm muscles. With no mechanical stimulus, exogenous
arachidonic acid was supplied in vitro, bypassing phospholipase A2 activity. Production of the
known arachidonic acid metabolites - PGE2 and PGF2α - was measured by their release into
incubation medium during a 2-hour period using radioimmunoassay. In vitro incubation with
43

arachidonic acid elicited a 20-35% increase in degradation in soleus, EDL, and diaphragm muscles.
Addition of arachidonic acid caused no significant change in net protein synthesis in any of muscles
except the soleus (slow twitch), which repeatedly responded not only with a significant increase in
degradation but also a significant increase in synthesis (53%) upon addition of arachidonic acid. In
the soleus, however, the net effect of arachidonic acid was to shift the balance to a more catabolic
state. Differences in the response between the soleus and EDL may indicate potential differences in
patterns of prostaglandin synthesis between fast and slow twitch muscle fibers, but there is no
consensus linking fiber type and prostaglandin response (Palmer, 1990). However, type II fibers
have been reported to be more vulnerable to exercise–induced muscle damage (Lapointe et al.,
2002).
Rodemann and Goldberg (1982) additionally examined the effect of temperature on basal
and AA-stimulated degradation. Lower incubation temperatures (30-33°C versus 37°C) were found
to decrease basal protein degradation 20-30% without significantly affecting protein synthesis.
Adding arachidonic acid to the medium at this lower incubation temperature resulted in a greater
relative increase (40-50%) in net protein degradation compared to 37°C.
Three COX inhibitors (indomethacin, aspirin, meclofenamate) were then tested to elucidate
whether arachidonic-acid stimulation of protein degradation was due to increased prostaglandin
production. Theoretically, protein degradation should be blocked by COX inhibitors, which prevent
the formation of prostaglandins via COX inhibition. Similar to Lapointe et al. (2003), Rodemann
and Goldberg found indomethacin reduced arachidonic acid-induced stimulation of both protein
synthesis and degradation. When these tissues were incubated with indomethacin in the absence of
arachidonic acid, rates of protein synthesis and degradation were not altered. Therefore,
indomethacin, aspirin, and meclofenamate exert their specific inhibitory effects on protein synthesis
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and degradation through their actions on arachidonic acid metabolites generated in the COX
pathway.
Evidence to support this was provided even earlier by Vane (1971) who examined guinea pig
lung tissue supernatants incubated with arachidonic acid. Zero-point time samples contained 60-150
ng/ml of “PGF2α-like activity” and 120-750 ng/ml of “PGE2-like activity” (p.233). PGF2α and PGE2
did not increase when incubated in the absence of arachidonic acid; however, increases of 220-520
ng/ml and 100-500 ng/ml in PGF2α and PGE2, respectively, were seen when incubated with
arachidonic acid for 30 minutes. Vane further reported addition of indomethacin (5µg/ml) and
aspirin (40µg/ml) to samples resulted in little or no increase in PGF2α and PGE2 over time-zero
samples. Lower concentrations (1µg/ml indomethacin and 20µg/m aspirin) resulted in inhibition,
but curiously the inhibitory effects of both indomethacin and aspirin on PGF2α were greater than
those seen on PGE2. Peterson, Trappe, Mylone, White, Lambert, Evans, and Pizza (2003) similarly
found ibuprofen and acetaminophen reduced prostaglandin F2α after eccentric exercise but had no
effect on muscle biopsy PGE2 concentrations. Peterson et al.’s (2003) report of no NSAID-induced
PGE2 inhibition stands in contrast to Lapointe et al.’s (2002, 2003) animal research which reported
diclofenac treatment completely abolished the typical serum increases in PGE2 levels normally
accompanying electrical stimulation and voluntary contractions. Possible explanations for the
discrepancy between the two studies include the species examined and the NSAID employed.
To determine exactly which metabolites of arachidonic acid affect protein metabolism,
Rodemann and Goldberg (1982) tested six metabolites separately. Of these, only PGE2 and PGF2α
were found to have significant effects on protein metabolism. PGE2 consistently stimulated protein
degradation by ~22%. In contrast PGF2α had no effect on degradation but consistently increased
protein synthesis by ~35%. Additional in vivo studies performed by Rodemann and Goldberg
(1982) demonstrated arachidonic acid stimulated PGE2 synthesis 5-6 fold and PGF2α synthesis
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approximately 3-fold. These levels were dramatically reduced when indomethacin was added to the
medium, corroborating findings by Lapointe et al. (2003). Rodemann and Goldberg (1982)
concluded the effects of arachidonic acid and PGE2 on protein degradation seen in their study may
well underestimate changes occurring in vivo in well-nourished active organisms.
One year later, Smith, Palmer and Reed (1983) conducted a similar study to further
understand the prostaglandins’ role in protein synthesis specifically. Their study provided additional
evidence for the involvement of arachidonic acid metabolites in the stretch-induced stimulation of
muscle protein synthesis. In contrast to Rodemann and Goldberg (1982), Smith et al. (1983) utilized
isolated rabbit forelimb muscles and a tension stimulus. Muscles were incubated either under
intermittent mechanical stretching or constant tension for 90 minutes. Exogenous PGF2α, PGE2,
and arachidonic acid were added to the medium at the onset of incubation, and protein synthesis
was measured during 10-30 minutes period using radioimmunoassay.
Intermittent mechanical stretching significantly increased rates of protein synthesis (%/day)
with a simultaneous increase in PGF2α, compared to muscles held under constant tension (2.47 +
0.33 versus 5.21 + 0.77). The addition of indomethacin and meclofenamic acid to the incubation
medium significantly reduced rate of protein synthesis in the intermittently stretched muscle but did
not affect the basal rates of protein synthesis in the unstimulated muscle. In the intermittently
stretched muscle, rates of protein synthesis were significantly reduced 42.2% (p<0.05) upon addition
of indomethacin. Likewise, meclofenamate significantly reduced rates of protein synthesis 35.4%.
To confirm the potential of arachidonic acid metabolites to induce protein synthesis,
muscles were incubated, without stretching, with arachidonic acid in the presence and absence of
indomethacin. Arachidonic acid was found to mimic the stretch-induced stimulation of protein
synthesis, eliciting a significant increase in anabolic processes. The addition of indomethacin
(50µM) to muscles incubated with arachidonic acid caused a significant decrease in protein synthesis
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compared to the effect of arachidonic acid alone, and this decrease was not dependent on the
concentration of arachidonic acid. Even at lower concentrations (20µM), indomethacin decreased
protein synthesis rates by 30%.
Smith et al. (1983) determined activation of muscle protein synthesis persists 10-20 minutes
after removal of a 30 minute stretch stimulus, in what the authors referred to as residual activation.
Human evidence supporting these findings has been provided by Phillips, Tipton, Aarsland, Wolf
and Wolfe (1997), who demonstrated elevated levels of muscle protein synthesis 48 hours after
exercise in relatively untrained subjects (n=8). Smith et al. (1983) felt this was explained by
assuming arachidonic acid released by lengthening activity is retained intracellularly and continues to
be metabolized into prostaglandins. So while mechanical activity results in an initial increase in
prostaglandins and thus in vitro protein synthesis, additional protein synthesis continues as a result
metabolic activities occurring after removal of the stimulus. This effect has been reported to fall
progressively after the stimulus is withdrawn, and Irvine (1982) postulated this was due to the reesterification of free arachidonic acid. Recall, levels of free arachidonic acid in cells are low, but it is
stored in high concentrations in an esterified form in the membrane phospholipids (Pettipher, 1998).
The temporal sequence of residual activation may differ between models of mechanical stimulation
(Palmer, 1990). Smith et al. (1983) concluded their findings, along with those of Rodemann and
Goldberg (1982), support the hypothesis that stretch-induced stimulation of protein synthesis is
mediated by changes in intracellular concentrations of arachidonic acid metabolites. This study
provides additional evidence protein synthesis increases when skeletal muscles are subjected to
mechanical deformation, and the addition of a COX-inhibitor significantly decreases this increase in
protein synthesis. The negative implications of this are obvious if one is pursuing increases in
muscle size or strength.
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Novak, Billich, Smith, Sukhija, McLoughlin, Hornberger, and Koh (2009) found NS-398, a
selective COX-2 inhibitor, reduced compensatory hypertrophy in mice. A synergist ablation model
of mechanical overload was achieved by removing the soleus and gastrocnemius. Treatment groups
included non-ablated vehicle-treated controls, non-ablated NS-398-treated, ablated vehicle-treated
controls, and ablated, NS-398-treated mice. NS-398 was delivered by intraperitoneal injection 2
hours prior to ablation and at the same time daily until plantaris muscles were harvested. Controls
were treated with a vehicle solution of dimethyl sulfoxide in saline. In vehicle-treated mice, synergist
ablation resulted in an ~80% increase in the mass of the plantaris muscle and a ~50% increase in
total protein content 2-weeks post-ablation compared to non-ablated controls. In NS-398-treated
mice, the hypertrophic response was reduced 75% compared with vehicle-treated ablated controls.
Total protein content was also reduced in NS-398 treated mice relative to vehicle-treated and did not
differ significantly from non-ablated controls. In mice not subjected to synergist ablation, treatment
with NS-398 for 14 days did not alter plantaris mass or protein content, corroborating the lack of
effect of indomethacin and meclofenamic acid on basal protein synthesis in unstimulated musle
(Smith et al., 1983).
Novak et al. (2009) suggested the increase in muscle protein content during compensatory
hypertrophy was likely due to a combination of increased protein synthesis and decreased
degradation, as suggested by Sandri (2008), and NS-398 caused either a decrease in synthesis or
increase in degradation. Previous research would support an increase mediated by proportionately
greater synthesis, as hypertrophy is usually achieved by an increase in protein synthesis with a
relatively smaller increase in degradation (Palmer, 1990). However, human research has
demonstrated both synthesis and degradation are increased after mechanical loading, and ibuprofen
and acetaminophen blunt the increase in both associated prostaglandins (Trappe et al., 2001; Trappe
et al., 2002).
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Immunofluorescence analysis was employed to determine local expression of COX-2 during
compensatory hypertrophy. Novak et al. (2009) reported a sparse distribution at the muscle fiber
periphery in non-ablated control mice, while synergist ablation resulted in COX-2 expression in or
near nuclei, within or closely associated with muscle fibers or myogenic precursor cells, suggesting
that muscle fibers and/or myogenic precursor cells (satellite cells) are the primary source of COX-2
during hypertrophy. COX-2 inhibition also resulted in a 20% reduction in proliferating cells relative
to vehicle-treated mice, leading the authors to conclude COX-2 activity is required for compensatory
muscle hypertrophy.

Prostaglandins and Skeletal Muscle Protein Metabolism – Human Research
Trappe et al. (2001, 2002) extended Rodemann and Goldberg’s (1982) and Smith et al.’s
(1983) findings of prostaglandins’ role in protein metabolism to humans in two studies examining
fractional synthesis rate (2002) and PGF2α concentrations (2001) in subjects of a mixed training
status after an acute intense resistance training intervention. As a result of the exercise intervention,
both PGE2 and PGF2α increased significantly. Since these studies involved two analgesic treatment
groups in addition to a control group, they will be discussed in greater detail in the subsequent
section entitled “Effects of NSAIDs on Skeletal Muscle Fractional Synthesis Rate.”

Skeletal Muscle Fractional Synthesis Rate and Fractional Breakdown Rate
Fractional synthesis rate (FSR) represents the rate at which new proteins are incorporated
into a muscle. The essential amino acid phenylalanine is often utilized as the tracer to measure FSR
and FBR (fractional breakdown rate) because it is not oxidized in muscle or synthesized in the body;
thus, its appearance results entirely from protein breakdown (Phillips et al., 1997). Primed constant
infusions of [2H5] phenylalanine and 15N-phenylalanine were used by Phillips, Tipton, Aarsland,
49

Wolf, and Wolfe (1997) to determine fractional synthesis rate (FSR) and fractional breakdown rate
(FBR), respectively. Phillips et al. (1997) sought to examine the time course of muscle protein
synthesis and breakdown after an isolated bout of resistance exercise in a co-ed population of
aerobically-trained subjects, along with a secondary purpose of investigating potential differences in
FSR and/or FBR resulting from contraction type (concentric versus eccentric). Participants were
studied in a fasted stated at rest, 3, 24, and 48 hours after eight sets of eight concentric or eccentric
repetitions at 80% concentric 1RM with 2 minutes rest between sets.
FSR was significantly elevated in response to exercise at all time points: 3 hours, 122%; 24
hours, 65%; 48 hours, 34% (p<0.01). No significant differences were seen between the 24- and 48hour assessments of FSR. FBR was significantly elevated in response to exercise at 3 and 24 hours
but had returned to baseline levels by 48 hours. Exercise resulted in not only an initial increase in
FSR, but this heightened state of activity persisted 48 hours after exercise, resulting in a positive
change in net protein balance, findings in support of the residual activation reported previously
(Smith et al., 1983). It was not clear whether this time course of activation would be the same across
all fitness levels, so Phillips et al. sought to clarify this in a 1999 study, which will be discussed next.
Phillips et al.’s (1997) comparison of concentric and eccentric muscle activity revealed no
significant differences in FSR, FBR, or muscle net balance between the two types of muscle actions,
a somewhat surprising finding in light of the wealth of information demonstrating greater
myofibrillar damage and enzyme release resulting from eccentric activity. Phillips et al. (1997) also
reported a highly significant correlation (r=0.88, p<0.001) between FSR and FBR.
To clarify the time course of protein turnover in trained and untrained subjects, Phillips,
Tipton, Ferrando, and Wolfe (1999) equally divided co-ed subjects (N=12) into untrained (n=6) and
trained (n=6) groups. Untrained subjects were recreationally active, engaging in no more than 1.5
hours per week of exercise and participating in no resistance exercise. Trained subjects were
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performing a minimum of three resistance training sessions per week and had been doing so for >5
years.
After one bout of resistance exercise (8 sets of 10 unilateral eccentric leg extensions at 120%
1RM; 3 minutes rest between sets), FSR and FBR were determined in muscle biopsy samples after
amino acid infusions of [2H5] and [15N] phenylalanine. Both isotopic infusions were delivered at a
rate of 0.05 µmol • kg • min and were designed to achieve steady state in muscle and plasma pools.
Biopsies were taken from both the resting and exercise leg to compare the effects of resistance
exercise between trained and untrained subjects. Biopsy samples were analyzed for protein-bound
and free intracellular enrichment and concentration. Free and protein-bound enrichments were
determined by taking heptafluorobutyric (HFB) derivatives of the pooled intracellular fractions and
hydrolyzed muscle protein pellets. According to the authors, the HFB derivative of phenylalanine
facilitates the determination of phenylalanine enrichment using chemical ionization in gas
chromatography-mass spectrometry. Mixed muscle protein FSR was determined using the free
intracellular phenylalanine enrichment. Actual mixed muscle protein FSR was calculated as the
mean of the incorporation of [2H5] phenylalanine into mixed muscle proteins over the 4- hour
duration after exercise divided by the free intracellular enrichment.
There were no significant differences between trained and untrained subjects in FSR at rest
(0.045% per hour trained; 0.036% per hour untrained) or after exercise (0.067% per hour trained;
0.080% per hour untrained). However, both groups responded to exercise with significant withingroup increases in FSR. Untrained subjects’ FSR increased 118 + 18% (0.036 to 0.080 % per hour)
(p<0.01), while trained subjects’ FSR increased 48 + 6% (0.045 to 0.067% per hour) (p<0.01) as a
result of exercise. This compares similarly to Trappe et al. (2001), who reported a 77% increase in
FSR in muscle biopsy taken 24-hours after an acute bout of resistance training in a mixed sample of
sedentary and recreationally-trained males.
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There was also no significant difference in resting FBR between trained and untrained
subjects; however, untrained subject exhibited a significant 37 + 5% increase in FBR as a result of
exercise. Conversely, trained subjects responded to exercise with a non-significant increase of 15 +
3% increase in FBR. Phillips et al. (1999) again reported a significant correlation (r=0.84, p<0.001)
between mixed muscle FSR and FBR, as well as a significant correlation between the change in the
two variables as a result of exercise (r=0.91, p<0.001). Such correlations, the authors concluded,
suggest a coupling between the two processes much like the coupling between inflammation and
regeneration (Martini, 2004).
Compared to rest, exercise resulted in a significant improvement in muscle protein net
balance for both groups, with reductions in the negative balance of 37 + 4% and 34 + 11% for
untrained and trained subjects, respectively. Although FSR increased in both groups as a result of
exercise, the overall net balance (FSR-FBR) remained negative compared to time zero, which
marked the onset of [2H5] phenylalanine infusion. According to the authors, this was the expected
outcome due to the fact participants were studied in a fasted state. The authors did not report an
effect of training status on muscle net balance at rest, after exercise, or on the magnitude of change
in net balance.
Smaller increases in FSR and FBR in trained subjects in response to exercise led the authors
to conclude repeated resistance training seems to decrease muscle protein turnover after exercise.
This conclusion adds to the understanding of the repeated bout effect, suggesting a “traininginduced suppression of muscle protein turnover is related to a training-induced reduction in
exercise-induced muscle injury” (pE122). The number of bouts of resistance training required to
elicit this reduction in post-exercise muscle protein synthesis is not known, but even one bout
appears to afford protection, as demonstrated in animal research by Lapointe et al. (2002). These
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findings are important to bear in mind when considering Trappe et al.’s research (2001, 2002), which
employed both sedentary and recreationally-active males.

Effects of NSAIDs on Skeletal Muscle Fractional Synthesis Rate
Trappe, White, Lambert, Cesar, Hellerstein, & Evans (2002) examined the effects of
maximal over-the-counter doses of ibuprofen (1,200 mg/day), acetaminophen (4,000 mg/day), and
placebo on muscle protein synthesis and soreness in sedentary or recreationally-active males (n=24,
25 + 3 years) after an acute bout of 10–14 sets of 10 eccentric knee extensions at 120% concentric
1RM.

Sixty seconds rest was allowed between sets, and the set was concluded when the weight was

lowered in less than 0.5 seconds. Drugs were administered in three equivalent doses each day (8
AM, 2 PM, 8 PM), corresponding to the maximal non-prescription dose. The first dose was given at
the start of the eccentric exercise protocol, and a final fourth dose was given the morning following
the exercise session, ~5 hours before the second muscle biopsy. Biopsies were taken from the
vastus lateralis of the dominant leg two days before the exercise and from the non–dominant leg 24
hours after exercise.
Single doses of ibuprofen and acetaminophen at or near those provided in the study are
characterized by similar pharmacokinetic parameters. Such doses of ibuprofen are purported to
elicit only analgesic activity, with anti-inflammatory effects only seen with larger doses.
Acetaminophen (paracetamol) is considered a pure analgesic and antipyretic and is not believed to
elicit any anti-inflammatory activity (Vane and Botting, 1996). The two drugs are purported to
relieve muscle soreness and pain through separate mechanisms. Ibuprofen blocks cyclooxygenase,
reducing prostaglandins, which are responsible for inflammation and algesia. Acetaminophen is
believed to exert its action within the central nervous system, thus it would not be expected to
interfere with muscle protein metabolism in peripheral tissues after exercise.
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A catheter was placed in the antecubital vein for [2H5] phenylalanine infusion for
measurement of skeletal muscle fractional synthesis rate. Blood samples were analyzed for [2H5]
phenylalanine enrichment, and muscle samples were analyzed for free intracellular and proteinbound [2H5] enrichment by mass spectrometry. Creatine kinase was an additional measure found to
be significantly elevated in all three groups, with no significant differences between the treatment
groups due to the large and highly variable response seen in this measure.
Post–exercise skeletal muscle fractional synthesis rate (FSR) was significantly increased after
exercise in the placebo group but remain unchanged in both the ibuprofen and acetaminophen
groups. Variables than can potentially affect FSR, including training status, dietary state, and
exercise amount, were controlled in this study. Their results suggested non-prescription doses of
ibuprofen and acetaminophen suppressed the normal protein synthesis response in skeletal muscle
after eccentric resistance exercise, extending Rodemann and Goldberg’s (1982) findings to humans.
Acetaminophen’s inhibitory effect on post-exercise FSR was surprising due to the belief its
effects are exerted in the central nervous system. To account for this finding, the same muscles used
for FSR measurement were measured for PGF2α, since animal research has demonstrated its role in
skeletal muscle protein synthesis (Rodemann and Goldberg, 1982; Palmer, 1990). PGF2α levels
corroborated FSR levels, being significantly increased in the placebo group but unchanged in the
acetaminophen and ibuprofen groups. This led Trappe et al (2002) to conclude acetaminophen and
ibuprofen attenuate the increase in FSR by blocking production of PGF2α via the COX enzyme.
Furthermore, Trappe et al. (2002) concluded by stating continued inhibition of the normal increase
in protein synthesis after each session of resistance training could blunt the hypertrophic response to
exercise. The proposed study intended to address this possibility.
Krentz, Quest, Farthing, Quest, and Chilibeck (2008) proclaimed their study to be the only
study to investigate the chronic NSAID consumption on size and strength development in humans.
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In a seemingly convoluted design, co-ed subjects with roughly six years of resistance training
experience trained their right and left biceps on alternate days, 5 days per week for six weeks. The
exercise consisted of 3 sets of 8-10 concentric repetitions at 70% 1RM and 3 sets of 4-6 eccentric
contractions (3 seconds) at 100% 1RM, with 1 minute rest between sets. Of note, the exercise
intervention was not performed in a laboratory setting or under the supervision of the research
team. Rather, subjects were given guidelines to follow in terms of weight increases to personally
implement as strength improved over the duration of the study. Furthermore, 1RM testing was
performed with a unilateral bicep curl, an exercise which does not fulfill requirements for 1RM
testing. It appears subjects reported only for drug or placebo treatment and pre- and postmeasurements of size and strength.
Using one third of the dose administered by Trappe et al. (2001, 2002), ibuprofen (400mg)
was given immediately after training the biceps of one arm and placebo was given after training the
other arm the following day. Subjects receiving ibuprofen after training their dominant arm was
equal to the number receiving ibuprofen after training their non-dominant arm in what the authors
described as a counter-balancing measure. According to the authors, ibuprofen is virtually entirely
excreted within 24 hours of administration; thus, it was purported to have a negligible effect on the
arm receiving placebo the subsequent day. Krentz et al. (2008) cited this as a potential weakness of
their study.
Krentz et al. (2008) reported no effect of ibuprofen consumption on muscle thickness as
determined by ultrasound or strength development as determined by 1RM. Although this is in
discord with Trappe et al.’s conclusion that medications such as ibuprofen and acetaminophen could
blunt the anabolic response to exercise, numerous methodological differences exist between the two
studies (Trappe et al., 2001; Trappe et al., 2002). While Krentz et al.’s (2008) findings do not
demonstrate a negative long term effect as suggested by Trappe et al. (2001), there are substantial
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methodological differences between the two studies that undoubtedly account for some of this
discord. Krentz et al. (2008) called for the need for research measuring blood markers of
inflammation and protein synthesis over the course of a strength training program was called for at
the conclusion of their study.

Prostaglandins and Satellite Cells
According to Petrella et al. (2007), the general consensus is that successful skeletal muscle
regeneration following injury or intense exercise is dependent upon protein synthesis mechanisms
and satellite cell recruitment. Research has shown prostaglandins stimulate satellite cell activity, and
evidence is mounting that NSAIDs interfere with satellite cell proliferation, differentiation, and
fusion (Zalin, 1987; Shen et al., 2005; Mackey et al., 2007; Mikkelsen et al., 2008; Mikkelsen et al.,
2009; Novak et al., 2009).
Some of the seminal research highlighting the role of prostaglandins in human myoblast
proliferation and differentiation was performed by Zalin (1987). Aborted human fetuses were
cultured and studied in vitro. Addition of PGF2α to the culture positively affected myoblast
proliferation, suggesting that PGF2α is an endogenously-produced growth factor. Stimulation of cell
increase was most marked 24-48 hours after hormone addition. Addition of PGE2 was found to
stimulate myoblast fusion and differentiation, with fusion seen 2 hours earlier versus control cells
not exposed to PGE2. The relationship between prostaglandin production and satellite cell
proliferation was evidenced by the addition of two prostaglandin inhibitors, indomethacin and
aspirin. These resulted in some inhibition as early as 24 hours and complete inhibition 48-72 hours
after exposure. The reason for the delay between the addition of prostaglandin antagonists and
inhibition was concluded to be unknown, although it was suggested effective levels of prostaglandin
inhibition may not be reached until successive (third) administrations. If true, chronic use would
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theoretically blunt the regenerative response, and this was indeed demonstrated in comparisons of 2versus 7-day NSAID treatments (Lapointe et al., 2003)
To test this, Zalin (1987) exposed some cells to consecutive 24 hour doses of indomethacin,
while others were exposed to only one dose at 48 hours. Indomethacin added to cell cultures in a
single dose (10-4 M) at 48 hours was not found to inhibit the increase in cell number normally
occurring at that time (48-72 hours). In contrast, less than that same amount added daily resulted in
a marked inhibition when administered from time zero. Since a smaller amount resulted in marked
inhibition of proliferation, the authors concluded the time delay was not due to insufficient
prostaglandin antagonists. These findings suggest chronic low dose administration of NSAIDs may
have negative impacts on myoblast proliferation and hold serious implications for those persons
chronically consuming NSAIDs while anticipating hypertrophic gains.
Both aspirin and indomethacin were found to markedly and rapidly reduce rate of fusion.
These drugs were found to inhibit cell fusion even when added 1 day after the initial detection of
fusion in cell cultures. Zalin (1987) reported greater inhibitions of fusion could be obtained with
earlier exposure, with maximum inhibitions achieved when cells are exposed to the PG antagonists
24 hours or more before the expected time of fusion onset. During fusion, cell content of PGE
decreased, while the content of the culture medium increased two-fold. This finding holds
implications for the metabolism of PGE and suggests the rate of secretion exceeds the rate of
metabolism in the culture medium and lends credence to research by Pradelles et al. (1985) and
Trang et al. (1977), which validated measurement of prostaglandin metabolites in blood plasma and
joint fluid.
Horsley and Pavlath (2003) examined the role of PGF2α on satellite cell activity in an in vitro
study of primary (adult) myoblast cultures of mice tibialis anterior muscles. To investigate PGF2α’s
role in muscle growth, differentiating primary muscle cultures of mice tibialis anterior muscles were
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treated with vehicle or PGF2α. Twenty-four hour assessments of myoblast size revealed no apparent
differences between vehicle- and prostaglandin-treated cells; however, by 48 hours, prostaglandintreated myoblasts were larger, suggesting a role for PGF2α in skeletal muscle growth. Unlike Zalin
(1987) who found a role for PGF2α in myoblast proliferation, Horsely and Pavlath (2003) reported
no effect of PGF2α on cell proliferation (determined by quantification of DNA content), cell
differentiation (determined by embryonic myosin heavy chain staining), or cell fusion index
(determined by dividing the total number nuclei within myotubes (2 or more nuclei) by the total
number analyzed (100-250). While these results are different from Zalin’s (1987), it is important to
note Zalin (1987) examined fetal human myoblasts, while Horsely and Pavlath (2003) examined
primary (adult) mice myoblasts.
Horsely and Pavlath (2003) determined the role of PGF2α on skeletal muscle growth is
dependent on the developmental stage of the myotube. During the embryonic developmental
period, PGF2α enhances cell fusion processes that initially form myotubes. During regeneration
periods, PGF2α enhances the accretion of myonuclear cells. Specifically, compared to vehicle-treated
controls, PGF2α-treated cells demonstrated a significant increase in the percentage of myotubes
expressing five or more nuclei per fiber at a 48 hour assessment. Another remarkable finding of
Horsley and Pavlath’s (2003) study was the effect of time on PGF2α’s role in fusion. These effects
were examined by treating differentiating muscle cells with exogenous PGF2α at different stages of
fusion, which itself involves the processes of cell motility, alignment, recognition, adhesion, and
membrane union (Horsley and Pavlath, 2003). Cells were treated either at the onset of
differentiation (0 h) or at 24 hours, a time when fusion processes begin and a few multinucleated
muscle cells are present. In both cases, myotubes were analyzed 48 hours later. When given at 0 h,
no significant differences in the percentage of myotubes expressing 5 or more nuclei were seen
between vehicle- or PGF2α-treated myofibers. Conversely, at 24 hours, PGF2α-treated cells displayed
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significantly more nuclei than vehicle-treated, indicating PGF2α acts at a later stage of fusion to
facilitate an increase in cell size. This holds important implications for use NSAIDs therapeutically.
According to Horsley and Pavlath’s findings (2003), inhibition of PGF2α 24 hours post-injury would
be detrimental to muscle cell growth. Coincidentally, this 24 hour time point coincides with the
initial onset of symptoms of DOMS.
Both Mackey et al. (2007) and Crameri et al. (2004) found a single bout of high intensity
exercise sufficient for satellite cell activation. In Crameri et al.’s (2004) study, the experimental
design included eccentric exercise (50 single leg drop jumps, 8 sets of 10 maximal eccentric
contractions performed at 30 degrees • sec and 8 sets of 10 maximal isokinetic eccentric knee
extensions performed 180 degrees • sec.) performed by sedentary young males (n=8). Conversely,
Mackey et al. (2007) used trained males and a long-distance (36-km) aerobic intervention. While
both found a single bout of exercise to be sufficient for satellite cell activation, Crameri et al. (2004)
stated a single bout is not sufficient for terminal differentiation. Crameri et al. (2004) suggested that
the number of cells expressing satellite cell protein markers, including neural cell adhesion molecule
(N-CAM) and fetal antigen 1 (FA1,) can be up-regulated in readiness for a second bout of exercise.
However, unless subsequent bouts of activation occur, the satellite cells will again become quiescent.
Similar to Mackey et al. (2007), Crameri et al. (2004) identified satellite cells through N-CAM and
FA1 staining, while necrosis was identified by the presence of desmin-negative cell, dystrophinnegative cells, fibronectin-positive cells, and centralized nuclei. There is still debate concerning the
ideal satellite cell marker (Bamman, 2007).
Crameri et al. (2004) reported a significant increase in cells positively staining for N-CAM
and FA1 on days 4 and 8 post-eccentric dominant resistance exercise. Mackey et al. (2007) also
reported a significant increase (27%) in the number of N-CAM+ cells eight days post-36 km run but
no significant changes over time in FA1+ cells. The training intervention (36-km aerobic versus
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210 voluntary contractions) and the subject population (trained versus sedentary males) are two key
differences between Crameri et al.’s (2004) and Mackey et al.’s (2007) research. Particularly in
regards to the training status, Crameri et al. (2004) reported 200% increases in N-CAM+ cells on
days 4 and 8 post-exercise in sedentary participants, while Mackey et al. (2007) reported increases of
27% in N-CAM+ cells by day eight in trained participants. The difference in N-CAM+ cells
between trained and untrained populations is reminiscent of Philips et al. (1999) findings of
significantly different exercise-induced fractional synthesis and breakdown rates between trained and
untrained populations. Thus, not only does the magnitude of the response appear to be substantially
different between trained and untrained populations, but the time course of peak activation seems
different between the two exercise modalities as well.
In Mackey et al.’s (2007) study of satellite cell activation post-36 km run, indomethacin (100
mg/day for 4 days pre-run to 8 days post run) was found to blunt the increase in N-CAM positive
cells after exercise, but differences between indomethacin and placebo groups were not statistically
significant. Even in the absence of significant differences, the authors argued their findings
provided in vivo support for the COX pathway in satellite cell activity.
Novak et al. (2009) reported satellite cells are the primary source of COX-2. Curiously,
Mackey et al. (2007) reported FA1 stained 25% more satellite cells in healthy untrained individuals
versus trained individuals. Of these additional FA1+ satellite cells, some were located in the classic
position under the basal lamina, while others were located outside the muscle fiber, finding similar to
Novak et al. (2009), who found COX-2 expressed in the muscle fiber periphery in control mice;
while in those subjected to mechanical overload, COX-2 was found in or near nuclei associated with
satellite cells. According to Mackey et al. (2007), this may support the theory that skeletal muscle is
comprised of different subpopulations of myogenic precursor cells.
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Similar to Philips et al. (1999), Mackey et al. (2007) suggested the findings of lower numbers
of FA1+ cells in trained versus untrained could represent a loss of regenerative capacity for cell
division; however, Mackey et al. (2007) reported no necrotic fibers in the muscles post-run, similar
to Crameri et al. (2004) who reported necrosis in only one of eight males. In the one case of
necrosis, expression of myogenic regulatory factors (myogenin) was coincident. Taken together with
Crameri et al.’s findings (2004), it appears satellite cell activation is not dependent on muscle
damage. Bamman (2007) stated “the fact that N-CAM+ satellite cells number was inhibited by
NSAID treatment, even in the absence of visible myofiber necrosis or detectable increases in
regeneration, suggests that COX-mediated prostaglandin synthesis may be initiated simply by
exercise” (p 415), a conclusion which, of course, been demonstrated by previous research
(Rodemann and Goldberg, 1982; Smith et al., 1983).
Mikkelsen et al. (2009) also examined satellite cell activation post-resistance exercise in males
(n=8) who were described as well-trained yet unaccustomed to intense eccentric exercise.
Immunohistochemistry was utilized to investigate satellite cells, which were identified by N-CAM
and Pax7 staining of muscle biopsies before and eight days after an acute exercise intervention
consisting of 200 eccentric knee extensions on an isokinetic dynamometer. A microdialysis catheter
was used to locally infuse indomethacin into one leg, while the other leg served as the control.
Indomethacin infusion began during exercise and continued for 4.5 hours after completion of knee
extensions. Compared to baseline, exercise resulted in an impressive 96% increase in the number of
Pax7+ cells (expressed per myofiber) eight days post-exercise in the control leg, while the number
remained unchanged in the leg infused with indomethacin. Mikkelsen et al. (2009) reported a 22%
increase in N-CAM+ cells in the control leg, results similar to the Mackey et al. (2007) who reported
a 27% increase in N-CAM+ cells in a trained population. Mikkelsen et al. (2009) concluded their
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results provided evidence that NSAIDs negatively affected satellite cell proliferation during an 8 day
period post-exercise when administered before, during, and 4.5 hours after exercise.
Mendias, Tatsumi, and Allen (2004) examined the role of COX-1 and COX-2 on satellite cell
proliferation in an in vitro study of isolated rat skeletal (hindlimb) muscle. The authors
hypothesized if COX-2 is involved in satellite cell regulation during muscle repair, it should be
expressed in activated satellite cells. Of course, this was confirmed later by Novak et al. (2009).
Satellite cells were isolated and cultured, and were examined for proliferation, differentiation, and
fusion. To examine the effects of COX-inhibitors on satellite cell activity, cultures were grown in
the presence of naproxen sodium (non-selective COX-inhibitor), NS-398 (selective COX-2
inhibitor), or SC-560 (selective COX-1 inhibitor) from 24 h to 120 hours. Satellite cell lysates from
cultures at 30 h, 72 h, 120 h, and 168 h were all positive for COX-2. Results revealed a significant
increase in proliferation from 72-120 hours in control cell cultures. Cultures grown in the presence
of naproxen sodium and NS-398 revealed a significant decrease in proliferation. Cultures grown in
the presence of naproxen sodium, NS-398, and SC-560 revealed a significant decrease in
differentiation as well as fusion. In summary, Mendias et al. (2004) found inhibition of COX-2
alone resulted in decreased proliferation, and inhibition of both isoforms of COX resulted in
decreased differentiation and fusion. These findings are in accord with McLennan (1987), who
found chicken egg embryos treated with aspirin or indomethacin exhibited less proliferation than
vehicle-treated embryos; but not in accordance with Thorsson et al. (1998), who reported no effect
of naproxen on satellite cell proliferation in female rat skeletal muscle subjected to contusion injury.
To investigate the effects of mechanical stretch on cultured primary mice myoblasts, Otis,
Burkholder, and Pavlath (2005) subjected them to 5 hours of cyclical stretch at 5 Hz. The stretch
stimulation resulted in a 32% and 41% increase in proliferation (BrdU+ cells) 24 hours and 48 hours
after stretch, respectively. However, stretch was found to decrease mRNA levels of myogenin, one
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of primary myogenic regulatory factors. According to the authors, these results suggested
mechanical deformation delays differentiation to facilitate increased cell proliferation. The authors
postulated this “stretch-induced delay of differentiation allows for increases in the myoblast pool
and ultimately may lead to enhanced myotube formation” (p423). Otis, Burkholder, and Pavlath
(2005) determined stretched myoblasts secrete a soluble factor that facilitates cell proliferation and
sought to determine if this factors was a product of the COX-2 pathway. To test this, COX2
activity was disrupted through treatment with SC-236, a selective COX-2 inhibitor, or through
removal of the COX2 gene. Both myoblasts treated with SC-236 and those deficient for the COX2
gene (COX2-/-) failed to proliferate upon stretch stimulation. In fact, in those cells treated with SC236, prolilferation was actually decreased compared to non-stretch controls.
Compared to vehicle-treated (95% ethanol), there was a significant decrease in proliferative
cells. To determine if products of the COX-2 pathway are required for stretch-induced
proliferation, PGE2 and PGF2α were added to COX-2 deficient myoblasts to determine if these
growth factors could correct the proliferative deficiency in these mice. While PGE2 only partially
compensated for this lack, PGF2α corrected a significant portion of this deficit. According to the
authors, these pharmacologic and genetic approaches to COX-2 inhibition confirm the idea that
COX-2 pathway products, PGE2 and PGF2α, are necessary for myoblast proliferation.
With human and animal research demonstrating a role for PGF2α in skeletal muscle protein
synthesis (Rodemann and Goldberg, 1982; Smith et al., 1983; Trappe et al., 2001; Trappe et al.,
2002) and satellite cell activity (Zalin, 1987; Mackey et al., 2007; Mikkelsen et al., 2009) and the
current idea that PGF2α is an endogenously produced growth factor (Trappe et al., 2001; Horsley and
Pavlath, 2003), a strong line of previous research has led to the current investigation. While negative
effects of prostaglandin-inhibiting drugs have been seen after acute resistance training, whether
these acute effects continue to suppress parameters of adaptation is not known. In consideration of
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the ability to self-medicate with a readily-accessible drug that may potentially inhibit reparative
processes in the muscle, the purpose of this study was to investigate the effects of a chronic
prophylactic dose of naproxen sodium on skeletal muscle adaptation to resistance exercise in
recreationally-trained college-aged males.
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Chapter III
Methodology

The purpose of this study was to investigate the effects of chronic prophylactic naproxen
sodium on skeletal muscle adaptation to resistance exercise in recreationally-trained college-aged
males. Recreationally-trained was defined as individuals who were currently performing resistance
exercise 3-5 times per week and had been doing so a minimum of 6 weeks. Performance of a total
body workout three times per week, upper/lower split routine totaling four sessions per week, or
push/pull/lower split routines totaling five sessions per week qualified a participant for assignment
as recreationally-trained. Participants (n=23) were recruited from the University of Mississippi to
engage in a 6-week resistance training protocol designed to develop size and strength of upper body
musculature.
Due to the potential confounding effects of sex hormones, as well as sex differences in the
inflammatory response associated with exercise-induced muscle injury (MacIntyre et al., 1996;
MacIntyre et al., 2000; Stupka, 2000), only males were recruited for this investigation. Further
rational for this decision came from a study that reported males are more likely to take over-thecounter analgesics for muscle ache (Wilcox et al., 2005). Primary outcome variables included acute
and chronic changes in systemic plasma PGF2α metabolite concentrations, acute and chronic
changes in dominant arm circumference, strength, and arm tissue (bone, adipose, and lean skeletal)
composition as a result of exercise (placebo) or exercise and NSAID (naproxen sodium).
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Pilot Study
Due to a lack of literature describing normal resting or exercise-induced PGF2α metabolite
concentrations or using a systemic approach to its measurement, the study was piloted for a 2-week
period. During the pilot study, male participants (n=4) were randomly assigned to placebo (n=2) or
naproxen sodium (n=2) treatment groups, subjected to baseline strength testing, and supervised in
the performance of upper body resistance exercise similar to that used in the formal 6-week study.
During the pilot study, each participant provided a pre- and post-exercise blood sample (3.0 ml) with
every supervised workout, resulting in a total of 8 samples for each subject. Pilot study drug
assignment was double blind, and the blind was not broken until after enzymeimmunoassay (EIA)
and statistical analyses were completed. Blood samples obtained during the pilot study were
analyzed for 13,14-dihydro-15-keto PGF2α concentrations using the EIA kit intended for analysis of
formal study samples (Cayman Chemical, Catalog No. 516671, Ann Arbor, MI). The results of the
pilot study supported the systemic measurement approach employed during the formal study, for
which the following methodological sections detail.

Screening
Participants were screened using IRB-approved documentation, consisting of a general
physical activity readiness questionnaire and an expanded health status questionnaire, which included
a series of questions to determine characteristics of their exercise program, current supplement use,
and contraindications to the use of naproxen sodium. After explanation of all procedures, risks, and
benefits, IRB-approved informed consent was provided by all participants. Nine participants did
not pass pre-screening qualification for reasons including frequent indigestion, failure to meet
recreationally-trained status, and/or use of numerous and varied ergogenic supplements.
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Recent (within 1 month) regular use of non-prescription or prescription NSAIDs precluded
participation, as did any history of sensitivity to NSAIDs, gastric ulcers, and heart, kidney, or liver
disease. Potential participants who were using any type of performance enhancing supplements,
including creatine, ephedrine, amphetamines, or anabolic-type products were also excluded from
participation. Individuals who regularly consumed alcohol in excess of moderate amounts (>3
drinks per day for a male) were also precluded due to liver concerns. Subjects were randomly
assigned to placebo or naproxen sodium treatment groups, and drugs were administered in doubleblind fashion prior to each biweekly workout.

Familiarization Session
An initial familiarization session was first performed to acquaint the participants with
specific characteristics of each exercise and to conduct baseline testing. This familiarization session
occurred 1-8 days prior to the onset of the 6-week intervention. Within this session, dual energy xray absorptiometry (DXA) was used to determine baseline body composition, with specific emphasis
on bone mineral content, lean tissue (g), fat tissue (g), and fat percentage in right and left arms.
DXA measures tissue absorption of high- and low-energy x-ray beams. Mazess, Barden, Bisek, and
Hanson (1990) reported precision errors (1 SD) for total body BMD, percent fat in soft tissue, fat
mass, and lean tissue mass were <0.01 g/cm2, 1.4%, 1.0 kg, and 0.8 kg, respectively. These precision
error rates corresponded to a relative error of 0.8% for total body BMD and 1.5% for lean body
mass. In addition to its initial use during the familiarization session, DXA was also performed at the
conclusion of the 6-week study to determine changes in arm tissue composition.
Dominant upper arm circumference (cm) and body weight (kg) were recorded during the
familiarization session. A minimum of two circumference measurements were performed pre- and
post-exercise to examine the acute change in arm circumference in response to exercise. If the two
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circumference measures differed by more than 0.3 cm, a third measurement was taken, and the
average of the three was recorded. Upper arm circumference was measured to the nearest tenth of
a centimeter. To measure circumference, participants were directed to first extend the arm shoulder
level in the frontal plane and then contract the bicep. A Gulick tape measure was placed around the
visually-determined widest circumference of the dominant upper arm, which was reported as the
right arm by all participants. Resting blood pressure was assessed during the familiarization session.
In addition to its initial measurement during the familiarization session, body weight (kg) was also
measured prior to each exercise session. An initial 6-ml blood sample was also collected during the
familiarization session.
During the familiarization session, participants’ 1-repetition maximum (1RM) was
determined for each exercise performed in the study (Figures A1-4). Participants were also initially
1RM tested in the bench press and plate-loaded leg press, and these results were used to formulate
an individualized, periodized, and unsupervised chest and leg exercise prescription for the
participants to perform during the six weeks. The chest, shoulder, tricep workout included (1) flat
barbell bench press, (2) dumbbell military press, (3) machine chest fly, and (4) cable tricep extension.
The lower body workout included the (1) plate-loaded leg press, (2) Romanian deadlift, (3) leg
extension, and (4) bent-knee calf raise. Participants were verbally provided with specific
performance guidelines for all unsupervised exercise sessions to ensure safety. While this had been
offered as an incentive for participation, most participants performed their own personallydeveloped chest and leg programs during the 6-week training study.
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One repetition maximum testing followed NSCA guidelines. One repetition maximum was
directly determined for the Nautilus® lat pulldown, t-bar row, bench press, and plate-loaded leg
press. Procedures for one repetition maximum testing entail the following:
1.

Warm-up set allowing 10 repetitions.

2.

1 minute rest.

3.

Addition of absolute or relative increase of 10-20 lbs. or 5-10%, respectively, for
performance of first set, for which the intention is to complete 3-5 repetitions.

4.

2 minute rest.

5.

Addition of absolute or relative increase of 10-20 lbs. or 5-10%, respectively, for
performance of second set, for which the intention is to complete 2-3 repetitions.

6.

2-4 minute rest.

7.

Addition of absolute or relative increase of 10-20 lbs. or 5-10%, respectively, for
performance of third set, for which the intention is to complete 1 repetition.

Care was taken to ensure 1RM was determined within three sets, not including the warm-up
set. A 10-repetition warm-up set was performed only for the first exercise tested (lat pulldown).
For those unable to complete the goal repetitions for each respective set in the 1RM process,
absolute or relative weight was decreased 5-10 lbs. or 2.5-5.0%, respectively, until only one repetition
could be completed with good technique.
Due to their classification as assistance exercises, the barbell bicep curl and barbell upright
row 1RM were determined indirectly via a 10RM test. Guidelines for 10RM are similar to those for
1RM, except load increases over sets are 50% of the amounts used during 1RM testing (Brzycki,
1993) and goal repetitions are always ten. Assessment of barbell bicep curl and upright row 10RM
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were not preceded by warm-up sets, and 10RM was determined in 1-2 testing sets. Exercises were
always tested in the same order.
Prior to determination of 1RM, subjects were specifically instructed on technicalities of each
exercise, including body posture, joint position, range of motion, and tempo of movement, all of
which were standardized. Standardization information has been provided as captions along with
each respective figure (Figures A1-4).

Exercise Sessions
The resistance training program consisted of four resistance training exercises targeting the
upper back and bicep musculature. These included the lat pulldown (Figure A1), t-bar row (Figure
A2), barbell upright row (Figure A3), and barbell bicep curl (Figure A4). Specific details for the
performance of each exercise accompany each picture in Appendix A. Prostaglandins are
considered to act locally, and these specific exercises load musculature near the venipuncture site.
Thus, it was believed a relatively large prostaglandin response would be seen in an antecubital vein
after performance of these exercises, as exercised-induced PG increases in local tissues have been
reported (Mikkelsen et al., 2008) and diffusion from in vitro cells into incubation medium has been
shown (Zalin, 1987). Furthermore, muscle contractions >45% 1RM results in venous pooling in the
peripheral circulation, which effectively increase hormonal concentrations in the venous blood
(Kraemer et al., 2008).
Participants performed two workouts per week, with workouts separated by 48 hours.
Participants performed 3 sets of 6-10 repetitions of each exercise at 66-86% 1RM with 90 seconds
rest between each set and each exercise. Following a “heavy-light” approach to the resistance
workout, the first workout of the week utilized a greater percentage of 1RM (76-86% 1RM), while
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the second workout utilized a lighter percentage of the 1RM (66-76% 1RM). The periodization
protocol is provided in Table 4.

Table 4
Periodization Program
Workout 1

Workout 2

Intensity

Sets x Reps

Intensity

Sets x Reps

Week 1

76%

3x8

66%

3 x 10

Week 2

78%

3x8

68%

3 x 10

Week 3

80%

3x6

70%

3 x 10*

Week 4

82%

3x6

72%

3 x 10

Week 5

84%

3x6

74%

3 x 10

Week 6

86%

3x6

76%

3 x 10

*

Second strength assessment conducted prior to workout. Subsequent intensities based on results of
this assessment.

Participants were instructed to complete the concentric phase of the lift in ~1 second and
the eccentric phase slightly slower. With few exceptions, participants performed each supervised
workout at the same daily time throughout the 6-week study in order to standardize measurement.
In anticipation of strength increases, participants’ 1RM was re-evaluated for each exercise at
week 3 to determine appropriate load adjustments for the final three weeks of the program. This
second 1RM test occurred prior to the second, or light, workout of the week. On this re-assessment
day, 1RM was first assessed according to aforementioned guidelines, treatments (placebo or
naproxen sodium) were orally administered with nutritional supplement, thirty minutes rest was
provided, and the scheduled workout was completed. Subjects were prohibited from performing
71

any additional back or bicep resistance training exercise over the 6-week period. Subjects were also
prohibited from performing any type of exercise (aerobic or resistance) prior to lab workouts.

Blood Sampling
Blood was sampled at three time points: workout 1 of week 1, workout 7 of week 4, and
workout 11 of week 6. A pre- and post-exercise blood draw was performed at each of these time
points, resulting in a total of three pre-exercise and three post-exercise blood samples per subject, in
addition to the baseline sample obtained during the familiarization session. Arms used for pre- and
post-exercise blood draws were alternated over the seven venipunctures. Venipuncture was
performed using a 25 to 23 gauge BD Vacutainer® Push Button Blood Collection Set (BD, Franklin
Lakes, NJ) to draw 6 milliliters (mls) of blood from an antecubital vein of participant's arm. Preexercise and post-exercise blood samples were collected in BD Vacutainer® K2
ethylenediaminetetraacetic acid (EDTA)-treated tubes. Samples were placed on a brief ice bath and
promptly centrifuged (15 minutes, 2600 rpm, 18˚C), aliquoted, and frozen at -80°C.
After the pre-exercise blood draw during workouts 1, 7, and 11, and at the beginning of all
other non-blood collection sessions, each subject was provided an 8-ounce serving of a
commercially-available meal replacement (Boost®) to standardize nutritional intake and buffer
potential gastrointestinal effects of naproxen sodium. Both Aleve® and placebo were placed inside
identical quick-dissolving gelatin capsules (Health Care Logistics, Inc. Item #14012W), and drugs
were orally administered in double-blind fashion immediately after the pre-exercise blood draw, if
draws were scheduled, or immediately upon reporting to the lab if draws were not scheduled. A
440mg dose of Aleve® was administered, in accordance with the manufacturer’s over-the-counter
dosing regimen. This dose is delivered in two Aleve® caplets, which contain 400mg of the active
ingredient naproxen plus 40mg of sodium to accelerate absorption. The non-prescription dosing
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regimen for pain is an initial oral dose of 200-400 mg followed by 200 mg every 8-12 hours as
needed (MICROMEDEX, 2011). The double-blind was not broken until after all blood assays and
statistical analyses had been completed.
Although blood was only drawn in conjunction with workouts 1, 7, and 11, treatments were
administered at both supervised exercise sessions each week. After allowing 30 minutes for the
initial analgesic action of naproxen sodium, participants were supervised in the performance of the
four resistance exercises. Seventeen participants were trained solely by the primary investigator. Six
participants were trained by a research assistant, who was first trained by the primary investigator to
ensure consistency in the implementation of the supervised workouts.

Enzyme Immunoassay (EIA)
The primary metabolite of prostaglandin F2α metabolite in the peripheral circulation is 13,
14-dihydro-15-keto PGF2α (Trang et al., 1977; Guthrie and Rexroad, 1981), and measurement of
13,14-dihydro-15keto PGF2α in plasma can be used as a marker of the in vivo production of PGF2α
(Del Vecchio, Maxey and Lewis, 1992). Enzyme immunoassay (EIA) has been shown to be a viable
alternative to radioimmunoassay (Pradelles, Grassi and Maclouf, 1985; Del Vecchio et al., 1992) for
the quantification of this metabolite. Plasma samples analyzed with both EIA and RIA have shown
a correlation of 0.95 (Del Vecchio et al., 1992).
Plasma concentration of prostaglandin F2α metabolites were analyzed with a commercially
available EIA kit (13,14-dihydro-15-keto PGF2α EIA Kit, Catalog No. 516671, Cayman Chemical,
Ann Arbor, MI). This is a competitive assay validated for determination of this downstream
metabolite in plasma and other sample matrices. Manufacturers state the EIA displays an IC50 value
(50% B/B0) of approximately 120 pg/ml and a detection limit (80% B/B0) of approximately 15
pg/ml. The assay is based on competition between free 13,14-dihydro-15-keto PGF2α and a 13,1473

dihydro-15-keto PGF2α tracer linked to acetylcholinesterase (AChE) for a limited number of 13, 14dihydro-15-keto PGF2α-specific anti-serum binding sites. Concentration of 13,14-dihydro-15-keto
PGF2α tracer remains constant, while the concentration in the sample varies. The amount of 13,14dihydro-15-keto PGF2α tracer that is able to bind to the available binding sites is inversely
proportional to the concentration of free 13, 14-dihydro-15-keto PGF2α in the well.
Using one pre- and post-exercise sample obtained from one participant who chose to
discontinue participation after completion of baseline testing and the first two supervised workouts,
a second preliminary EIA was performed to examine potential interference in plasma samples and
appropriate dilutions for the assay. Along with the pilot study experiment, this provided a second
opportunity for refinement of the procedures and techniques associated with the specific EIA kit.
Based on the results of this experiment, purification protocols were not deemed necessary and a
single dilution factor of one (undiluted) was deemed acceptable due to consistency in absorbance
readings.
EIA kits were stored at -20°C. Plasma samples (1.5 ml) were removed from -80°C freezer
and allowed to thaw on an ice bath (approximately 30 minutes). Samples were then centrifuged at
1500 rpm for 6 minutes at 20°C. UltraPure water (Cayman Chemical, Item No. 400000) was used
not only to prepare all buffers and reagents but also to wash all glassware used during the EIA
procedure. Diluted buffers were stored at 4°C.
Not including 24 baseline samples, a total of 160 blood samples were analyzed. Processing
was divided into 3 batches, with 2 plates being run simultaneously in each batch. An 8-point
standard curve was generated for each 96-well plate using the 13,14-dihydro-15-keto PGF2α kit
standard. Each standard was run in duplicate. Plasma samples (50µl) were then added to the wells.
Sample numbers 25-68 were run in duplicate, and samples 69-168 were run in triplicate. Standard
and sample addition to the plate was followed by addition of AchE tracer, which consists of one
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molecule of 13, 14-dihydro-15-keto PGF2αcovalently attached to one molecule of AChE. PGF2α
antiserum was then added to each well. Plates were covered and incubated 18 hours at 4°C.
Immediately after incubation, each 96-well plate was washed five times with wash buffer containing
potassium phosphate, UltraPure water, and Tween 20 using an automated washer (BioRad, Model
1575 ImmunoWash).
Ellman’s reagent (acetylthiocholine and 5,5’-dithio-bis-(2-nitrobenzoic acid)), which is used
to measure AChE activity and thus quantify the amount of tracer bound to the well, was
reconstituted with UltraPure water immediately before use on day two of the EIA procedure. After
addition to each well, plates were covered and incubated an additional 2 hours in the dark at room
temperature on an orbital shaker. When acetylthiocholine is hydrolyzed by AChE, thiocholine is
produced. The reaction of thiocholine with 5,5’-dithio-bis-(2-nitrobenzoic acid) produces 5-thio-2nitrobenzoic acid, which produces a distinct yellow color that absorbs strongly at 412 nm.
Spectrophotometry was then employed to measure the intensity of the color, which is
proportional to the amount of 13, 14-dihydro-15-keto PGF2α tracer bound to the well and indirectly
proportional to the amount of free 13, 14-dihydro-15-keto PGF2α in the well. An endpoint assay
was conducted, and optical density of PGF2α was read at 415 nm using an automated microplate
spectrophotometer (BIO-RAD, Model 680, Hercules, CA) operating Microplate Manager Software
(BIO-RAD, Version 5.2.1, Hercules, CA).
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Using MyAssays Analysis Software Solutions, a four parameter logistic (4PL) curve was
generated for each 8-point standard curve, and the resulting equation was used to determine
concentration of the unknowns. A standard 4PL regression equation is given by
y = [ (A-D)/(1 + (x/C)^B) ] + D, where
y = concentration
x = absorbance at 415 nm
A = minimum asymptote or lower boundary
B = slope
C = inflection point
D = maximum asymptote

Concurrent Medication Use
During the 30 minute wait after treatment administration, participants completed a brief
recall of any recent use of additional NSAIDs and/or any other medications. If a participant
reported taking anti-inflammatory drugs or other medicines believed to affect plasma hormonal
measurements prior to blood collection, the lab session was rescheduled for the following day.
While this necessitated a rescheduled lab session only twice, there were two participants who
received steroid shots from the student health center 4 and 6 days before blood collection. One
participant used Flonase®, but this did not overlap blood collection. There were nine reports of
non-prescription analgesic (ibuprofen or acetaminophen) for personal reasons not related to the
exercise intervention. Of these 9 instances of analgesic self-medication, only one occurred at a time
such that the blood collection overlapped the presence of the medication in the system. Three
subjects took one 7- or 10-day cycle of antibiotics. There were also two instances of Sudafed® use,
one of which coincided with a blood draw for one subject; four instances of antihistamine use
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(Benadryl®, Claritin D®, Zyrtec®), none of which overlapped blood collection; four instances of
multi-ingredient cold/flu medications, none of which interfered with sample collection; and two
instances of prescription narcotic/prescription analgesic use (codeine, ultram), with neither
interfering with blood collection.

Physical Activity and Dietary Measurement
Participants were provided with instructions for participation (Appendix B), which included
exercise restrictions, alcohol consumption guidelines, and a comprehensive list of all potential
serious and less serious reactions to naproxen sodium. During the 30-minute wait after pill
administration, information concerning the most recently performed aerobic and resistance exercise
was documented. Physical activity was also measured for two 3-day time periods using the
BodyMedia SenseWear PRO2 armband (Figure A5). This device is worn on the posterior surface of
the upper dominant arm. It has been validated as a tool to assess physical activity in free-living
conditions, and significant correlations between indirect calorimetry were determined for supine
resting and walking conditions have been reported (Hallam, Lacey, Hatchett and Wadsworth, 2007).
The first and second 3-day physical activity collection periods were scheduled to overlap the
second (week 4), and third (week 6) blood draws. Participants were provided the armband and
instructed to wear it continuously for those three days. Each participant thus provided six days of
physical activity data. The BodyMedia SenseWear PRO2 armband uses a proprietary formula to
estimate energy expenditure. Biaxial accelerometers, thermistors to record not only the exchange of
heat with the environment but also the galvanic skin response, and a pedometer are used to obtain
the raw data for the estimation of energy expenditure. Galvanic skin response is a measure of the
electrical conductivity between two points on the skin and is used to quantify maximal sweat rates.
Daily and average total energy expenditure, active energy expenditure, physical activity duration,
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number of steps taken, and duration of sleep were all measured. Using skin thermistors, the
armband is able to detect when it has been removed from the body. Participants were compliant in
wearing the armband for the majority of the 3-day period. Participants in placebo treatment group
kept the device on their body 88 + 13.8% and 86.2 + 19.2% of the first and second 3-day collection
period, while those in the placebo treatment group two kept the device on their body 90.5 + 12.4%
and 91.5 + 9.1% of the first and second 3-day periods.
Two 3-day dietary recall collection periods were attempted, with an initial plan to measure
intake over a weekend (Friday-Sunday) and weekday (Monday-Thursday) period. Participants were
provided with Nutrient Data System for Research diet recall documents and instructed to record the
type and amount of food and beverages consumed for three days, which overlapped 3-day physical
activity measurement (3-day period during weeks 4 and 6) and the blood draws accompanying
workouts 7 (week 4) and 11 (week 6). The intent of overlapping collection of dietary and physical
activity data with blood collection was to collect ancillary data which could potentially affect plasma
concentrations of PGF2α metabolites.
After receiving instructions on how to complete the recall documents, participants
personally recorded their dietary intake for 3-days. Immediately after the collection period,
participants were interviewed by a dietetic professional to complete the information collection
process. The Nutrient Data System for Research (NDSR) was utilized to analyze each participant’s
diet for total energy (kilocalories), total protein (g), percent calories from protein, arachidonic acid
(g), total polyunsaturated fatty acids (g), calcium (mg), vitamin D (µg), and antioxidant content.
Mixed-design repeated measures ANOVAs were utilized to determine potential interactions
between treatment and time, which was measured both acutely and chronically. Acute responses to
exercise are represented in the pre-to-post exercise change. Chronic responses are represented by
the changes exhibited over the 6-week training period.
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The following null hypotheses were tested:
Ho1:

There will be no significant difference in the acute PGF2α response to exercise between
groups over time. This will be tested using a 2 x 2 x 3 mixed-design repeated measures
ANOVA. The potential three-way interaction (treatment x pre-post x time) was interpreted
first.
Three potential two-way interactions were examined after the omnibus test.

Ho1a:

There were will be no significant difference in the acute PGF2α response to exercise between
treatment groups, when all three pre-exercise concentrations and post-exercise
concentrations are averaged within treatment group. This will be tested using a 2 x 2
(treatment x pre-post) ANOVA.

Ho1b: There will be no significant difference in the acute PGF2α response to exercise over time,
when pre-exercise concentrations and post-exercise concentrations are averaged across
treatment groups at each blood sampling time. This will be analyzed using a 3 x 2 (time x
pre-post).
Ho1c: There will be no significant difference in the PGF2α response to exercise over time, when preand post-exercise data are averaged within each treatment group at each blood sampling time
point. This will be analyzed using a 2 x 3 (treatment x time) repeated measures ANOVA.
After two-way interactions, main effects of time, treatment, and exercise were
examined.
Ho1d: There will be no effect of time on acute PGF2α response to exercise.
Ho1e: There will be no effect of treatment on acute PGF2α response to exercise.
Ho1f:

There will be no effect of exercise on the acute PGF2α response to exercise.

Ho2:

There will be no difference in acute arm circumference response to exercise between groups
over time. This was tested using a 2 x 2 x 6 mixed-design repeated measures ANOVA.
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The potential three-way interaction was interpreted first (treatment x pre-post x
time), followed by examination of potential two-way interactions.
Ho2a:

There will be no significant difference in the acute arm circumference response to exercise
between treatment groups, when all pre-exercise measurements and post-exercise
measurements are averaged within treatment group. This will be tested using a 2 x 2
(treatment x pre-post) repeated measures ANOVA.

Ho2b: There will be no significant difference in the acute arm circumference response to exercise
over time, when pre-exercise measurements and post-exercise measurements are averaged
across treatment groups at each measurement time point. This will be analyzed using a 2 x 6
(pre-post x time) repeated measures ANOVA.
Ho2c:

There will be no significant difference in the arm circumference response to exercise over
time, when pre- and post-exercise data are averaged within each treatment group at each
measurement time point. This will be tested using a 2 x 6 (treatment by time) repeated
measures ANOVA.
Main effects of time, treatment, and exercise were also examined.

Ho1d: There will be no effect of time on acute arm circumference response to exercise.
Ho1e: There will be no effect of treatment on acute arm circumference response to exercise.
Ho1f:

There will be no effect of exercise on the acute arm circumference response to exercise.

Ho3:

There will be no difference in strength development between treatment groups over time.
This will be tested using a 2 x 3 repeated measures ANOVA.
Main effects of treatment and time were also examined.

Ho3a:

There will be no main effect of treatment on strength development.

Ho3b: There will be no main effect of time on strength development.
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Ho4:

There will be no significant difference in arm tissue composition changes between groups
over time. Arm tissue includes bone mineral content (BMC), adipose, and lean tissue, and
each tissue component was analyzed separately with a 2 x 2 repeated measures ANOVA.
After the interaction term, main effects of treatment and time were examined.

Ho4a:

There will be no main effect of treatment on arm tissue composition changes.

Ho4b: There will be no main effect of time on arm tissue composition changes.

All assumptions inherent to analysis of variance were tested to ensure appropriate use of the
statistical tool. To account for correlation and consequent lack of independence between repeated
measures over time for each subject, Mauchly’s test of sphericity was utilized to assess the
homogeneity of the variances across time points. If sphericity was violated, the F statistic was
adjusted using either the Greenhouse-Geisser or Huynn-Feldt estimates. If any null hypotheses
were rejected, significant omnibus F tests were followed with multiple dependent t tests, in which
the alpha level was adjusted using the Bonferonni correction. Trend analysis was also employed to
see any potential trends that emerged over the 6-week period. Statistical tests were chosen to elicit a
medium effect size of 0.25 (Cohen’s F). Power was set a priori at 0.90, and significance was
accepted below 0.05. With the aforementioned effect size and power, analyses revealed twenty-four
subjects were necessary to detect statistical significance. SPSS 17.0 (Chicago, IL) was used to
perform all statistical analyses, and MyAssays Analysis Software Solutions was used to calculate
plasma PGF2α metabolite concentrations fit to a 4-parameter logistic regression fit.
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Chapter IV
Results

Twenty-four participants were successfully recruited; however, one subject discontinued
participation due to scheduling conflicts after completion of baseline testing and the first two
supervised exercise session. Data from these three sessions was not included in any statistical
analyses. Participants were randomly assigned to placebo (n=11) or naproxen sodium (n=12)
treatment group. Two hundred ninety-nine supervised exercise sessions were scheduled over the 6week period, and 295 (98.7%) were completed.

Participant Anthropometrics
Participant anthropometrics are provided in Table 5. With the exception of one participant
in the placebo treatment group who failed to undergo initial measurement, all participants completed
pre- and post-study DXA analysis. One-way ANOVA revealed no significant differences between
treatment groups in initial total body, left arm, or right arm skeletal muscle tissue (g), which is
important to note in preparation for interpretation of data concerning gains in strength. Likewise,
one-way ANOVA revealed no significant differences in initial total, left arm, or right arm adipose
tissue (g).
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Table 5
Participant Anthropometrics

Placebo (n=11)

Naproxen Sodium (n=12)

Age (years)

20.6 + 1.3

20.9 + 1.4

Height (cm)

174.2 + 9.9

178.8 + 5.6

Initial Body Mass (kg)

77.9 + 11.5

80.7 + 9.5

Final Body Mass (kg)

77.6 + 10.4

80.8 + 8.8
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Table 6
DXA Tissue Composition
Initial

Final

2937.845 + 490.164
204.098 + 33.750
228.303 + 31.300

2936.496 + 437.156
202.437 + 33.794
230.930 + 35.669

Total Fat (g)
Left Arm Fat
Right Arm Fat

12244.570 + 5581.916
576.370 + 257.125
596.930 + 269.441

12719.882 + 5012.037
567.236 + 235.917
618.300 + 293.795

Total Lean (g)
Left Arm Lean
Right Arm Lean

61301.400 + 7789.383
3852.540 + 488.235
4065.210 + 518.816

60799.036 + 7221.434
3752.655 + 490.735
4141.600 + 526.297

Total Body % Fat
Left Arm % Fat
Right Arm % Fat

15.570 + 5.325
12.240 + 4.549
12.000 + 4.516

16.327 + 5.286
12.391 + 4.485
12.127 + 4.841

2917.416 + 354.459
207.888 + 18.208
226.761 + 34.737

2920.628 + 363.646
204.149 + 24.868
232.518 + 30.660

Total Fat (g)
Left Arm Fat
Right Arm Fat

13801.892 + 4588.963
616.350 + 219.334
662.175 + 217.552

13646.317 + 4557.519
610.092 + 203.905
647.100 + 221.934

Total Lean (g)
Left Arm Lean
Right Arm Lean

61996.433 + 654.015
3982.933 + 643.414
3997.625 + 471.430

62458.392 + 6719.558
3960.917 + 513.099
4235.167 + 528.532

Total Body % Fat
Left Arm % Fat
Right Arm % Fat

17.283 + 4.662
13.000 + 4.098
13.192 + 3.994

17.058 + 4.713
12.792 + 4.070
12.617 + 4.027

Placebo
Total BMC (g)
Left Arm BMC
Right Arm BMC

Naproxen Sodium
Total BMC (g)
Left Arm BMC
Right Arm BMC

Values provided as means + standard deviations.
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Plasma 13, 14-dihydro-15-keto Prostaglandin F2α Concentrations
Participants (n=23) provided one baseline blood sample (6ml) during the familiarization
session, prior to any exercise testing. In addition, participants provided a pre- and post-exercise
blood sample in conjunction with workouts 1, 7, and 11, resulting in a total intended collection of
161 blood samples (23 baseline samples, 138 pre- and post-exercise samples).
One participant did not complete a scheduled draw due to a potential contraindication
reported after the final pre-exercise sample was obtained. This potential adverse event was reported
to the medical advisor of the Institutional Review Board, and the participant was not allowed to
perform the scheduled workout or post-exercise blood draw. In an attempt to retain this data, an
intent-to-treat analysis was employed by using the average of his first two post-exercise
concentrations for his third and final concentration.
Concentrations were determined using the 4PL regression equations determined by
MyAssays Data Analysis Software. An 8-point standard curve was created, with the resulting 4PL
regression equations from which concentrations were calculated:
Samples 25-68: y = {(-11.467 – 562.821) / 1 + (x/0.193)^-0.319}+ 562.821
R2 = .9908
Samples 69-118: y = {(5.790 – 3682.54) / 1 + (x/0.004)^-0.420}+ 3682.54
R2 = .9399
Samples 119-142: y = {(-3.500 – 125.491) / 1 + (x/52.979)^-0.483}+ 125.491
R2 = .9857
Samples 143-168: y = {(0.663 – 204.382) / 1 + (x/37.714)^-0.485}+ 204.382
R2 = .9955
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Pre-exercise plasma concentrations represent resting conditions. Post-exercise
concentrations represent the response to exercise (placebo) or exercise and medication (naproxen
sodium). The acute change in PGF2α metabolite concentrations (pg/ml) were examined by
application of a 2 x 2 x 3 repeated measures ANOVA. Pre- and post-exercise systemic plasma
concentrations (pg/ml) for each treatment group and for workouts 1, 7, and 11 are provided in
Table 7, with the log concentration of each respective draw presented graphically in Figure 2.

Table 7
PGF2α Metabolite Concentrations (pg/ml)
Placebo

Naproxen Sodium

Pre-Workout 1

71.75 + 40.30

119.08 + 65.38

Post-Workout 1

92.72 + 44.86

125.89 + 110.48

Pre-Workout 7

50.06 + 19.12

69.14 + 51.56

Post-Workout 7

57.58 + 18.82

64.08 + 54.57

Pre-Workout 11

163.14 + 100.13

160.51 + 158.83

Post-Workout 11

175.24 + 112.32

166.96 + 137.60

Values provided as mean + standard deviation.
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Pre- and Post-PGF2α Metabolite Concentrations
by Treatment

Log Concentration (pg/ml)

1000

100

10

1
Pre 1

Post 1

Pre 7
Placebo

Post 7

Pre 11

Post 11

Naproxen Sodium

Figure 2
Error bars represent standard deviation.
Interpretation of the three-way interaction term (treatment x acute change x time) was nonsignificant (p=0.937), indicating no significant difference in the acute PGF2α metabolite response
between groups over time. All two-way interaction terms (time x treatment (p=0.381), acute change
x treatment (p=0.093) and acute change x time (p=0.596)) were also non-significant. These results
led to the decision to fail to reject Ho1 and Ho1a-c.
Main effects for treatment, time, and exercise were then examined, with significant effects
for time and exercise revealed. With Mauchly’s test of sphericity violated by time, the significance
value was appropriately adjusted. Both Greenhouse-Geisser and Huynh-Feldt corrections yielded
significant p values (p<0.05), indicating the acute response (average of pre- and post-exercise
concentrations) changed over time, regardless of treatment group (Figure 3). This led to the
conclusion to reject Ho1d. Post hoc analysis using the Bonferroni correction showed all time points
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were statistically different from one another (workout 1 and 7, p<0.005; workout 1 and 11, p<0.008;
workout 7 and 11, p<0.005). Trend analysis revealed both significant linear (p=0.003) and quadratic
(p<0.005) trends for time. The quadratic trend indicated a significant reduction in the average of
pre- and post-exercise concentrations at the second measurement time (workout 7, week 4), which
was followed by an increase in the pre- and post-exercise average at the final measurement time
(workout 11, week 6).
PGF2α Metabolite Concentrations Over Time
250

*

Concentration (pg/ml)

200

150

100
*
50

0
1

7

11

Workout

Figure 3 – Average pre-exercise and post-exercise concentrations collapsed across treatments.
Error bars represent standard error.
*All time points significantly (p<0.05) different from one another.
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Statistics also revealed a significant main effect of exercise on plasma PGF2α metabolite
concentrations, with trend analysis revealing a linear trend (p=0.015). Thus, regardless of treatment
group, average post-exercise plasma concentrations were higher than average pre-exercise
concentrations (pre-exercise mean + standard error 105.61 + 14.90; post-exercise 113.74 + 16.25
pg/ml). Placebo-treated participants demonstrated an average acute increase of 13.5 + 11.3 pg/ml,
versus 2.7 + 24.2 pg/ml in naproxen-treated. Without a significant treatment effect, the overall
average increase was 8.13 + 15.58 pg/ml or approximately 7.15% as a result of exercise. This is
presented graphically in Figure 4.

Acute Systemic Increases Plasma PGF2α Metabolites
140

Concentration (pg/ml)

*

125

110

95

80
Pre Exercise

Post Exercise

Figure 4
Error bars represent standard error.
*Significantly different from pre-exercise.
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With substantial variability in systemic PGF2α metabolites, concentrations were normalized
to pre-exercise values and analyzed as a percent change in response to the intervention. The percent
change in plasma PGF2α metabolites for each treatment group resulting from exercise (placebo) or
exercise and drug (naproxen sodium) are presented in Table 8 and Figure 5. Statistical analyses
revealed a significant (p=0.04) treatment effect with data expressed as a percent change from pre- to
post-exercise.

Table 8
Plasma PGF2α Metabolite Concentration Response to Treatment – Expressed as % Change
Workout 1

Workout 7

Workout 11

Placebo

23.62 ↑

13.06% ↑

6.91% ↑

Naproxen Sodium

5.41% ↑

-7.91% ↓

3.86% ↑

*Significantly (p<.05) different from placebo.

PGF2α Metabolite Response to Treatment Over Time
Expressed as % change from pre- to post-exercise
25
20

% Change

15
10
5
0
-5
-10
Workout 1

Workout 7
Placebo

Naproxen Sodium

Figure 5
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Workout 11

The effects of naproxen sodium, expressed as a percent change from pre- to post-exercise
and in comparison to placebo, revealed reductions in exercise-induced increase in PGF2α metabolites
of 76.08, 160.60, and 44.14%, at workouts 1, 7, and 11, respectively.

Arm Circumference
For each participant, upper arm circumference was measured before and after each of the
three strength assessments and before and after all exercise sessions, resulting in a total of 28
circumference measures for each participant. Seven participants were initially excluded from the 2 x
2 x 6 repeated measures ANOVA due to one or two missing data points. To prevent the loss of this
data, an intent-to-treat analysis was employed. Pre- and post-exercise arm circumference averages
were calculated for each participant for each week. The average calculated from the closest time
points was then inserted at the appropriate time point for the participants for whom data was
missing. Statistical analyses were thus conducted on weekly average pre- and post-exercise
measurements rather than individual workout measurements.
The three-way interaction term (treatment x pre-post x time, 2 x 2 x 6) approached
significance (p=0.060); however, the decision was made to fail to reject Ho2. This conclusion
indicated that the acute response to exercise (pre-to-post-exercise change) did not differ significantly
between groups over the 6-week training period. Interestingly, trend analysis revealed a significant
fourth order polynomial trend for the three-way interaction (p=0.035). The data for the 3-way
interaction is presented graphically in Figure 6, with the average weekly acute change (pre-to-postexercise difference score) plotted for each treatment group.
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Arm Circumference Response
Acute Change Over Time by Treatment
Pre-to-Post Exercise Change (cm)

1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
1

2

3

4

5

6

Week
Placebo

Naproxen Sodium

Figure 6
Two-way interactions were then interpreted. The treatment x acute response (2 x 2)
interaction was non-significant (p=0.567), leading to the decision to fail to reject Ho2a. This
conclusion indicated there were no significant differences between treatment groups in the 6-week
average of all pre-exercise and post-exercise arm circumference measures.
With Mauchly’s sphericity test violated (p<0.005) in the acute response x time (2 x 6)
interaction term, the significance value was appropriately adjusted. Both Greenhouse-Geisser and
Huynh-Feldt corrections revealed a significant interaction (p<0.005), leading to the decision to reject
Ho2b. This conclusion indicated, regardless of treatment, there was a significant effect of time on
the acute arm circumference response to exercise and/or naproxen sodium (Figure 7).
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Trend analysis of the 6-week acute response x time interaction yielded significant p values
for all possible polynomial contrasts, up to the fifth order (linear p<0.05, quadratic p=0.011, cubic
p=0.013, fourth order p=0.027, fifth order p=0.005), indicating an undulating circumference
response to the stimulus.
Arm Circumference Response
Acute Change Over Time (6-weeks)

Pre-to-Post Exercise Change (cm)

2.5

2

1.5

1

0.5

0
1

2

3

4

5

6

Week

Figure 7
Error bars represent standard error.
Programs characteristics associated with week three were then subjected to closer
examination in an attempt to understand the acute response which reached a 6-week low at the week
3. While week three consisted of the typical heavy and light intensity resistance workouts, the
second strength assessment occurred prior to the second workout of week 3. While placebotreated participants exhibited average acute increases in arm circumference of 1.18 cm versus 0.89
cm in naproxen-treated, the response was 0.29 and 0.04 cm in the respective treatment group after
the second workout of week 3. It appears the re-assessment of strength prior to the second
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workout attenuated the typical circumference response. With week three removed, the acute
response decreased linearly over time (Figure 8).

Arm Circumference Response
Acute Change Over Time (5 weeks)
2.5

Pre-to-Post Change (cm)

2.0

1.5

1.0

0.5

0.0
Week

Figure 8
Error bars represent standard error.
The treatment by time interaction term was non-significant (p=0.614), leading to the
decision to fail to reject Ho2c. This indicated the weekly averages of pre and post-exercise
circumferences were not statistically different between treatment groups over the 6-week training
period.
Examination of main effects revealed a significant main effect of time on arm circumference
response to exercise. With Mauchly’s test violated for this within-subjects, both GreenhouseGeisser and Huynh-Feldt corrections yielded significant p values (p=0.012 and 0.008) for time.
Multiple comparison procedures using the Bonferonni correction revealed the response in week 2
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was statistically different from the response in week 4 (p<0.005), week 5 (p=0.002), and week 6
(p=0.003). Trend analyses for time revealed three significant polynomial trends, including linear
(p=0.03), cubic (p=0.004), and fourth order (p=0.003). Main effects for time are presented
graphically in Figure 9.

Arm Circumference Response
Over Time

Arm Circumference (cm)

35.5
*
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34.5
34.0
33.5
33.0
32.5
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2

3

4
Week

Figure 9
* Significantly different from weeks 4, 5, and 6.
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5

6

A main effect for exercise was also demonstrated in the acute change pre- to-post-exercise
(p<0.005). This indicated post-exercise circumference measures were greater than pre-exercise
measures (Figure 10). Regardless of treatment group, the average change in arm circumference from
pre-to-post exercise was 0.879 + 0.641 cm (mean + standard error).

Acute Effect of Exercise on Arm Circumference
38
*

Arm Circumference (cm)

37
36
35
34
33
32
31
30
Pre-Exercise

Post-Exercise

Figure 10
*Significantly greater than pre-exercise.
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Over time, pre-exercise arm circumferences reflect hypertrophy resulting from the training
intervention. Comparison of the first and last pre-exercise arm circumference revealed the naproxen
sodium treatment group demonstrated a 0.58 + 1.59 cm increase in pre-exercise arm circumference
over the 6-week training period versus a 0.31 + 1.15 cm increase in the placebo treatment group
(Figure 11) The difference between groups did not reach statistical significance.

Dominant Upper Arm Hypertrophy
2.5

Arm Circumference Growth (cm)

2
1.5
1
0.5
0
-0.5
-1
-1.5
Treatment
Placebo

Naproxen Sodium

Figure 11
Error bars represent standard deviation.

Post-exercise arm circumferences are related to the hyperemic response to exercise. Postexercise arm circumferences declined over time, with all groups exhibiting a final post-exercise arm
circumference less than that exhibited after the first workout (Figure 12). In response to the first
workout, participants in the placebo and naproxen sodium treatment groups exhibited a 1.47 + 1.21
cm and 1.69 + 1.22 cm increase, respectively. By the final workout, participants responded with
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only a 0.58 + 0.59 cm and 0.48 + 0.36 cm increase in placebo and naproxen sodium treatment
groups, respectively. This data can be seen in Figures 6, 7, 8, and 12.
Within Figure 12, several responses can be seen. First, the acute effect of exercise is seen,
with post-exercise values being greater than pre-exercise values. Also, hypertrophy across groups
can be seen by the slight but non-significant increase in pre-exercise measurements. The generally
decreasing hyperemic response to exercise can be seen by the downward trend in post-exercise
measurements.

Acute & Chronic Arm Circumference Response to Exercise
Weekly Average Pre- & Post-Exercise Circumferences
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Figure 12
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Strength
All subjects completed three strength assessments, which were conducted at (1) baseline, (2)
week 3, pre-workout 6, and (3) week 6, workout 12. The final workout (12) consisted of the final
strength assessment only, in contrast to workout 6, which entailed the second strength assessment in
addition to the regularly scheduled workout for that day. Workout 6 began with the mid-point
strength assessment. Subjects were then provided with their respective treatment and nutritional
supplement and allowed 30 minutes rest for both metabolism of naproxen and recovery from
strength testing.
The overall omnibus test (treatment x time interaction) for strength was not statistically
significance, indicating no significant difference in the rate of strength development between
treatment groups. Since the main effect for treatment was also determined to be non-significant,
both Ho3 and Ho3a failed to be rejected.
For all four resistance training exercises, 2 x 3 repeated measures ANOVA revealed a
significant main effect for time (p<0.05), a significant linear time trend, and statistically significant
differences between all time points within each treatment group (Figures 13-20). Ho3b was thus
rejected. Overall absolute increases in strength, for each exercise and both treatment groups are
provided in Table 9. Values are provided in both units of weight (mean + standard deviation) and
overall percent change. Table 10 details the rate of change in strength across 1RM testing intervals.
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Table 9
Strength Increases - Overall
Placebo

Naproxen Sodium

Absolutea (kg)

Absolute(%)

Absolute (kg)

Absolute(%)

LP

36.36 + 11.94*

27.89

34.56 + 10.63*

29.58

TB

19.21 + 11.91*

23.08

22.54 + 10.59*

29.38

UR

23.14 + 4.68*

34.78

16.48 + 3.89*

29.69

BC

25.0 + 16.1*

22.56

11.78 + 2.96*

25.36

* Significant at p<0.05 level.
Values given as means + standard deviations
LP – lat pulldown, TB – t-bar row, UR – upright row, BC – bicep curl

a

Table 10
Strength Increases (kg)a - Across Testing Intervals
Placebo

Naproxen Sodium

Interval 1

Interval 2

Interval 1

Interval 2

LP

18.39 + 9.98

17.98 + 11.70

17.33 + 8.14

17.24 + 7.94

TB

10.33 + 10.18

8.89 + 5.88

10.42 + 6.16

12.12 + 6.81

UR

9.09 + 3.11

10.95 + 4.97

7.77 + 4.59

8.71 + 5.72

BC

3.35 + 3.66

8.02 + 6.02

5.79 + 3.85

5.37 + 3.26

a

Values (kg) presented as means + standard deviation.
LP – lat pulldown, TB – t-bar row, UR – upright row, BC – bicep curl
Interval 1 = 1st to 2nd assessment (3 weeks); Interval 2 = 2nd – 3rd assessment (3 weeks)
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Strength Increase (kg) by Treatment - Lat Pulldown
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Figure 13
Error bars represent standard deviations.
*Significantly greater than preceding strength assessment(s) within group.
Stength Increase (kg) - Lat Pulldown
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Figure 14
Error bars represent standard error.
* Significantly greater than preceding strength assessment(s).
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3

Strength Increase (kg) by Treatment - T-Bar Row
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Figure 15
Error bars represent standard deviation.
*Significantly greater than preceding strength assessment(s) within group.
Strength Increase (kg) - T-Bar Row
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Figure 16
Error bars represent standard error.
* Significantly greater than preceding strength assessment(s).
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Strength Increase (kg) by Treatment - Upright Row
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Figure 17
Error bars represent standard deviation.
* Significantly greater than preceding strength assessment(s) within group.
Strength Increase (kg) - Upright Row
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Figure 18
Error bars represent standard error.
* Significantly greater than preceding strength assessment(s).
103

3

Strength Increase (kg) by Treatment - Bicep Curl
70
*
60

*

*
*

Strength (kg)

50
40
30
20
10
0
1

2

3

RM Testing
Placebo

Naproxen Sodium

Figure 19
Error bars represent standard deviation.
* Significantly greater than preceding strength assessment(s) within group.
Strength Increase (kg) - Bicep Curl
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Figure 20
Error bars represent standard error.
* Significantly greater than preceding strength assessment(s).
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3

Body Composition
DXA was performed both at the beginning and end of the 6-week intervention. One
subject in treatment one did not complete the initial DXA scan. Statistical analysis of body
composition was carried out on a per-case basis (placebo n=10; naproxen sodium n=12). All
subjects reported the right arm as the dominant arm for the performance of all gross motor skills, a
fact which is important in the interpretation of tissue changes in the right and left arms. Statistical
analyses of each tissue type (skeletal muscle tissue, adipose tissue, and bone mineral content) were
conducted separately. Examination of tissue changes was restricted to total body and right and left
arms.

Total Body Tissue – Bone Mineral Content, Lean Tissue, Total Fat (g), Total Fat (%).
Repeated measures ANOVA (2 x 2) revealed no main effects for treatment, time or any
treatment by time interaction for any total body tissue measures.

Left (Non-Dominant) Arm Bone Mineral Content
A 2 x 2 repeated measures ANOVA revealed a significant main effect for time (p<0.05), no
significant main effect for treatment, and no significant difference in the rate of change in left arm
bone mineral content between treatment groups over time. A significant linear time trend was
revealed (p<0.05); and surprisingly, this was a significant decrease in left arm bone mineral content
in both treatment groups over time (Figures 21-22). Based on individual participant results, bone
mineral content declined 4.25 + 6.38 g (1.64 + 4.17%) in placebo-treated participants, and 3.74 +
8.54 g (2.21 + 4.40%) in naproxen-treated participants (Figure 21). Without significant treatment
effects, this averaged to a 3.995 + 7.46 g (1.93 + 4.29%) decrease (Figure 22).
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Non-Dominant Arm Bone Mineral Content
by Treatment
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Figure 21
*Significantly less than within-group DXA 1.
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Figure 22
Error bars represent standard error.
*Significantly less than DXA 1.
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Right Arm Bone Mineral Content
With all ANOVA assumptions being met, 2 x 2 repeated measures ANOVA revealed no
main effects of treatment or time and no treatment x time interaction.

Left Arm Lean Tissue (g)
With all ANOVA assumptions being met, 2 x 2 repeated measures ANOVA revealed no
main effects of treatment or time and no treatment x time interaction.

Right Arm Lean Tissue (g)
With all ANOVA assumptions being met, 2 x 2 repeated measures ANOVA revealed a
significant main effect and linear trend for time (p=0.037) but no significant main effect for
treatment or treatment by time interaction. Both treatment groups significantly increased dominant
arm lean tissue. Participants in the placebo group gained an average of 117.88 + 233.51 grams
(2.82%) of lean tissue in their dominant arms, while those in the naproxen sodium group gained an
average of 237.54 + 452.66 grams (5.61%) of lean tissue (Figure 23).
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Dominant Arm Skeletal Muscle Tissue
by Treatment
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Figure 23
Error bars represent standard deviation.
*Significantly greater than within-group DXA 1.
Dominant Arm Skeletal Muscle Tissue
4400

*

Lean Tissue (g)

4300

4200

4100

4000

3900

3800
DXA 1

DXA 2

Figure 24
Error bars represent standard error.
*Significantly greater than DXA 1.
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Left Arm Fat (g)
With all ANOVA assumptions being met, 2 x 2 repeated measures ANOVA revealed no
main effects of treatment or time and no treatment x time interaction.

Right Arm Fat (g)
With all ANOVA assumptions being met, 2 x 2 repeated measures ANOVA revealed no
main effects of treatment or time and no treatment x time interaction.

Left Arm Fat Percent
With all ANOVA assumptions being met, 2 x 2 repeated measures ANOVA revealed no
main effects of treatment or time and no treatment x time interaction.

Right Arm Fat Percent
With all ANOVA assumptions being met, 2 x 2 repeated measures ANOVA revealed a
significant main effect and linear trend for time (p=0.035), no significant main effect treatment, and
no significant interaction. Both treatment groups significantly decreased dominant arm fat
composition. Placebo treated participants decreased from 12.0 + 4.52% to 11.29 + 4.48%, and
naproxen sodium-treated participants decreased from 13.19 + 4.17% to 12.62 + 4.03% (Figure 25).
With no significant treatment effect, the average decrease in dominant arm percent fat composition
was 0.65% + 0.92% (Figure 26).
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Dominant Arm % Fat
by Treatment
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Figure 25
Error bars represent standard deviation.
*Significantly less than preceding within-group DXA.
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Figure 26
Error bars represent standard error.
*Significantly less than DXA 1.
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Table 11
Summary of Tissue Changes in Dominant and Non-Dominant Arms
Non-Dominant Arm

Dominant Arm

Bone Mineral Content (g)

↓*

↔

Skeletal Muscle Tissue (g)

↔

↑*

Adipose Tissue (g)

↔

↔

Adipose Tissue (%)

↔

↓*

Placebo

Naproxen Sodium

Total energy (calories)

2594.6 + 559.6

2383.6 + 754.4

Calcium (mg)

1175.8 + 319.0

939.1 + 369.7

Vitamin D (mcg)

5.8 + 3.3

8.5 + 9.5

Protein (g)

123.1 + 44.0

134.2 + 56.9

Kilocalories derived from protein (%)

19.7 + 5.0

23.0 + 6.4

↔ - no change; ↓ - decrease; ↑ - increase
* Significant at p<0.05 level.

Table 12
Average Daily Dietary Intakes

Values presented as means + standard deviation.

111

With four primary outcome variables, a condensed summary of the statistical results is
presented in Table 13.

Table 13
Summary of Statistically Significant Findings

Outcome Variable

Statistical Results

Plasma PGF2α Metabolite Concentrations
Time

F(1.34,28.12)=21.37; p<.005

with Huynh-Feldt df correction

Exercise

F(1,21)=7.030; p=.015

Upper Arm Circumference
Time

F(2.56, 53.70)=4.69; p=.008

with Huynh-Feldt df correction

Exercise

F(1,21)=164.66; p<.005

Time x Pre-Post
with Huynh-Feldt df correction

F(3.06, 64.27)=11.09; p<.005

Strength
Time
Lat Pull

F(2,42)=140.86; p<.005

T-Bar Row
with Huynh-Feldt df correction
Upright Row
with Huynh-Feldt df correction
Bicep Curl

F(1.57,32.89)=63.50; p<.005
F(1.64,34.45)=71.47; p<.005
F(2,42)=84.47; p<.005

Left Arm BMC
Time

F(1,20)=5.96; p=.024

Right Arm Skeletal Muscle Tissue
Time

F(1,20)=5.02; p=.037

Right Arm Percent Fat Composition
Time

F(1,20)=5.12; p=.035
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Chapter V
Discussion

To the author’s knowledge, this is the first study to examine the stable downstream
metabolite of PGF2α in the systemic circulation during the course of a training study in a strictly
defined participant pool. All previous research involving this hormone is a mixture of acute training
studies, animal models of imposed injury, and/or in vitro investigations. Both the chronic and
systemic hormonal measurement characteristics of the study are unique factors that contribute to the
existing body of literature concerning the PGF2α hormonal response to chronic resistance exercise.
This study sought to examine the anabolic growth factor at three time points over a 6-week
periodized resistance training program and to attempt to clarify how its response to exercise and/or
prostaglandin-inhibiting drugs may affect functional outcomes such as strength and hypertrophy.
The combined measurement of systemic prostaglandin F2α metabolites with functional parameters of
muscle performance is also a unique characteristic of the study.

Systemic PGF2α Metabolite Concentrations
While there are many hormones that may play a role in skeletal muscle growth, this paper
sought to further investigate metabolites of an endogenously-produced growth factor shown to be
intimately involved in satellite cell activity and the incorporation of new proteins into skeletal
muscle. Along with Wilson and Kapoor (1993), it is one of only two studies to demonstrate a
systemic increase in prostaglandin F levels in response to resistance exercise, validating a less
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invasive approach to its measurement. This is the first investigation to demonstrate an acute
exercise-induced increase in PGF2α metabolites, using plasma samples derived from the general
systemic circulation. Furthermore, the current study is the first to show a change in the acute PGF2α
metabolite response to exercise over a chronic (6-week) period of time.
There is no research to which these findings can be compared since no previous studies have
sampled PGF2α metabolites from the systemic circulation over time. The most similar study was
performed by Wilson and Kapoor (1993), who reported significant five-fold increases in PGF1α and
PGE2 (pg.min-1•100 ml-1) in response to two levels of acute wrist flexion (0.2 and 0.4 W) in 12
normal subjects using arterial and venous catheter techniques. Their assumption was that the
difference between arterial and venous circulations in the forearm reflected increases in synthesis,
which are then reflected as “spillover” from the local muscular tissue.
The average increases of 13.5 + 11.3 pg/ml and 2.7 + 24.2 pg/ml in placebo- and naproxensodium-treated participants in this study are difficult to compare to previous studies, due to the
different sources of measurement. It is not surprising, however, that concentrations were lower
when derived from the general venous circulation. It is believed the measurement approach
employed in the current investigation contributes to our understanding of the relationship between
local and systemic values of this growth factor and may hopefully encourage more training studies
that examine PGF2α metabolites using less invasive techniques which facilitate repeated
measurement in the same participant(s).
FSR has been shown to correlate PGF2α concentrations (Smith et al., 1983; Trappe et al.,
2002). With that correlation, increases of 48 + 6% and 76 + 19% in FSR (PGF2α) have been
reported after acute exercise (Phillips et al., 1999; Trappe et al., 2002). There were strong similarities
between Phillips et al.’s and Trappe et al.’s research, with both using similar participants who
performed acute resistance exercise with FSR measured by phenyalanine incorporation into muscle.
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While placebo-treated participants demonstrated ~77% increases in FSR and PGF2α after acute
resistance exercise, maximal non-prescription doses of ibuprofen (1,200 mg/day) and
acetaminophen (4,000 mg/day) were found to blunt the typical increase, leading to the conclusion
these medications attenuate the increase in FSR by inhibition of PGF2α and that continued inhibition
of the normal increase in synthesis after each session of resistance training would blunt the
hypertrophic response to exercise (Trappe et al., 2002).
Using one-third of the dose administered by Trappe et al. (2001, 2002), Krentz et al. (2008)
found no significant effect of ibuprofen (400 mg) on strength or hypertrophy but measured no
biochemical markers of inflammation or protein synthesis. With findings that were in opposition to
Trappe et al. (2001, 2002), Krentz et al. (2008) stated the importance of measuring biochemical
markers of inflammation and protein synthesis over the course of a strength training program.
Thus, the primary purpose of this investigation was to address the issues presented by these
researchers.
While acute response revealed an increase post-resistance exercise, the chronic response,
when expressed in picograms per ml of blood, demonstrated an unexpected quadratic trend over
time (Figure 3). There are several factors which may explain this trend. First, it may be a function
of stimulus intensity, as demonstrated by previous acute studies (Wilson and Kapoor, 1993; Boushel
et al., 2002). The intensities of the workouts when blood was sampled were 76%, 82%, and 86%
1RM, respectively. Thus, the smallest acute response, and coincident lowest concentration (pg/ml),
occurred when a 6% increase in intensity had been progressively imposed over 3.5 weeks. This was
followed by a dramatic increase in the response after an additional 4% increase was imposed over
the last 2.5 weeks of training. Strength had been re-assessed at the end of week three, and training
load intensities for weeks 4-6 were set on the basis of this re-assessment; thus the decrease in
concentration was unexpected and difficult to explain.
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Dietary factors may also partially explain PGF2α metabolite concentrations. The
prostaglandin precursor, arachidonic acid, is found in all animal tissue; thus a diet high in meat
should also be high in arachidonic acid. While it was planned for the first and second 3-day dietary
collection periods to overlap the first and final blood draw, only the second dietary collection period
actually overlapped the final blood draw. A bivariate correlation was performed to examine a
potential relationship between dietary arachidonic acid content (g) and PGF2α metabolite
concentrations (pg/ml); however, analysis revealed no significant correlation was revealed (p=0.313).
This analysis was conducted only for the final blood draw, as it was the only draw for which
coincident dietary data was available.
It is important to remember the hormone was only measured before and after three of the
twelve supervised resistance training sessions. It is not possible to know the activity of the hormone
at intervals between. However, a strength of the study’s design that adds to the validity of the three
blood collections is the consistent conditions under which blood was sampled. To account for the
circadian rhythm of many hormones (ie., cortisol), blood was always sampled at the same time.
Also, in light of the fact stimulus intensity is known to influence the hormonal response (Boushel et
al., 2002), blood was always sample before and after the most intense weekly workout.
The large response in PGF2α metabolites exhibited from the second to third blood draws
may also be explained by other phenomenon. Histological markers in Mishra’s (1995) study of
isolated intact rat skeletal muscle followed a somewhat curious time course. While significantly less
embryonic myosin was seen in NSAID-treated rabbits 3-day post-stimulation, 7-day observations
showed expression of this regenerative marker to be greater in treated versus untreated animals.
While the authors purported this finding suggested a “delayed or ineffectual regenerative response”
treated animals, it may also be considered super-compensatory type of response. It is possible
PGF2α metabolites also exhibited a super-compensatory type of response, reaching a low at the
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seventh workout but dramatically rebounding by the final workout and blood sample (Figure 3).
One explanation for the significant increase in PGF2α metabolites measured at workout 11 of week 6
may reside in the significant increase in lean muscle tissue in the dominant arm. Comparatively
larger muscle mass presents a greater source of the PG precursor arachidonic acid.
The lock-and-key hypothesis is a basic tenet of endocrinology. According to this theory, all
hormones must interact with their receptors to produce their effects. PGF2α exerts its effects by
binding to its receptor, FP. With no previous research concerning the FP response to exercise, it is
not possible to say how it might be affected by exercise and/or naproxen sodium; however, skeletal
muscle growth is mediated through FP, which activates stretch-activated calcium channels on
skeletal muscle membrane (Horsley and Pavlath, 2003). Eccentric exercise has been postulated to
up-regulate neutrophil’s ability to produce reactive oxygen species (Pizza et al., 1999). While there is
no literature describing the effect of exercise or analgesics on the FP receptor, the potential for upor down-regulation of FP receptor sensitivity as a result of these stimuli cannot be ignored. It may
be possible a similar phenomenon to that seen in neutrophils could be seen in PGF2α-producing
cells. The hormonal response exhibited could be attributed to up- and/or down-regulation of FP
receptor sensitivity due to exercise intensity, naproxen, or other adaptive mechanisms.
In both an attempt to relate our data to that presented by previous studies and to account
for substantial intra-individual variability in PGF2α metabolites, post-exercise concentrations were
normalized to pre-exercise concentrations. With data expressed as a percent change from pre- to
post-exercise, significant treatment effects were revealed (p=0.04) (Table 8 and Figure 5).
Exercise resulted in PGF2α metabolite increases in placebo-treated participants at each
measured time point, but this response decreased linearly over time. Within the placebo group, each
workout for which blood was sampled resulted in a progressively smaller increase in PGF2α over
time, with increases of 22.6, 13.1, and 6.9% after workouts 1, 7, and 11, respectively (Figure 5).
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These findings support those of Phillips et al. (1999), who demonstrated trained participants
respond to exercise with a smaller increase in FSR and may suggest hormonal adaptation to the
exercise intervention. It would be reasonable to assume continued training in the current participant
sample would result in progressively smaller increases in PGF2α, which correlate FSR (Trappe et al.,
2002).
Conversely, the naproxen sodium treatment group demonstrated a non-linear chronic
response in PGF2α activity, with an initial 5.4% increase in PGF2α metabolites. This was followed by
complete inhibition of the typical increase in PGF2α, with levels completely abolished, ~8% below
pre-exercise levels. The final naproxen sodium blood sample showed only a slight 3.9% increase in
PGF2α metabolite concentrations. It is not clear, however, why levels were so drastically reduced at
only the second measured time point (workout 7); however, it may lie in individual responses to
medications.

Arm Circumference
The acute change in dominant arm circumference was used as an indirect measure of
exercise-induced hyperemia. The significant time x pre-post response interaction indicated this
response decreased over time, even in a periodized resistance training program in which intensity
was increased 2% each week. While both groups exhibited a significant increase in the acute
response (cm) from week 1 to week 2 (Figure 9), all subsequent pre- and post-exercise
measurements decreased toward their respective initial baseline value after week two. Participants in
the placebo treatment group demonstrated an average increase in upper arm circumference of 1.47
+ 1.21 cm (4.05%) in response to the first workout, versus those in the naproxen sodium treatment
group, who demonstrated an average increase of 1.69 + 1.22 cm (4.69%). By the eleventh and final
complete workout, the average increase was 0.58 cm + 0.59 cm (2.5%) in the placebo treatment
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group versus 0.48 + 0.36 cm (1.45%) in the naproxen sodium treatment group. Whether or not this
lends support to the use of pre-workout vasodilators is not clear; however, use of such ergogenic
supplements is relatively common in certain subsets of recreationally-trained individuals.
Howell et al. (1998) reported modest (1%) swelling of the upper arm in response to acute
elbow flexion consisting of 3 consecutive workloads of 90%, 80%, and 70% maximum voluntary
isometric force. Repetitions at each workload were performed until the subject could no longer
maintain a 2 second eccentric contraction. Progressively fewer repetitions were performed in each
successive set, with an average total number of 18.6 repetitions. Howell et al. (1998) reported no
differences between control, placebo, high dose ibuprofen (800 mg 4 x day for 6 days), or low-dose
ibuprofen (400 mg 4 x day for 6 days) groups in the acute swelling of the upper arm in response to
this exercise intervention. Our results were substantially greater than those reported by Howell et al.
(1998), with those in the placebo treatment group responding with a 4.05% increase in arm
circumference in response to workout one, and participants in the naproxen sodium treatment
group responding with a 4.69% increase. In comparison to the average 18.6 repetition total
performed by participants in Howell et al.’s study, the repetitions which elicited an approximate 4%
increase in acute arm circumference totaled 96 in the current investigation.
An interesting finding related to the arm circumference response to exercise was the
attenuation of the typical response by a preceding strength assessment, as seen in week 3. Although
participants were provided 30 minutes recovery after the second strength assessment, the typical
circumference response was attenuated by the prior muscular work. These results may suggest a
refractory period for the hyperemic response to exercise, in that 30 minutes is not sufficient time for
recovery of the hyperemic-related processes.
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Strength
When strength gains were averaged for all four exercises, participants in the placebo
treatment group demonstrated an average increase in strength of 27.1% compared to a 28.5%
increase in strength for those in the naproxen sodium treatment group. This rate of strength
development compares somewhat to Krentz et al. (2008), who reported a 21% increase in the
strength of the elbow flexors after 6 weeks of unsupervised unilateral elbow flexion exercise
performed by trained co-ed subjects 5 days per week. Krentz et al. (2008) only performed RM
tested at the beginning and end of the study, a fact which may explain the larger gains in strength
elicited by this study’s periodized design and mid-point strength testing.
Recreationally-trained males in the current investigation consistently increased strength in
each exercise throughout the duration of the study. As shown in Figures 14, 16, 18, and 20, the rate
of strength development was maintained across 1RM testing intervals, with no diminution seen
during the final 3-week 1RM testing interval. Although this consistent increase was likely due to the
3-week re-assessment in strength which allowed for appropriate adjustment of training loads, the
continued increase in the absence of significant growth is somewhat surprising considering the
relatively well-trained status of the participants.
These significant increases in strength were not accompanied by significant hypertrophy of
the dominant upper arm (0.31+1.15 cm increase in placebo versus 0.58+1.59 cm increase in
naproxen sodium). By selecting trained males, it was assumed participants were outside the
adaptation window predominated by neurological adaptations. In the absence of significant
anthropometric (cm) adaptations, neurological phenomenon, including increased motor unit
recruitment and/or their discharge rate, may partially explain the increases in strength in the absence
of hypertrophy.
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It is important to distinguish between morphology, relating to structure or form, and
hypertrophy, as the latter term certainly falls under the umbrella term of morphology. Although
significant hypertrophy did not occur, there were significant morphological changes, evidenced in a
significant increase in dominant arm lean tissue and a significant decrease in dominant arm fat
composition (percent). It is believed the significant decrease in fat tissue composition balanced the
significant increase in lean tissue, thus resulting in no significant gross changes in arm circumference.
Various responses to both aerobic and resistance exercise are known to be strongly dictated
by the initial fitness status of the individual, with relatively larger gains in strength possible in
sedentary and/or less-trained populations. Resistance-training status was one of the main prerequisites for participation, and all participants were classified as recreationally-trained. While
authors provide different definitions of recreationally-trained, in this study, recreationally-trained
was operationally-defined as individuals who were currently performing resistance exercise 3-5 times
per week and had been doing so a minimum of 6 weeks. Performance of a total body workout three
times per week, upper/lower split routine totaling four sessions per week, or push/pull/lower split
routines totaling five sessions per week qualified a participant for assignment as recreationallytrained.
In a meta-analysis of 37 studies of collegiate or professional athletes employing a strength
training intervention, Peterson, Rhea, and Alvar (2004) reported that maximal strength gains in
athletes are achieved with a mean intensity of 85% 1RM, frequency of twice per week, and mean
training volume of 8 sets per muscle group. Eight set per muscle group training was reported to
elicit strength increases of approximately one standard deviation above that of 1-set interventions in
regards to magnitude of effect (Peterson, Rhea and Alvar, 2004).
The current investigation was characterized by an undulating (heavy-light) microcycle nested
within a progressively periodized mesocycle. The heavy day was performed at 76-86% 1RM
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intensity for 3 sets of 6-8 repetitions, and the light day was performed at 66-78% 1RM for 3 sets of
10 repetitions. Thus, the mean intensity was 76% 1RM over the 6-week mesocycle, and the number
of sets per muscle group was always 12. The continued development of strength to an equal extent
across both 3-week 1RM testing intervals supports the heavy-light approach to resistance exercise,
which is useful when considering the potential for overuse injuries resulting from exercise. Also,
continued increases in strength with 12 sets in the current study stands in contrast to the metaanalysis research indicating that the magnitude of strength gains are decreased with training above 8
sets per muscle group in a trained population (Peterson et al., 2004). There was no decrease in
strength observed in this study’s recreationally-trained participants. This discrepancy in doseresponse may be explained by differences between participant pools (recreationally-trained athlete
versus collegiate/professional athlete).

Segmental Tissue Composition
Changes in bone mineral content and skeletal tissue were inconsistent between dominant
and non-dominant arms (Table 11). While the non-dominant arm in both treatment groups lost
bone mineral content without significant increases in skeletal muscle tissue or decreases in adipose
tissue (grams or percent), the dominant arm exhibited no significant changes in bone mineral
content but a significant increase in lean tissue and significant decrease in adipose tissue, expressed
as a percentage (Table 11).
The statistically significant decrease in non-dominant arm BMC fell within the standard error
of the DXA machine (+2.0%). While it is possible to argue the decrease may not be statistically
significant due to this fact, any decrease in BMC seen in recreationally-trained college-aged males
performing resistance training seems clinically significant and warrants further inspection.
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According to the 2004 Surgeon General’s Report on Bone Health and Osteoporosis, bone
mineral content is progressively developed up until age 30 in both sexes, provided daily intakes of
calcium and vitamin D are sufficient and weight-bearing physical activity is performed (Carmona
and Moritsugu, 2004). Other factors which may adversely affect bone mineral content include
excessive alcohol consumption, smoking, underweight status, and thyroid medications (Carmona
and Moritsugu, 2004).
The average age of participants in the current study was 20.8 years. Participants were prescreened for alcohol consumption behaviors and cigarette smoking, thus these potential contributing
factors do not seem to explain the decrease in bone mineral content in the non-dominant arm.
Components of dietary intake which have the potential to affect bone mineral content were
examined (Table 12). Due to scheduling conflicts, two participants in the placebo treatment group
were unable to complete the first 3-day dietary collection period, and two additional participants in
the placebo group were unable to complete the second 3-day collection period for follow-up
interview with study nutritional personnel. Two participants in the naproxen sodium treatment
group completed one 2-day collection (n=1) period and one 3-day collection period (n=1), but
were able to complete the other respective 3-day collection period. For those with incomplete 3-day
dietary assessments, an intent-to-treat analysis was employed, using the average intakes for the
completed collection periods.
Averages for each collection period were calculated from the actual number of days of
record. Average calcium, vitamin D, protein (g), and percent kilocalories from protein are
presented in Table 12. Two-tailed independent samples t-tests revealed no significant between
group differences in the intake for the presented macro- and micronutrients.
The majority (63.6%) of participants in the placebo treatment group met their daily
recommended dietary allowance for calcium (1,000 mg/day), while exactly 50% of participants in the
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naproxen sodium treatment group met their daily allowance. Thus, between the two treatment
groups, more than half (56.5%) met the recommended dietary reference intake (DRI) for calcium.
In contrast, only one participant in the placebo group and two participants in the naproxen sodium
treatment group met the RDA for Vitamin D. Thus, only 13.4% (3) of participants met the 2011
Institute of Medicine RDA for vitamin D for persons 1-70 years. Group averages were well below
the 2011 Institute of Medicine RDA of 15µg. The placebo group averaged 5.8µg, and the naproxen
sodium treatment group averaged 8.54µg. Based on their training status and initial body mass,
protein recommendations for study participants fall between 1.5 – 2.0 g/kg of body mass (Reimers,
2004). Using this value, recommended ranges were determined using the average initial body mass
for each treatment group. Both treatment groups average daily protein intake fell within their
respective recommended range (placebo treatment group recommendation 116.9–155.8 g/kg;
naproxen sodium treatment group recommendation 121.05–161.4 g/kg).
Dietary deficiencies may partially explain the decrease; however, these deficiencies would be
expected to manifest systemically, with decreases in bone mineral content seen throughout the body.
This was not the case, however. While the change in dominant arm bone mineral content was not
significant, values did increase, however slightly, in both treatment groups over the 6-week training
intervention. It is believed the decrease in BMC exhibited by the non-dominant arm is best
explained by the bilateral nature of the exercise intervention.
Strength was assessed bilaterally, but tissue composition was examined unilaterally with
DXA. To make a connection between unilateral tissue changes in response to a bilateral resistance
training intervention is difficult with the study’s design. Had both bilateral and unilateral strength
been assessed at the onset of the study, it may be more possible to speak to potential corresponding
changes in strength and tissue.
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One likely explanation for the decrease would be regular performance of unilateral exercises
prior beginning the 6-week bilateral exercise intervention. While subjects had been pre-screened for
resistance training, the specific type of exercise (barbell versus dumbbell) was a program
characteristic participants were not asked to specify. Thus, subjects were contacted roughly 6
months after the study’s conclusion to determine if a substantial number had indeed been
performing regular unilateral upper body exercise (ie., dumbbell curl) prior to enrolling in the study.
Nineteen of twenty-three participants responded. Eleven reported having been regularly performing
unilateral upper body resistance exercises prior to beginning the study, while eight reported they
were not. It is thus possible that non-dominant arm bone mineral content decreased as a result of
the substitution of a unilateral exercise with a bilateral exercise. To support this theory, not only did
lean skeletal muscle tissue not significantly increase in the non-dominant arm, but the trend was for
a decrease in lean tissue. The average decrease in non-dominant arm lean skeletal muscle tissue was
60.95 grams. It is highly likely resistance trainers subconsciously exert greater force with the
dominant arm when performing bilateral exercises.

Limitations
The Nautilus lat pulldown selectorized resistance training machine, or the exercise itself,
revealed itself as a potential issue as the study progressed. During the initial 1RM assessment, the
maximum weight allowed by the machine was beyond the strength capabilities of all participants;
however, as strength increased, the maximum weight limit of the machine was exceeded by several
of the participants. As a result, the planned 1RM test became a multiple RM assessment, with 1RM
values estimated using the Brzycki equation (Brzycki, 1993). While meeting 1RM test prerequisites
for being a core exercise, its gravity-assisted nature may artificially inflate strength measures. Also,
due to pain, one subject substitute the seated cable-row for the t-bar row, and one subject
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substituted an upright row performed with a rope for the barbell upright row. A few subjects
reported discomfort using the straight barbell for bicep curls, and these were allowed to substitute
the easy-curl bar. If the substitution was made, strength testing was carried out using the easy-curl
bar.
A total of three researchers assisted in measuring arm circumference, and although the
average of 2-3 measurements pre- and post-exercise were taken to determine a official pre- and postexercise value, arm circumference measures were associated with large standard deviations. While
the average of the measurements attends to intra-rater reliability concerns, inter-rater reliability was
not established. Thus, the lack of this may explain the large measures of variance and subsequent
lack of statistically significant findings. Finally, there were several instances of random medication
use during the 6-week study. Ideally, all other medications other than that employed in the study
would be prohibited; but, ethical concerns arise when prohibiting participants from pharmacological
aide for ailments such as headaches or colds.

Conclusion
General consensus holds that skeletal muscle regeneration is contingent upon protein
synthesis and satellite cell activity. Satellite cells are the foundation of myogenesis, and many wellcontrolled studies have presented convincing evidence for the role of prostaglandins in the cell cycle.
Research has shown detrimental effects of prostaglandin-inhibiting drugs on satellite cell activity
after various mechanical forms of acute muscle injury. While the author acknowledges the precision,
sensitivity, and quality of this measure, this study sought to examine the more ultimate and
functional outcomes of satellite cell activity, including muscular strength and hypertrophy. In
addition, this study sought to investigate how a repeated consumption of naproxen sodium might
affect the PGF2α response to exercise and potentially corroborate strength and hypertrophy
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measures. While muscle biopsy and catheter techniques to measurement more accurately reflect
tissue-specific changes in this hormone, these approaches are also invasive, and as a result, are
generally limited to measurement after acute interventions. As noted in the introduction, three of
the four studies to examine the efficacy of NSAIDs in DOMS prevention/treatment and to report
beneficial effects (preserved strength, torque, decreased soreness) used naproxen sodium after acute
exercise (Dudley et al., 1997; Lecomte et al., 1998; Baldwin et al., 2001). In light of these findings,
further investigation of treatment effects on chronic muscle adaptation seem warranted.
The results of the study indicate this dose does not interfere with the development of
strength, size, or lean skeletal muscle tissue in recreationally-trained college-aged males. It is not
possible to extrapolate these finding to other populations, other models of injury, or other time
courses of analgesic use. Regenerative potential could logically be contingent upon whether NSAID
administration is limited to the immediate post-injury period or continued during the regenerative
phase, as longer duration treatments have been shown to impose even greater decrements in muscle
performance (Lapointe et al., 2003). Our findings are now added to those reporting no negative
effects of a non-selective NSAID on skeletal muscle adaptation over a 6-week period (Krentz et al.,
2008).
The inflammatory response can be mediated through multiple cellular pathways.
Arachidonic acid, once cleaved from the membrane, can be converted into prostaglandins and
thromboxanes through the COX pathway, or into leukotrienes through the lipoxygenase pathway.
In vitro studies of human tendon fibroblasts subjected to cyclic mechanical deformation with or
without indomethacin have shown a concomittant increase in leukotriene B4 (LTB4) when PGE2 is
inhibited (Almekinders et al., 1993). It appears the marvelous human body finds a way to overcome
exercise-induced inflammation.
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Appendix A

Figure A1
1.
2.
3.
3.
4.
5.
6.

Sit with feet flat on floor hip-width apart with thighs supported by machine pads.
Assume a wide (slightly greater than shoulder-width) overhand closed grip on the bar.
Slightly recline the trunk so bar will pass just in front of the nose during the concentric phase
of the lift.
With head in a neutral position and eyes forward, contract upper back musculature, pulling
bar to breastbone (1 second).
Slowly (2 seconds) return the bar to starting position, allowing shoulder blades to protract
slightly.
Ensure trunk remains stationary throughout exercise.
Exhale during the concentric phase; inhale during the eccentric phase.

Figure A2
1.
2.
3.
4.
5.
6.

Lat Pulldown

T-Bar Row

Assume a prone position on machine, allowing pad to support chest (not shown).
Assume a hip-width stance with feet.
Assume a neutral closed grip on the diagonal grips.
With head in a neutral position and eyes down, contract upper back musculature, pulling bar
to chest (1 second).
Slowly (2seconds) return the bar to starting position, allowing shoulder blade protraction.
Exhale during the concentric phase; inhale during eccentric phase.
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Figure A3
1.
2.
3.
4.
5.
6.

Stand with feet in a hip-width stance with arms extended.
Assume a shoulder-width or slightly more narrow overhand closed grip on barbell.
With head in a neutral position and eyes forward, contract the shoulders (1 second), pulling
bar to neck, allowing elbows the lead the movement.
Allow wrists to flex during this concentric phase.
Slowly lower (2 seconds) the bar to starting position.
Exhale during the concentric phase; inhale during eccentric phase.

Figure A4
1.
2.
3.
4.
5.
6.

Upright Barbell Row

Bilateral Barbell Bicep Curl

Stand with feet in a hip-width stance with arms extended.
Assume a shoulder-width underhand closed grip on the barbell.
With head neutral and eyes forward, flex the elbows (1 second), bringing bar to shoulders.
Slowly (2 seconds) lower arms to extended staring position.
Ensure upper arms, elbows, and trunk remain stationary throughout the exercise.
Exhale during the concentric phase; inhale during eccentric phase.

Figure A5 BodyMedia SenseWear PRO2 Armband
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Appendix B
Participant Instructions
Exercise
(1)
The day before you are scheduled to report to the lab, please do not perform resistance
training exercises involving the upper back or biceps. This includes the following:
o
Pull ups
o
DB pullovers
o
Lat pull downs
o
Rows
o
Bicep Curls
o
Rear deltoid pulls
o
Rear deltoid flys (reverse flys)
(2)

The day you report, please do not perform any type of exercise (aerobic or resistance) 2
hours before you come in to exercise with me. Please wait until after our lab session to do
your personal workout.

Alcohol/Medicines/Supplements
(3)
Please do not drink more than 3 drinks the evening after your workout with me. Both Aleve
and alcohol are metabolized by your liver. It is wise not to drink when taking any medicine.
One drink is equal to 12 ounces beer, 5 ounces wine, or 1.5 ounces (~1 shot) of liquor.
(4)

If your doctor prescribes any new medication to you while you are enrolled in this study,
please tell me immediately. You should also tell your physician about being involved in this
research study. S/he will need to know that you have been taking 440mg of Aleve two days
per week.

(5)

If you begin taking any new over-the-counter medicines while you are enrolled in this study,
please tell me immediately.

(6)

Please do not begin taking any new supplements (creatine, amino acid pills or powder) while
you are enrolled in this study.

(7)

Please do not ingest over-the-counter stimulants (energy pills) prior to exercising with me.
Please do not drink any caffeine (coffee, coke, Red Bull, Rockstar, etc) in the 2 hours before
working out with me.

(8)

If you have a headache and need to take a pain reliever, take only the recommended dose of
your preferred pain reliever. Report any additional use of pain relievers to me during the
course of the study. You can email me at cbrewer2@olemiss.edu, text me at 801-9691, or
tell me when you come in to exercise.

(9)

The manufacturer of Aleve directs that no more than 3 Aleve caplets are to be taken in a 24
hour period, unless directed by a physician. I will be giving you 2 caplets. If you find
yourself in need of a pain reliever later on during the days we work out, do not take more
than 1 additional caplet within that 24 hour period. For sore muscles, often low-moderate
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intensity exercise, such as walking or swimming, can alleviate pain. Other options include a
warm shower and/or massage. It is wise to avoid taking additional pain relievers for muscle
ache if at all possible while participating in this study.
Specific Patient Instructions for Oral Naproxen Sodium
(1)
(2)
(3)
(4)

You should not use this medicine if you have had an allergic reaction (including asthma) to
naproxen, aspirin, or other NSAID medicines, such as diclofenac, ibuprofen, Advil®,
Celebrex®, Ecotrin®, Motrin®, or Voltaren®.
It is best to take this medicine with food or milk, so it does not upset your stomach. Drink a
full glass of water after a dose.
If you see a doctor or dentist while participating in this study, make sure you inform them of
your participation in this study. Tell them you are taking 2 Aleve caplets before exercise
twice per week.
This medicine may make you drowsy or dizzy. Avoid drinking, using machines, or doing
anything else that could be dangerous if you are not alert.

Possible Side Effects While Using This Medicine
Call your doctor immediately if you notice any of the following signals of a serious reaction:
(1)
Allergic reaction – itching, hives, swelling in your face or hands, swelling or tingling in your
mouth or throat, chest tightness, trouble breathing
(2)
Blistering, peeling, or red skin rash
(3)
Blood in your urin
(4)
Bloody or black, tarry stools
(5)
Change in how much or how often you urinate
(6)
Chest pain, shortness of breath, or coughing up blood
(7)
Flu-like symptoms
(8)
Numbness or weakness in your arm or leg or on one side of your body
(9)
Pain in your lower leg (calf)
(10) Problems with vision, speech, or walking
(11) Redness or swelling of the body area where you have pain
(12) Severe stomach ache
(13) Shortness of breath, cold-sweat and bluish-colored skin
(14) Skin rash or blisters with fever
(15) Sudden severe headache
(16) Swelling in hands, ankles, or feet
(17) Trouble swallowing
(18) Unusual bleeding, bruising, or weakness
(19) Vision changes
(20) Vomitting blood or something that looks like coffee grounds
(21) Yellowing of your skin or whites of your eyes
Tell me immediately if you notice any of the following less serious side effects:
(1)
Headache
(2)
Mild nausea, stomach pain, heartburn, gas, diarrhea, constipation
(3)
Mild skin rash or itching
(4)
Ringing in your ears
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Fall 2008
Role: Co-Investigator
The effects of cold temperature on gait initiation and dynamic balance in young and older females
Thesis
Fall 2007-Spring 2008
Role: Primary Investigator
SUPERVISION OF STUDENTS
o Aaron Proctor – Research Assistant, Exercise Biochemistry Laboratory (Fall 2010)
o Sarah Annand, Jonathan Collins, Christopher Hawkins – Research Assistants, Exercise
Biochemistry Laboratory (Spring 2011)
PROFESSIONAL SERVICE
Delmar Cengage Learning - Book proposal review (April 2011)
UM Womens’ Soccer - Consultant (May 2011-present)
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PROFESSIONAL AFFILIATIONS
o National Strength and Conditioning Association – Certified member (2004-Present)
CERTIFICATIONS
o American Red Cross, CPR/AED, First Aid Instructor (May 2008-present)
o National Academy of Sports Medicine (NASM), Certified Personal Trainer (2003-2008)
o National Strength and Conditioning Association (NSCA), Certified Strength and Conditioning
Specialist (CSCS) (2004-present)
COMMUNITY SERVICE
o
o
o
o
o
o

DII U10 Boys Soccer Team Manager (2010-2011)
Oxford Park Commission Youth Soccer Coach (Fall 2005, Spring 2006, Fall 2007, Spring 2008)
FITNESSGRAM administration, Pope Elementary School (December 2007)
Relay for Life - Participant & Fundraiser, Baton Rouge, LA (2005)
BP Multiple Sclerosis Tour - Participant & Fundraiser (April 2005)
Multiple Sclerosis Tour for Cure - Participant and Top Tour Fundraiser, Hammond, LA
(October 2004)

o
UNIVERSITY SERVICE
o Facilitation of adult and child CPR/AED expedited courses for University groups, including
Mississippi Teacher Corps (2009, 2010), Literacy for Life (2010), RebelQuest Summer Camp
(2010), Human Resources (2010), and Physical Plant (2010)
o Jean Jones Run – Volunteer, University of Mississippi (April 2008)
o Rebel Man Triathlon - Volunteer, University of Mississippi (2007-2011)
CONTINUING EDUCATION AND CONFERENCES
o American College of Sports Medicine National Conference (May 2009)
o University of Mississippi Strength Clinic (February 2006)
o National Strength and Conditioning Association Regional Conference (August 2011)
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